[["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP (TAR DNA-binding protein) gene encodes TDP-43, a RNA-binding protein involved in RNA processing and stress granule dynamics. Mutations in TARDBP are a well-established cause of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). In FTLD, TDP-43 pathology is a major hallmark, often presenting with behavioral changes and language deficits. In ALS, TDP-43 mislocalization and aggregation contribute to motor neuron degeneration. TDP-43 pathology is also observed in some cases of Alzheimer\u2019s and Parkinson\u2019s diseases. The pathway includes components of complex I, suggesting a link between mitochondrial dysfunction and neurodegeneration. The biological effect of TARDBP mutations is the disruption of RNA metabolism and protein homeostasis, leading to neuronal loss. This primarily contributes to \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP (TAR DNA-binding protein) gene encodes TDP-43, a crucial RNA-binding protein involved in RNA processing and stress responses. Mutations in TARDBP are associated with abnormal accumulation of TDP-43 protein in neurons, leading to neurodegeneration. This contributes to amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease characterized by the loss of motor neurons. TDP-43 proteinopathy is a hallmark of ALS and also occurs in frontotemporal lobar degeneration (FTLD). TARDBP mutations disrupt normal protein homeostasis, leading to neuronal dysfunction and cell death. These genetic alterations highlight TARDBP's critical role in maintaining neuronal health and its involvement in ALS and related diseases. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: TARDBP* -| CxI -> Q\nGenes in the pathway: TARDBP; TAR DNA binding protein | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this TARDBP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TARDBP (TAR DNA-binding protein) gene encodes TDP-43, a protein involved in RNA processing and stress granule dynamics. Mutations in TARDBP are strongly associated with frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). In particular, TARDBP mutations lead to the mislocalization and aggregation of TDP-43, contributing to neuronal dysfunction and cell death. This pathology is a hallmark of ALS, especially the familial form, and is also linked to FTLD with TDP-43 pathology. The interaction between TARDBP and components of complex I in the electron transport chain suggests a potential link between mitochondrial dysfunction and neurodegeneration. Overall, TARDBP mutations contribute to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele contributes to **Hypertension**. The pathway involves the VHL-RBX1-ELOC-ELOB-CUL2 complex, which targets HIF1A for degradation under normoxic conditions. In VHL mutations, this complex is impaired, leading to stabilization of HIF1A. HIF1A activates ARNT, forming a transcription factor complex that drives expression of genes like VEGFA, PDGFB, and TGFB, promoting vascular endothelial growth and smooth muscle cell proliferation. This leads to vascular remodeling and increased vascular resistance, contributing to hypertension. The pathway is critical in hypoxia response and vascular homeostasis, and its dysregulation due to VHL mutations is linked to hypertension and vascular disorders. \n\n\\boxed{Hypertension}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, when mutated, disrupts the VHL-RBX1-ELOC-ELOB-CUL2 ubiquitin ligase complex, leading to the stabilization of HIF1A under normoxic conditions. This results in the constitutive activation of the HIF1A-ARNT transcriptional program, which drives the expression of genes such as VEGFA, PDGFB, and TGFB, promoting angiogenesis, cell proliferation, and fibrosis. This dysregulation is a hallmark of VHL-mediated tumor suppression loss, contributing to the development of clear cell renal cell carcinoma (ccRCC) and other hypoxia-driven cancers. The pathway described is central to the pathogenesis of VHL-associated malignancies. The biological effect of the VHL allele mutation is the initiation and progression of kidney cancer. \n\n\\boxed{Clear Cell Renal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // HIF1A == ARNT => (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | HIF1A; hypoxia inducible factor 1 alpha subunit | ARNT; aryl hydrocarbon receptor nuclear translocator | SLC2A1; solute carrier family 2 member 1 | VEGFA; vascular endothelial growth factor A | TGFB1; transforming growth factor beta 1 | TGFB2; transforming growth factor beta 2 | TGFB3; transforming growth factor beta 3 | PDGFB; platelet derived growth factor subunit B | TGFA; transforming growth factor alpha\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 network, is central to the regulation of the hypoxia-inducible factor (HIF) pathway. VHL functions as an E3 ubiquitin ligase component, targeting HIF1A for degradation under normoxic conditions. Mutations in VHL lead to stabilization of HIF1A, resulting in constitutive activation of hypoxia-responsive genes such as VEGFA, PDGFB, and TGF\u03b2. This uncontrolled angiogenesis and fibrosis are hallmarks of a specific disease. The biological effect of the VHL allele mutation is the development of clear cell renal cell carcinoma (ccRCC), a type of kidney cancer. \\boxed{Clear cell renal cell carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nCDKN2A encodes p16INK4a, a potent inhibitor of CDK4/6, which complexes with cyclins D to phosphorylate RB1. This prevents RB1 from inhibiting E2F transcription factors, which drive cell cycle progression. In the given pathway, CDKN2A negatively regulates MDM2, a E3 ubiquitin ligase that targets TP53 for degradation. Loss of CDKN2A leads to increased MDM2 activity, reducing TP53 stability and impairing the DNA damage response. This results in unchecked cell proliferation and genomic instability. The loss of CDKN2A is a key genetic alteration in melanoma, where it contributes to uncontrolled cell growth by disrupting the p53 and RB1 tumor suppressor pathways. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a potent tumor suppressor that inhibits the cyclin D-CDK4/6 complex, thereby preventing phosphorylation of the retinoblastoma protein (RB1). This inhibition blocks the release of E2F transcription factors, which are critical for cell cycle progression. By suppressing the CDK4/6-cyclin D complex, CDKN2A also indirectly regulates TP53, as MDM2 normally promotes TP53 degradation. Loss or mutation of CDKN2A disrupts this pathway, leading to unchecked cell proliferation. This dysfunction is a hallmark of several cancers, particularly those involving the RB1 pathway. CDKN2A mutations are strongly associated with melanoma and pancreatic cancer, where they contribute to uncontrolled cell growth and tumor progression. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a protein that inhibits cyclin-dependent kinases, including CDK4 and CDK6, thereby preventing the phosphorylation of RB1. This inhibition blocks the release of E2F transcription factors, which are crucial for cell cycle progression. In the given pathway, CDKN2A also negatively regulates MDM2, a protein that promotes the degradation of TP53. By suppressing MDM2, CDKN2A enhances TP53 stability, which in turn induces cell cycle arrest and apoptosis. Loss of CDKN2A function leads to uncontrolled cell proliferation and resistance to apoptosis, contributing to tumor formation. This gene is frequently inactivated in various cancers, most notably melanoma and pancreatic cancer. The loss of CDKN2A function disrupts the tumor suppressor network, promoting malignant transformation. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the intracellular signaling cascade initiated by the amyloid beta precursor protein (APP), leading to the production of amyloid-beta, activation of muscarinic acetylcholine receptors (mAChR), and subsequent downstream signaling through GNAQ, PLCB, IP3, and mitochondrial calcium influx. This ultimately leads to the release of cytochrome c (CYCS), promoting apoptosis. This pathway is central to the pathogenesis of Alzheimer's disease (AD), as the aggregation of amyloid-beta is a hallmark of AD and contributes to neuronal toxicity. The involvement of mAChR and mitochondrial dysfunction further supports the role of this pathway in neurodegeneration. Mutations or dysregulation in genes such as APP, CHRM1, and MCU are associated with increased risk and progression of AD. Thus, this pathway is a key contributor to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the intracellular signaling cascade initiated by the amyloid beta precursor protein (APP), leading to the production of amyloid-beta (Abeta), which activates muscarinic acetylcholine receptors (mAChR), GNAQ, and subsequently phospholipase C beta (PLCB). This results in the release of calcium ions (Ca2+) from the endoplasmic reticulum via IP3 receptors, followed by mitochondrial calcium uptake through the mitochondrial calcium uniporter (MCU). This calcium influx triggers the permeability transition pore (MPTP) and the release of cytochrome c (CYCS), initiating apoptosis. This pathway is central to Alzheimer's disease pathology, where APP processing leads to amyloid-beta accumulation, mitochondrial dysfunction, and neuronal apoptosis. The involvement of multiple genes in this pathway underscores its role in neurodegeneration. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes a signaling cascade initiated by the amyloid beta precursor protein (APP), leading to the production of amyloid-beta, activation of muscarinic acetylcholine receptors (mAChRs), and subsequent activation of GNAQ and PLCB, resulting in the release of Ca\u00b2+ from the endoplasmic reticulum via ITPR. The Ca\u00b2+ enters mitochondria through MCU, triggering the permeability transition pore (MPTP) and the release of cytochrome c (CYCS), promoting apoptosis. This pathway is central to neurodegenerative processes. Mutations in APP or its downstream components are strongly associated with Alzheimer's disease, as they contribute to amyloid-beta accumulation, mitochondrial dysfunction, and neuronal apoptosis. The pathway's role in neurodegeneration and the involvement of key genes like APP and CYCS make it a critical contributor to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit, which plays a critical role in repolarizing cells, particularly in the nervous system. Mutations in KCNC3 can disrupt normal ion homeostasis, leading to hyperexcitability of neurons. This is most notably associated with neurological disorders. Specifically, pathogenic variants in KCNC3 are linked to **familial hemiplegic migraine type 1 (FHM1)**. This condition is characterized by episodic migraines accompanied by transient hemiplegia (paralysis on one side of the body). The disrupted potassium channel function leads to abnormal neuronal activity, contributing to the migratory and neurological symptoms observed in FHM1. Thus, the KCNC3 allele contributes to **familial hemiplegic migraine type 1**.\n\n\\boxed{familial hemiplegic migraine type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit, which plays a critical role in repolarizing neurons and maintaining membrane potential. Mutations in KCNC3 are associated with neurological disorders, particularly those involving hyperexcitability. A specific mutation in KCNC3, such as the Pro247Leu variant, has been linked to generalized epilepsy with febrile seizures plus (GEFS+), a genetic disorder characterized by seizures triggered by fever. This mutation reduces the function of the potassium channel, leading to prolonged neuronal depolarization and increased seizure susceptibility. The altered ion flow disrupts normal neuronal activity, contributing to the pathophysiology of the condition. Therefore, the biological effect of this KCNC3 allele is the disruption of potassium homeostasis, leading to hyperexcitability and contributing to GEFS+.\n\n\\boxed{Generalized epilepsy with febrile seizures plus}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit (Kv3.3), which plays a critical role in repolarizing neurons by facilitating the outflow of potassium ions (K+) during action potentials. Mutations in KCNC3 can disrupt this function, leading to abnormal neuronal excitability. Specifically, gain-of-function mutations in KCNC3 have been linked to epilepsy, particularly generalized idiopathic epilepsies. These mutations increase channel activity, resulting in hyperexcitability of neurons and seizure susceptibility. KCNC3 is also implicated in cardiac arrhythmias, as the channel contributes to repolarization in cardiac tissue. Mutations affecting K+ homeostasis, such as those involving KCNC3, can perturb the balance of extracellular K+, further contributing to neurological and cardiac disorders. The most well-documented disease associated with KCNC3 is \\boxed{Generalized Idiopathic Epilepsy}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the intracellular signaling cascade initiated by the amyloid beta precursor protein (APP), leading to the production of amyloid-beta, activation of muscarinic acetylcholine receptors (mAChR), and subsequent downstream signaling through GNAQ, PLCB, IP3, and calcium release from the endoplasmic reticulum and mitochondria. This process is critical in neuronal signaling and calcium homeostasis. Mutations in APP can lead to the abnormal accumulation of amyloid-beta, which is a hallmark of Alzheimer's disease. The pathway's involvement in calcium dysregulation and mitochondrial dysfunction further supports its role in neurodegeneration. The accumulation of toxic amyloid-beta and mitochondrial calcium overload can trigger cell death, contributing to the pathogenesis of Alzheimer's disease. Therefore, the biological effect of this APP allele is the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the intracellular signaling cascade initiated by the amyloid beta precursor protein (APP), leading to the production of amyloid-beta (Abeta), activation of muscarinic acetylcholine receptors (mAChR), and subsequent downstream signaling through GNAQ, PLCB, IP3, and mitochondrial calcium flux. The accumulation of mitochondrial calcium via MCU and the opening of MPTP leads to the release of cytochrome c (CYCS), a key event in apoptosis. This pathway is central to Alzheimer's disease (AD) pathology, as APP processing and amyloid-beta accumulation are hallmark features of AD. Mutations in APP and its downstream components contribute to neuronal damage, synaptic dysfunction, and neurodegeneration. The involvement of mitochondrial calcium dysregulation and cytochrome c release further supports the role of this pathway in AD-associated cell death. Thus, this APP allele contributes to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> mAChR -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | CHRM1; cholinergic receptor muscarinic 1 | CHRM3; cholinergic receptor muscarinic 3 | CHRM5; cholinergic receptor muscarinic 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the signaling cascade initiated by the amyloid beta precursor protein (APP), leading to the production of amyloid-beta, activation of muscarinic acetylcholine receptors (mAChRs), and subsequent intracellular calcium dysregulation through the mitochondrial calcium uniporter (MCU). This dysregulation triggers the mitochondrial permeability transition pore (MPTP), causing the release of cytochrome c (CYCS), which is a key step in apoptosis. This pathway is closely associated with neuronal damage and is a hallmark of Alzheimer's disease. The accumulation of amyloid-beta and subsequent mitochondrial dysfunction contribute to neurodegeneration, synaptic loss, and cognitive decline. Therefore, the biological effect of this APP allele is the pathogenesis of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein degradation and transcriptional regulation. Mutations in ATXN3, specifically expansions of the polyglutamine tract, lead to the accumulation of abnormal ataxin-3 protein, disrupting cellular function. This results in neurodegeneration due to the toxic gain of function of the mutant protein. The pathway involving ATXN3 is linked to mitochondrial calcium homeostasis, oxidative stress, and apoptosis, all of which contribute to neuronal death. These processes are central to the pathogenesis of spinocerebellar ataxia type 2 (SCA2), a hereditary neurodegenerative disorder characterized by progressive loss of coordination and motor control. The involvement of ATXN3 in calcium signaling and mitochondrial dysfunction further supports its role in disease progression. \\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in the ubiquitin-dependent protein degradation pathway. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, resulting in the formation of toxic protein aggregates. This is the genetic cause of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and cerebellar atrophy. The expanded polyglutamine repeats in ataxin-3 disrupt protein folding and function, leading to cellular stress and neuronal death, particularly in the cerebellum. The pathway involving ATXN3 is part of a broader network that includes glutamate signaling, calcium homeostasis, and mitochondrial dysfunction, all of which contribute to neuronal damage. The interaction of ATXN3 with ITPR1 and other components of the pathway underscores its role in calcium signaling and neurodegeneration. \\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein quality control. In the given pathway, ATXN3 is implicated in the IP3-mediated release of calcium from the endoplasmic reticulum, which influences mitochondrial calcium levels via the MCU. This calcium dynamics are critical for mitochondrial function and cell survival. Mutations in ATXN3 cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive cerebellar ataxia. The disease results from polyglutamine expansions in ataxin-3, leading to protein misfolding, aggregation, and neuronal dysfunction. The pathway highlights the role of ATXN3 in calcium homeostasis, which is disrupted in SCA2, contributing to mitochondrial dysfunction and neurodegeneration. \\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-established contributors to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The provided pathway illustrates a stress response mechanism, where SOD1 may influence the unfolded protein response via BIP (HSPA5), leading to the activation of EIF2AK3 and subsequent regulation of EIF2S1, ATF4, and ultimately DDIT3. This pathway is involved in cellular stress and protein homeostasis, which are dysregulated in neurodegenerative conditions. The pathological aggregation of mutant SOD1 protein is a key driver of neuronal toxicity in ALS. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is central to a pathway involving protein folding and stress response. SOD1, a copper-zinc superoxide dismutase, catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by motor neuron degeneration. The pathway includes HSPA5 (binding immunoglobin protein), EIF2AK3 (a sensor of endoplasmic reticulum stress), and downstream effectors like EIF2S1, ATF4, and DDIT3, which collectively regulate cellular stress responses. SOD1 mutations lead to protein misfolding and toxicity, disrupting these pathways and contributing to neuronal death. This genetic pathway is therefore directly implicated in the pathogenesis of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is central to a pathway involving stress response and protein translation. SOD1, a copper/zinc superoxide dismutase, catalyzes the conversion of superoxide radicals to hydrogen peroxide. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. The pathway involving SOD1 \u2192 BIP \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3 reflects a stress response mechanism, where misfolded proteins (e.g., mutant SOD1) trigger the unfolded protein response. This leads to the activation of ATF4 and DDIT3, promoting cellular stress and apoptosis. The accumulation of toxic mutant SOD1 proteins disrupts motor neuron function, contributing to the progressive degeneration characteristic of ALS. Thus, the biological effect of pathogenic SOD1 alleles is the induction of neurodegeneration through aberrant stress response pathways. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele, as indicated by the pathway involving APP \u2192 Abeta \u2192 26S, is the production of amyloid-beta peptides, which are central to the pathogenesis of Alzheimer's disease. The pathway involves the proteasome, specifically the 26S subunits, which are involved in degradation of misfolded or toxic proteins. The accumulation of amyloid-beta, due to impaired proteasomal degradation, leads to the formation of plaques in the brain, a hallmark of Alzheimer's. This pathway highlights the role of APP processing and proteasomal dysfunction in disease progression. The involvement of multiple proteasomal subunits underscores the complexity of protein degradation in neurodegeneration. Therefore, this pathway contributes to the development of \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this pathway is the production of amyloid-beta (Abeta), a key component in the pathogenesis of Alzheimer's disease. The pathway involves the proteasomal degradation of Abeta, with multiple subunits of the 20S and 26S proteasomes playing roles in this process. Mutations or dysregulation in this pathway can lead to impaired clearance of Abeta, resulting in its accumulation and the formation of amyloid plaques, a hallmark of Alzheimer's disease. The involvement of proteasome subunits suggests that proteasomal dysfunction may contribute to neuronal toxicity and disease progression. Therefore, this pathway is directly associated with Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| 26S\nGenes in the pathway: APP; amyloid beta precursor protein | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this pathway is the production of amyloid-beta (Abeta), a key component in the pathogenesis of Alzheimer's disease. The pathway involves the proteasomal degradation of Abeta, with multiple proteasome subunits (20S and 26S) playing roles in this process. Impaired proteasomal function can lead to the accumulation of Abeta, contributing to the formation of amyloid plaques, a hallmark of Alzheimer's disease. Mutations or dysfunction in APP or proteasome subunits can disrupt this clearance mechanism, accelerating neurodegeneration. Therefore, this pathway is central to Alzheimer's disease pathology. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cell proliferation and differentiation. Mutations in FGFR3, particularly gain-of-function mutations, lead to constitutive activation of the downstream signaling cascade, including RAS and RAF, resulting in uncontrolled cell growth. This aberrant signaling is strongly associated with skeletal dysplasias, most notably achondroplasia, the most common form of short-limbed short stature. Achondroplasia is caused by heterozygous missense mutations in FGFR3, leading to impaired endochondral ossification. These mutations enhance FGFR3 signaling, disrupting normal bone growth. While primarily a skeletal disorder, dysregulated FGFR3 signaling can also contribute to oncogenesis, though its primary pathological effect is in skeletal development. \\boxed{Achondroplasia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 signaling pathway is critical for cell proliferation and differentiation. Mutations in FGFR3, particularly gain-of-function mutations, lead to constitutive activation of downstream effectors such as GRB2, SOS, RAS, RAF, MEK, and ERK, ultimately increasing MYC activity. This aberrant signaling drives uncontrolled cell growth and contributes to oncogenesis. Specifically, activating mutations in FGFR3 are strongly associated with **multiple myeloma**. These mutations result in sustained signaling that promotes survival and proliferation of plasma cells, contributing to tumor progression. Therefore, the biological effect of an activating FGFR3 allele is the promotion of **multiple myeloma**.\n\n\\boxed{Multiple Myeloma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cell growth and differentiation. Mutations in FGFR3 can lead to constitutive activation of downstream signaling, promoting uncontrolled cell proliferation. This is particularly associated with skeletal development and tumor formation. Inactivation or gain-of-function mutations in FGFR3 are linked to skeletal dysplasias such as achondroplasia, the most common form of short-limbed short stature. Additionally, aberrant FGFR3 signaling can contribute to oncogenesis, particularly in bladder cancer, where FGFR3 mutations are frequently observed. These mutations drive tumor progression by enhancing cell survival and proliferation through the RAS-RAF-MEK-ERK pathway. Therefore, FGFR3 mutations are implicated in both developmental disorders and cancers. \\boxed{Bladder Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein involved in neuronal function. In the given pathway, HTT interacts with STX1A and VGCC (N-type), leading to Ca\u00b2\u207a influx, crucial for synaptic transmission. Mutations in HTT, specifically expansions of the CAG trinucleotide repeat, result in the production of an abnormally long huntingtin protein. This toxic protein disrupts cellular processes, including protein degradation and mitochondrial function, leading to neuronal death. This genetic mutation is the causative factor in Huntington\u2019s disease, a neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and behavioral changes. The pathway disruption contributes to synaptic dysfunction and neuronal loss, hallmark features of the disease. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction is central to Huntington\u2019s disease. In this pathway, HTT interacts with STX1A, a key component of synaptic vesicle docking, and VGCC (N-type), which regulates calcium influx. Mutations in HTT, such as CAG trinucleotide repeat expansions, lead to the production of an abnormal, polyglutamine-expanded huntingtin protein. This disrupts synaptic function by impairing vesicle exocytosis via STX1A and perturbing calcium homeostasis through VGCC. These disruptions contribute to neuronal death, particularly in the striatum and cortex. The resulting pathological features include progressive motor dysfunction, cognitive decline, and psychiatric symptoms. This pathway is thus critically involved in the pathogenesis of Huntington\u2019s disease. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| STX1A -| VGCC(N-type) -> Ca2+\nGenes in the pathway: HTT; huntingtin | STX1A; syntaxin 1A | CACNA1B; calcium voltage-gated channel subunit alpha1 B\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein involved in intracellular transport and synaptic function. The pathway described includes HTT \u2192 STX1A \u2192 VGCC (N-type) \u2192 Ca\u00b2\u207a, highlighting a role in neurotransmitter release via calcium signaling. Mutations in HTT, specifically expansions of the CAG trinucleotide repeat, lead to the production of an abnormal huntingtin protein. This protein accumulates and forms toxic aggregates, disrupting cellular processes and causing neurodegeneration. The most well-known disease associated with mutant HTT is Huntington\u2019s disease, an autosomal dominant neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. The pathogenic mechanism involves disrupted synaptic vesicle fusion and calcium homeostasis, contributing to neuronal death. \\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase involved in ubiquitin-mediated protein degradation. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. The pathway includes ubiquitin-conjugating enzymes (UBE2L3, UBE2L6) and septin 5 (SEPTIN5), which may contribute to mitochondrial quality control and proteostasis. Impaired PRKN function disrupts ubiquitin-proteasome system activity, leading to the accumulation of damaged proteins and mitochondrial dysfunction, which are key features of Parkinson's disease. Therefore, the biological effect of this PRKN allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase involved in ubiquitin-mediated protein degradation. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. In the given pathway, PRKN interacts with UBCH7/8 (E2 conjugating enzymes) and CDCREL1, suggesting a role in ubiquitin-dependent degradation of misfolded proteins. Dysfunction in this pathway leads to the accumulation of damaged proteins, mitochondrial dysfunction, and neuronal death, particularly in dopaminergic neurons. This contributes to the pathogenesis of Parkinson's disease. The specific PRKN allele in question, when mutated, impairs this degradation process, leading to neurodegeneration. Therefore, the biological effect of this PRKN allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // CDCREL1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SEPTIN5; septin 5\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with impaired mitophagy, the selective autophagy of damaged mitochondria. This leads to the accumulation of dysfunctional mitochondria, oxidative stress, and neurodegeneration. PRKN mutations are a key cause of autosomal recessive Parkinson's disease. The pathway involving UBCH7/8 (E2 conjugases) and CDCREL1 supports ubiquitin conjugation, a critical step in the ubiquitin-mediated degradation process. Dysfunction in this pathway, particularly due to PRKN mutations, disrupts neuronal survival and contributes to the pathogenesis of Parkinson's disease. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nAXIN1 is a key component of the \u03b2-catenin destruction complex in the WNT signaling pathway. Its role is to promote the degradation of \u03b2-catenin (CTNNB1), preventing its accumulation in the cytoplasm and nucleus. When AXIN1 is mutated or inactivated, this degradation is impaired, leading to the stabilization and nuclear translocation of \u03b2-catenin. This results in the aberrant activation of TCF/LEF transcription factors, which drive the expression of oncogenes such as MYC and CCND1. This dysregulated signaling contributes to uncontrolled cell proliferation and genomic instability. Mutations in AXIN1 are associated with the development of colorectal cancer, where they disrupt the WNT pathway, leading to tumor progression. Thus, the biological effect of a pathogenic AXIN1 allele is the promotion of colorectal cancer.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AXIN1 gene is a key component of the WNT signaling pathway, functioning as a scaffold for the destruction complex that includes APC and GSK3B. This complex targets CTNNB1 (\u03b2-catenin) for degradation, preventing its accumulation in the cytoplasm and nucleus. When AXIN1 is mutated or dysfunctional, this degradation process is impaired, leading to the stabilization and nuclear accumulation of \u03b2-catenin. This activates TCF/LEF transcription factors, driving the expression of downstream genes such as MYC and CCND1, which promote cell proliferation. Dysregulation of this pathway is a hallmark of colorectal cancer. Mutations in AXIN1 contribute to the destabilization of the WNT pathway, leading to uncontrolled cell growth and tumor formation. \n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: (GSK3B+APC) // AXIN* // CTNNB1 -> TCF/LEF => (MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | APC; APC, WNT signaling pathway regulator | AXIN1; axin 1 | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this AXIN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AXIN1 allele plays a critical role in the WNT signaling pathway. AXIN1 functions as a scaffold protein that promotes the degradation of \u03b2-catenin (CTNNB1), thereby inhibiting the stabilization and nuclear translocation of \u03b2-catenin. When AXIN1 is mutated or dysfunctional, this degradation is impaired, leading to the accumulation of \u03b2-catenin. This results in the activation of TCF/LEF transcription factors, which drive the expression of oncogenic genes such as MYC and CCND1. This deregulation of the WNT pathway contributes to uncontrolled cell proliferation and is a key driver in the development of colorectal cancer. \\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) pathway described involves androgen ligands such as DHT, E2, and others, leading to activation of AR and subsequent induction of KLK3 (kallikrein-related peptidase 3). This pathway is central to prostate biology. Mutations or aberrant activation of AR can disrupt normal cellular regulation, leading to uncontrolled proliferation of prostate epithelial cells. This contributes to the development and progression of prostate cancer. KLK3, also known as prostate-specific antigen (PSA), is a biomarker for prostate cancer. Genetic alterations in AR, such as those causing androgen insensitivity or enhanced ligand binding, can drive oncogenic processes. Thus, the biological effect of this AR allele is the promotion of prostate cancer. \n\n\\boxed{Prostate Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) allele plays a critical role in prostate cancer progression. In the given pathway, AR activation by ligands such as DHT (dihydrotestosterone) and E2 (estradiol) leads to the expression of KLK3 (kallikrein-related peptidase 3), a serine protease implicated in prostate cancer aggressiveness. Increased KLK3 activity contributes to tumor growth, epithelial-to-mesenchymal transition, and metastasis. Mutations or aberrant activation of AR can drive uncontrolled cell proliferation and resistance to hormonal therapies, hallmark features of prostate cancer. Therefore, the AR allele is directly associated with the development and progression of prostate cancer. The biological effect of this pathway is the promotion of prostate cancer. \n\n\\boxed{Prostate Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (T,DHT,E2,P4,FLUT,DHA,A4,F,E) -> AR* => KLK3\nGenes in the pathway: AR; androgen receptor | KLK3; kallikrein related peptidase 3\n\nGiven this context, what is the biological effect of this AR allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe AR (androgen receptor) allele plays a critical role in the genomic pathway involving androgen metabolism (T, DHT, E2, P4, FLUT, DHA, A4, F, E) and ultimately influences the expression of KLK3 (kallikrein-related peptidase 3). This pathway is central to prostate biology and disease. The androgen receptor mediates the effects of androgens such as dihydrotestosterone (DHT), which promotes prostate growth and maintenance. Dysregulation of AR activity, including mutations or altered expression, can lead to aberrant KLK3 expression. KLK3 is a key biomarker and driver in prostate cancer progression. Therefore, alterations in the AR allele contribute to the development and progression of prostate cancer. \\boxed{Prostate Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a major genetic cause of early-onset familial Alzheimer's disease (FAD). In the given pathway, PSEN1 influences intracellular calcium homeostasis via its connection to ITPR (inositol 1,4,5-trisphosphate receptors) and mitochondrial calcium uptake through MCU (mitochondrial calcium uniporter), leading to mitochondrial dysfunction and increased production of reactive oxygen species. This disruption contributes to neuronal damage and apoptosis, hallmark features of Alzheimer's disease. The pathway culminates in the release of cytochrome c (CYCS), promoting apoptosis via the intrinsic mitochondrial pathway. Thus, PSEN1 mutations disrupt calcium signaling and mitochondrial function, directly contributing to neurodegeneration in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (FAD). In the provided pathway, PSEN1 influences intracellular calcium homeostasis via the ITPR channels, leading to mitochondrial calcium overload through the MCU. This disrupts mitochondrial function, increases reactive oxygen species, and triggers the mitochondrial permeability transition pore (MPTP), promoting the release of cytochrome c (CYCS) and initiation of apoptosis. This pathway is central to neurodegeneration in Alzheimer's disease. The accumulation of toxic amyloid-beta and disruption of calcium signaling contribute to neuronal death. Thus, PSEN1 mutations primarily contribute to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: PSEN1; presenilin 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is critical for the cleavage of amyloid precursor protein (APP) to generate amyloid-\u03b2 peptides. Mutations in PSEN1 are a leading cause of early-onset familial Alzheimer's disease (AD). These mutations disrupt the normal function of the \u03b3-secretase complex, leading to increased production of toxic amyloid-\u03b242 peptides, which aggregate into plaques in the brain. This pathological process contributes to neuronal toxicity, synaptic dysfunction, and neurodegeneration. The pathway described, involving PSEN1 \u2192 ITPR \u2192 Ca\u00b2+ \u2192 MCU \u2192 Ca\u00b2+ (mito) \u2192 MPTP \u2192 CYCS, highlights the connection between PSEN1 dysfunction and mitochondrial calcium dysregulation, which exacerbates oxidative stress and cell death. This underscores the role of PSEN1 in neurodegeneration. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SPTBN2 gene encodes spectrin beta non-erythrocytic 2, a structural protein involved in maintaining cell membrane integrity and cytoskeletal organization. In the described pathway, SPTBN2 interacts with GRM1, initiating a signaling cascade involving GNAQ, PLCB, IP3, and calcium release via ITPR. Mutations in SPTBN2 can disrupt this pathway, leading to impaired calcium signaling and cytoskeletal dysfunction. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, SPTBN2 mutations are associated with **familial hemiplegic migraine type 2 (FHM2)**, a rare inherited disorder characterized by severe migraines with hemiplegic episodes. The disruption of calcium homeostasis and neuronal function underlies the pathophysiology of this condition. \\boxed{Familial Hemiplegic Migraine Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SPTBN2 gene encodes spectrin beta chain, non-erythrocytic 2, a structural protein involved in maintaining cell membrane integrity and cytoskeletal organization. In the described pathway, SPTBN2 is upstream of GRM1, linking it to glutamate signaling via metabotropic receptors. This pathway ultimately leads to intracellular calcium release through IP3 receptors, influencing various cellular processes including neurotransmission and muscle contraction. Mutations in SPTBN2 have been implicated in neurodevelopmental and neurodegenerative disorders. Specifically, alterations in SPTBN2 contribute to **Finnish-type Congenital Myopathy (F-10)**, a rare inherited disorder characterized by muscle weakness and hypotonia. \\boxed{Finnish-type Congenital Myopathy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: SPTBN2* -| GRM1 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: SPTBN2; spectrin beta, non-erythrocytic 2 | GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this SPTBN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SPTBN2 gene encodes spectrin beta non-erythrocytic 2, a key structural protein involved in maintaining cellular integrity, particularly at synaptic sites. In the described pathway, SPTBN2 interacts with GRM1, initiating a signaling cascade involving GNAQ, PLCB, IP3, and ITPR, ultimately leading to intracellular calcium release. Mutations in SPTBN2 disrupt this pathway, impairing calcium homeostasis and synaptic function. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, pathogenic variants in SPTBN2 are associated with **Frontotemporal Lobar Degeneration (FTLD)**, a group of disorders characterized by progressive degeneration of the frontal and temporal lobes of the brain. These mutations are linked to the accumulation of TDP-43 protein, a hallmark of FTLD. \\boxed{Frontotemporal Lobar Degeneration}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the \u03b11A subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in calcium influx into neurons. Mutations in CACNA1A are associated with impaired calcium homeostasis, leading to excitotoxicity and neuronal dysfunction. This contributes to neurodegenerative processes. Specifically, gain-of-function mutations in CACNA1A are linked to familial hemiplegic migraine (FHM), a form of migraine with neurological symptoms. These mutations enhance calcium entry into neurons, causing excessive neurotransmitter release and neuronal hyperexcitability. Additionally, CACNA1A mutations have been implicated in spinocerebellar ataxia type 2 (SCA2), a progressive neurodegenerative disorder. The altered calcium signaling disrupts synaptic function and leads to neuronal loss, particularly in the cerebellum. \\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the \u03b11A subunit of the P/Q-type voltage-gated calcium channel, which is critical for neuronal excitability and neurotransmitter release. The pathway described involves extracellular calcium (Ca\u00b2\u207a) entering neurons through this channel, leading to intracellular Ca\u00b2\u207a elevation. Mutations in CACNA1A are associated with familial hemiplegic migraine (FHM), a genetic disorder characterized by recurrent migraines with motor weakness. These mutations disrupt calcium homeostasis, leading to hyperexcitability of neurons and abnormal neurotransmission. The altered calcium signaling contributes to the pathophysiology of FHM by triggering cortical spreading depression and neuroinflammation. Therefore, the biological effect of this CACNA1A allele is the development of familial hemiplegic migraine.\n\n\\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel, which plays a crucial role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with a range of neurological disorders, most notably familial hemiplegic migraine (FHM), a form of migraine with aura. These mutations lead to altered calcium influx into neurons, disrupting normal neuronal function and causing hyperexcitability. This contributes to the pathophysiology of migraine attacks, including aura symptoms such as hemiplegia. Additionally, CACNA1A mutations have been linked to other conditions such as ataxia and episodic limbic encephalopathy. The altered calcium signaling due to CACNA1A dysfunction disrupts synaptic transmission and neuronal homeostasis, making it a key player in these neurodevelopmental and neurodegenerative diseases. \\boxed{Familial Hemiplegic Migraine}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene encodes a precursor protein essential for the proper folding and activity of lysosomal enzymes involved in sphingolipid metabolism. Mutations in PSAP lead to reduced production of functional GBA, GBA2, and GALC enzymes, which are critical for breaking down glycosphingolipids. This results in the accumulation of toxic lipids in lysosomes, causing neuronal damage. The most well-known disease associated with PSAP mutations is **Fabry disease**, an X-linked lysosomal storage disorder. However, PSAP mutations can also contribute to **Gaucher disease** when they impair GBA function. The primary biological effect of a pathogenic PSAP allele is the disruption of lysosomal enzyme activity, leading to progressive neurodegeneration and multi-system involvement. This underscores the critical role of PSAP in maintaining lysosomal homeostasis.\n\n\\boxed{Fabry disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene is involved in the biosynthesis of sphingolipids and plays a critical role in the proper folding and trafficking of lysosomal enzymes, including GBA, GBA2, and GALC. Mutations in PSAP can lead to impaired processing of these enzymes, resulting in their accumulation in lysosomes and subsequent neurodegeneration. This pathway is central to the pathogenesis of several lysosomal storage disorders. Specifically, PSAP mutations are a known cause of metachromatic leukodystrophy (MLD), a severe neurological disorder characterized by the progressive destruction of myelin sheaths in the central nervous system. The defective PSAP allele disrupts the function of galactocerebroside sulfatase (GALC) and other enzymes, leading to the accumulation of toxic sphingolipids and neuronal damage. \\boxed{Metachromatic Leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP allele is involved in the lysosomal storage disorder metachromatic leukodystrophy (MLD). PSAP, or prosaposin, is a precursor molecule essential for the proper formation of sphingolipid activator proteins, including GBA (beta-glucocerebrosidase), GBA2, and GALC (galactocerebrosidase). Mutations in PSAP lead to reduced levels of these enzymes, disrupting sphingolipid metabolism and causing the accumulation of toxic lipid derivatives in the central nervous system. This results in progressive demyelination and neurodegeneration. The pathway involving PSAP, GBA, GBA2, and GALC is crucial for maintaining myelin integrity. Defects in this pathway are linked to MLD, a severe inherited disorder characterized by intellectual disability, motor dysfunction, and ultimately, early childhood mortality. The biological effect of the PSAP allele is thus the disruption of sphingolipid catabolism, leading to MLD.\n\n\\boxed{Metachromatic Leukodystrophy}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein degradation and transcriptional regulation. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, resulting in the formation of toxic protein aggregates. This contributes to the pathogenesis of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive degeneration of the cerebellum and associated motor coordination deficits. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy, a cellular process that clears misfolded proteins and damaged organelles. Dysregulation of this pathway due to ATXN3 mutations impairs autophagic clearance, exacerbating neurotoxicity. Thus, the ATXN3 allele contributes to the development of \\boxed{Spinocerebellar Ataxia Type 2}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein degradation. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, resulting in the formation of toxic protein aggregates. This pathology is a hallmark of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is implicated in autophagy, a cellular process that degrades damaged proteins and organelles. Dysfunction in this pathway can impair autophagy, contributing to the accumulation of misfolded proteins and neuronal death. Thus, the ATXN3 allele contributes to the development of \\boxed{Spinocerebellar Ataxia Type 2}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein degradation. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, resulting in the formation of toxic protein aggregates. This is the hallmark of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive degeneration of the cerebellum and brainstem. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy, a cellular process that degrades damaged proteins and organelles. Impaired autophagy due to ATXN3 dysfunction contributes to the accumulation of misfolded proteins, exacerbating neurodegeneration. Thus, the ATXN3 allele contributes to \\boxed{Spinocerebellar ataxia type 2}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, leads to the formation of infectious prions. This pathway involves PRNP -> CAV1/2/3 -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS, indicating a role in oxidative stress and cellular signaling. The accumulation of misfolded prion proteins causes neurodegeneration by triggering oxidative stress, inflammation, and neuronal death. This process is central to the development of **Creutzfeldt-Jakob Disease (CJD)**, a rare and fatal transmissible spongiform encephalopathy. The pathway contributes to the pathogenesis of CJD by promoting oxidative damage and disrupting cellular homeostasis. The activation of NOX2 and the production of ROS further exacerbate neuronal injury. Mutations or misfolding in PRNP directly influence the disease's onset and progression. \\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, and its mutation or misfolding leads to the accumulation of abnormal prion proteins (PrP^Sc), which disrupt cellular homeostasis. This pathway involves caveolins, Fyn, PI3K, PRKCD, and NOX2, leading to increased ROS production. This oxidative stress and signaling disruption are linked to neurodegeneration. The biological effect of the PRNP allele is the formation of infectious prions, which cause spongiform encephalopathies. These diseases are characterized by neuronal loss and formation of amyloid plaques. The most well-known disease associated with PRNP mutations is Creutzfeldt-Jakob Disease (CJD), a rapidly progressive and fatal neurodegenerative disorder. \\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> CAV -> FYN -> PI3K -> PRKCD -> NOX2 -> ROS\nGenes in the pathway: PRNP; prion protein | CAV1; caveolin 1 | CAV2; caveolin 2 | CAV3; caveolin 3 | FYN; FYN proto-oncogene, Src family tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | PRKCD; protein kinase C delta | CYBB; cytochrome b-245 beta chain | CYBA; cytochrome b-245 alpha chain | NCF4; neutrophil cytosolic factor 4 | NCF1; neutrophil cytosolic factor 1 | NCF2; neutrophil cytosolic factor 2 | RAC1; Rac family small GTPase 1 | RAC2; Rac family small GTPase 2\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, whose misfolding leads to the conversion of normal prion proteins (PrP^C) into pathogenic forms (PrP^Sc). This pathological process is central to the development of transmissible spongiform encephalopathies (TSEs), a family of rare, fatal neurodegenerative diseases. The pathway described, starting from PRNP and involving downstream molecules such as CAV1/2/3, FYN, PI3K, PRKCD, and ultimately NOX2 and ROS production, highlights the role of oxidative stress and signaling cascades in disease progression. These mechanisms contribute to neuronal damage and apoptosis. The most well-known disease associated with PRNP mutations is Creutzfeldt-Jakob Disease (CJD), a prion disease characterized by rapid neurodegeneration. \\boxed{Creutzfeldt-Jakob Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS oncogene family, activates the PI3K-AKT pathway by promoting the conversion of PIP2 to PIP3, which in turn recruits AKT to the plasma membrane. Activated AKT inhibits BAD, a pro-apoptotic protein, thereby promoting cell survival and proliferation. Mutations in NRAS, such as gain-of-function mutations, lead to constitutive activation of this pathway, driving uncontrolled cell growth and resistance to apoptosis. This contributes to the development and progression of various cancers. Specifically, NRAS mutations are strongly associated with **melanoma**, where they are frequently found in tumors arising from melanocytes. These mutations are also implicated in **non-small cell lung cancer (NSCLC)** and **colorectal cancer**, among others. The persistent activation of the PI3K-AKT pathway through NRAS mutations disrupts normal cellular homeostasis, leading to tumor formation and malignant transformation. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to oncogenic signaling by promoting sustained activation of the PI3K/AKT pathway. This leads to inhibition of BAD, a pro-apoptotic protein, thereby preventing programmed cell death. This pathway is critical for cell survival, proliferation, and resistance to apoptosis. Mutations in NRAS, like KRAS, result in constitutive activation of downstream signaling, driving uncontrolled cell growth. This is a hallmark of several cancers. The most well-known disease associated with NRAS mutations is **Melanoma**, where activating mutations in NRAS are frequently observed. These mutations are also found in other malignancies, including certain leukemias and colorectal cancers. However, the most specific and common disease linked to NRAS mutations is \\boxed{Melanoma}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to oncogenesis by activating downstream signaling that promotes cell survival and proliferation. Mutations in NRAS, like KRAS, lead to constitutive activation of the PI3K/AKT pathway, resulting in the inactivation of BAD, a pro-apoptotic protein. This disrupts apoptosis and enhances cell survival, contributing to uncontrolled cell growth. This pathway is critical in several cancers, particularly those arising from cells of mesenchymal origin. The most well-known disease associated with NRAS mutations is **Melanoma**, where activating mutations in NRAS are commonly found. These mutations drive tumorigenesis by enhancing cell survival and proliferation. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein degradation and stress responses. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, resulting in the formation of toxic protein aggregates. This is a hallmark of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. In the given pathway, ATXN3 is part of the IP3 receptor complex, which regulates calcium release from the endoplasmic reticulum. Dysfunction in this pathway disrupts calcium homeostasis, contributing to neuronal damage. The accumulation of mutant ATXN3 protein leads to mitochondrial dysfunction, oxidative stress, and ultimately neuronal death. These processes are central to the pathogenesis of SCA2. Therefore, the biological effect of the ATXN3 allele is the development of \\boxed{Spinocerebellar Ataxia Type 2}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein degradation and neurodegeneration. In the given pathway, ATXN3 is part of the IP3 receptor complex, which regulates intracellular calcium levels. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, causing dysfunctional protein clearance and neuronal damage. This is a hallmark of spinocerebellar ataxia type 2 (SCA2), an autosomal dominant neurodegenerative disorder characterized by progressive loss of coordination and cerebellar atrophy. The disrupted calcium signaling and protein misfolding contribute to neuronal dysfunction and degeneration. Thus, the ATXN3 allele is directly linked to SCA2. \n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein quality control and RNA metabolism. Mutations in ATXN3, specifically expansions of the polyglutamine tract, lead to the accumulation of misfolded proteins and neuronal dysfunction. This is the genetic basis for spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. In the given pathway, ATXN3 is part of the IP3-sensitive calcium release channel complex, suggesting a role in intracellular calcium homeostasis, which is critical for neuronal function. Disruption of this pathway due to ATXN3 mutations contributes to the pathophysiology of SCA2 by impairing calcium signaling and protein homeostasis in neurons. \\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene encodes a tumor suppressor phosphatase that dephosphorylates PIP3, thereby inhibiting the PI3K-AKT signaling pathway. This pathway is critical for cell survival, proliferation, and growth. When PTEN is mutated or inactivated, PIP3 levels increase, leading to constitutive activation of AKT. This results in uncontrolled cell growth and resistance to apoptosis, contributing to tumorigenesis. The loss of PTEN function is commonly associated with various cancers, including breast, prostate, and endometrial cancers. One of the most well-characterized diseases linked to PTEN dysfunction is Cowden syndrome, a rare genetic disorder characterized by multiple benign and malignant tumors. Additionally, PTEN mutations are a key driver in the development of glioblastoma multiforme. Therefore, the biological effect of a pathogenic PTEN allele is the promotion of cancer, with a notable contribution to \\boxed{Cowden syndrome}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene functions as a tumor suppressor by dephosphorylating PIP3, thereby inhibiting the PI3K/AKT signaling pathway. When PTEN is mutated or inactivated, PIP3 accumulates, leading to constitutive activation of AKT. This results in uncontrolled cell proliferation, survival, and resistance to apoptosis. The dysregulation of this pathway is associated with various cancers. Specifically, loss-of-function mutations in PTEN are strongly linked to Cowden syndrome, a hereditary disorder that predisposes individuals to develop benign and malignant tumors, particularly in the breast, thyroid, uterus, and skin. The most well-documented cancer associated with PTEN dysfunction is **Breast Cancer**, but it also contributes to other malignancies such as Endometrial Cancer and Thyroid Cancer. \\boxed{Breast Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene functions as a phosphatase that dephosphorylates PIP3, thereby inhibiting the activation of AKT. This pathway is central to cell survival, growth, and proliferation. When PTEN is mutated or lost, PIP3 levels increase, leading to persistent activation of AKT. This results in uncontrolled cell growth and survival, contributing to tumor formation. The most well-known disease associated with PTEN dysfunction is Cowden syndrome, a rare genetic disorder characterized by multiple hamartomas and an increased risk of various cancers, including thyroid, endometrial, and breast cancer. Additionally, PTEN mutations are frequently observed in glioblastoma multiforme. The loss of PTEN function disrupts growth factor signaling, leading to malignant transformation. \\boxed{Cowden syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in ubiquitin-dependent protein degradation. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, resulting in the formation of toxic protein aggregates. This contributes to the pathogenesis of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive cerebellar ataxia, motor dysfunction, and cognitive decline. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 suggests a role in autophagy, which is impaired in neurodegenerative diseases. Impaired autophagy leads to the accumulation of misfolded proteins, exacerbating neuronal damage. Thus, the ATXN3 allele contributes to the development of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein degradation. Mutations in ATXN3 lead to the expansion of a polyglutamine tract, resulting in the formation of toxic protein aggregates. This contributes to the pathogenesis of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is linked to autophagy, a cellular process that clears damaged proteins and organelles. Impaired autophagy due to ATXN3 dysfunction exacerbates protein aggregation and neuronal toxicity. Thus, the ATXN3 allele contributes to the development of \\boxed{Spinocerebellar Ataxia Type 2}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein degradation. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, resulting in the formation of toxic protein aggregates. This pathology is a hallmark of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor function. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy, a cellular process that clears protein aggregates. Impairment of this pathway due to ATXN3 mutations disrupts autophagy, exacerbating the accumulation of misfolded proteins and neuronal damage. This contributes to the pathogenesis of SCA2. \n\n\\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex involved in the cleavage of the amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (AD). The pathway described, PSEN1 \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3, reflects a downstream stress response involving translation regulation and DNA damage. Impaired PSEN1 function disrupts APP processing, leading to increased amyloid-\u03b2 production and aggregation, hallmark features of Alzheimer's disease. This disruption also activates stress pathways that may exacerbate neurodegeneration. Therefore, PSEN1 mutations primarily contribute to Alzheimer's disease. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex involved in the cleavage of the amyloid precursor protein (APP), generating \u03b2-amyloid peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (FAD). The pathway described, PSEN1 \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3, reflects a signaling cascade implicated in stress response and protein translation. PSEN1 mutations disrupt this pathway, leading to impaired regulation of protein synthesis and increased neurotoxicity, contributing to neuronal dysfunction and neurodegeneration. This disruption is central to the pathogenesis of Alzheimer's disease. Therefore, the biological effect of this PSEN1 allele is the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PSEN1; presenilin 1 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating beta-amyloid peptides. Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (AD). The pathway described, PSEN1 \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3, reflects a signaling cascade linked to stress response and protein translation. Altered PSEN1 function disrupts this pathway, leading to impaired cellular homeostasis, increased neurotoxicity, and neuronal loss. These molecular disruptions are central to the pathogenesis of Alzheimer's disease. The accumulation of amyloid-beta plaques and neurofibrillary tangles, hallmarks of AD, are exacerbated by PSEN1 dysfunction. Thus, the biological effect of this PSEN1 allele is the development of Alzheimer's disease. \\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex. Mutations in PSEN1 are well-established causes of early-onset Alzheimer's disease. In the given pathway, PSEN1 interacts with ERN1 (endonoplasmic reticulum to nucleus signaling 1), which activates XBP1 (X-box binding protein 1), a key regulator of the unfolded protein response. Disruption of this pathway due to PSEN1 mutations can lead to impaired protein folding and cellular stress, contributing to neurodegeneration. These molecular changes are closely linked to the pathogenesis of Alzheimer's disease, characterized by amyloid-beta plaques and neurofibrillary tangles. Thus, the biological effect of this PSEN1 allele is the contribution to Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (AD). The pathway PSEN1 \u2192 ERN1 \u2192 XBP1 suggests a link between PSEN1 dysfunction and the unfolded protein response (UPR), as ERN1 (IRE1) is a key sensor of ER stress and activates XBP1 through splicing. Dysregulation of this pathway may exacerbate ER stress and neuronal dysfunction, contributing to neurodegeneration. Therefore, altered PSEN1 function is directly implicated in Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -| ERN1 -> XBP1\nGenes in the pathway: PSEN1; presenilin 1 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is essential for the processing of amyloid precursor protein (APP) and other substrates. The pathway PSEN1 \u2192 ERN1 \u2192 XBP1 suggests a connection between PSEN1 and the unfolded protein response (UPR), mediated through ERN1 (IRE1) and XBP1. Mutations in PSEN1 are well-established as the most common cause of early-onset familial Alzheimer's disease (AD). These mutations lead to increased production of amyloid-\u03b2 peptides, contributing to plaque formation and neurodegeneration. The involvement of ERN1 and XBP1 indicates a potential link between proteostasis disruption and neurodegeneration. Therefore, the biological effect of this PSEN1 allele is the contribution to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a key component of the autophagy pathway, particularly in the ubiquitin-proteasome system and the formation of autophagosomes. Mutations in SQSTM1 disrupt its role in targeting damaged proteins and mitochondria for degradation, leading to the accumulation of dysfunctional proteins and impaired mitochondrial quality control. This dysfunction is strongly associated with neurodegenerative processes. Specifically, SQSTM1 mutations contribute to Parkinson's disease by impairing the clearance of damaged mitochondria and aggregated proteins, leading to neuronal loss. The pathway involving PINK1 and PRKN is critical for mitophagy, and disruptions in SQSTM1 further exacerbate this process. Thus, SQSTM1 plays a pivotal role in maintaining cellular homeostasis, and its dysfunction is a key factor in the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a key player in the PINK1-PRKN mitochondrial quality control pathway. SQSTM1 acts as a scaffold for ubiquitin-binding and recruits autophagy machinery, facilitating the clearance of damaged mitochondria. Mutations in SQSTM1 disrupt this pathway, leading to impaired mitophagy and accumulation of dysfunctional mitochondria. This contributes to oxidative stress and neurodegeneration. SQSTM1 is implicated in Parkinson's disease, where its dysfunction impairs the removal of damaged mitochondria, exacerbating neuronal loss. Mutations in SQSTM1 have been associated with autosomal recessive Parkinsonism. The loss of SQSTM1 function disrupts the PINK1-PRKN pathway, leading to mitochondrial dysfunction and neurodegeneration. Therefore, SQSTM1 mutations contribute to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a key component of the autophagy pathway, involved in the recognition and degradation of damaged mitochondria through mitophagy. In the context of the provided pathway, SQSTM1 is positioned downstream of PINK1 and PRKN, which are crucial for mitochondrial quality control. Mutations in SQSTM1 disrupt autophagy and mitophagy, leading to the accumulation of dysfunctional mitochondria and cellular stress. This dysfunction is associated with neurodegeneration. Specifically, SQSTM1 mutations contribute to Parkinson's disease by impairing the clearance of damaged mitochondria in neurons, leading to oxidative stress and neuronal death. The impaired autophagy and mitochondrial dysfunction resulting from SQSTM1 defects are central to the pathogenesis of this neurodegenerative disorder.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT signaling cascade. Mutations in NRAS lead to constitutive activation of the RAS protein, which in turn promotes continuous PI3K activity, increasing PIP3 levels and subsequent AKT activation. This suppresses BAD, a pro-apoptotic protein, thereby inhibiting programmed cell death and promoting cell survival and proliferation. This pathway is critical in oncogenesis, as its dysregulation leads to uncontrolled cell growth and resistance to apoptosis. The biological effect of mutated NRAS is thus the promotion of tumor growth. This pathway is a key driver in several cancers, including melanoma, non-small cell lung cancer, and colorectal cancer. The most well-known disease associated with NRAS mutations is **melanoma**, particularly in cases with NRAS mutations. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to constitutive activation of the PI3K-AKT signaling cascade. This leads to inhibition of BAD, a pro-apoptotic protein, thereby promoting cell survival and proliferation. Mutations in NRAS, like KRAS, result in gain-of-function mutations that lock the protein in its active GTP-bound state, driving continuous signaling. This aberrant signaling is a hallmark of several cancers, particularly those of the melanoma, pancreatic, colorectal, and lung. Specifically, NRAS mutations are most commonly associated with **melanoma**, where they occur in approximately 10-20% of cases. These mutations contribute to uncontrolled cell growth and resistance to apoptosis, promoting tumor initiation and progression. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele in this pathway contributes to oncogenic signaling by activating the PI3K-AKT axis. NRAS, a RAS family GTPase, when mutated, becomes constitutively active, leading to continuous stimulation of PI3K. This results in increased PIP3 levels, which activate AKT. Activated AKT inhibits BAD, preventing apoptosis and promoting cell survival and proliferation. This pathway is critical in tumor progression. Mutations in NRAS are commonly found in melanomas, particularly those arising from sun-damaged skin. These mutations drive uncontrolled cell growth and resistance to apoptosis, contributing to the development and progression of malignant melanoma. The activation of this pathway is a hallmark of NRAS-driven cancers. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the described pathway, plays a critical role in regulating hypoxia-inducible gene expression. VHL, in complex with RBX1, ELOC, ELOB, and CUL2, forms an E3 ubiquitin ligase complex that targets EPAS1 for degradation under normoxic conditions. Under hypoxia, VHL is inactivated, stabilizing EPAS1, which then dimerizes with ARNT to drive the transcription of genes like VEGFA, CXCL8, GLUT1, and EPO. This pathway is central to the cellular response to low oxygen. Mutations in VHL disrupt this regulation, leading to constitutive activation of the pathway, promoting angiogenesis and cell survival. This contributes to the development of **clear cell renal cell carcinoma**. \n\n\\boxed{Clear cell renal cell carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, plays a critical role in the ubiquitin-mediated degradation of hypoxia-inducible factors (HIFs), specifically EPAS1. When VHL is functional, it prevents the stabilization of HIF-1\u03b1 and HIF-2\u03b1, which are essential for transcription of genes like VEGFA, CXCL8, GLUT1, and EPO. Inactivation of VHL leads to HIF stabilization, promoting angiogenesis, inflammation, and erythropoiesis. This dysregulation is a hallmark of hemangiomas and clear cell renal cell carcinomas. The VHL pathway's disruption is central to the pathogenesis of von Hippel-Lindau disease, characterized by benign and malignant tumors in multiple organs. The genetic defect in VHL contributes to the development of this hereditary cancer syndrome. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the described pathway, plays a critical role in cellular processes involving ubiquitin ligase complexes, particularly in the regulation of hypoxia-inducible factors (HIFs). The pathway involves genes such as VHL, RBX1, ELOC, ELOB, and CUL2, which form part of the cullin-RING ligase complex. This complex targets HIF-2\u03b1 (EPAS1) for degradation under normoxic conditions. When VHL is mutated, this degradation is impaired, leading to the stabilization of HIF-2\u03b1. HIF-2\u03b1 then dimerizes with ARNT, promoting the expression of genes like VEGFA, CXCL8, GLUT1, and EPO, which drive angiogenesis, inflammation, and erythropoiesis. This dysregulation is a hallmark of clear cell renal cell carcinoma (ccRCC). The VHL mutation disrupts this regulatory mechanism, leading to uncontrolled cell growth and tumor formation. \n\n\\boxed{Clear Cell Renal Cell Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN allele, encoding parkin, is critical for mitochondrial quality control. Mutations in PRKN disrupt mitophagy, the process of selective autophagy of damaged mitochondria, by impairing the interaction between parkin and mitofusins (MFN1/2), which are mitochondrial fusion proteins. This dysfunction leads to the accumulation of dysfunctional mitochondria, oxidative stress, and neuronal damage. These processes are central to neurodegenerative disorders. Mutations in PRKN are a well-established cause of autosomal recessive Parkinson's disease (PD). The loss of parkin function impairs the removal of impaired mitochondria from neurons, particularly in dopaminergic neurons, contributing to their degeneration. Therefore, the biological effect of this PRKN allele is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway, involving PRKN (parkin) and mitofusins MFN1 and MFN2, is critical for mitochondrial dynamics and quality control. PRKN functions as an E3 ubiquitin ligase, mediating the ubiquitination and degradation of damaged mitochondria through mitophagy. Mutations in PRKN disrupt this process, leading to the accumulation of dysfunctional mitochondria and oxidative stress. This dysfunction is strongly associated with neurodegeneration. The most well-known disease linked to PRKN mutations is Parkinson's disease. Loss-of-function variants in PRKN are a major genetic cause of early-onset Parkinson's, contributing to the loss of dopaminergic neurons. This pathway's role in mitophagy highlights its importance in maintaining neuronal health and preventing neurodegeneration. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for mitochondrial quality control. Its interaction with MFN1 and MFN2, which mediate mitochondrial fusion, highlights its role in maintaining mitochondrial integrity. Mutations in PRKN lead to loss of function, impairing mitochondrial dynamics and quality control. This results in the accumulation of damaged mitochondria, oxidative stress, and neuronal dysfunction. PRKN mutations are a well-documented cause of autosomal recessive Parkinson's disease. The loss of parkin function disrupts mitophagy, leading to neurodegeneration, particularly in dopamine-producing neurons. This genetic defect is strongly associated with early-onset Parkinson's disease. Therefore, the biological effect of the PRKN allele is the development of Parkinson's disease due to impaired mitochondrial homeostasis.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves the interaction between cyclins (CCND1-3) and CDK4, which phosphorylates RB1, leading to the release of E2F transcription factors. The biological effect of the CDK4 allele is the deregulation of the cell cycle by inactivating RB1, allowing unrestricted cell proliferation. This disruption is a key driver of uncontrolled cell division. Mutations or overexpression of CDK4 can lead to the loss of cell cycle control, promoting malignant transformation. This contributes to the development of cancers characterized by cell cycle dysregulation. The most well-documented disease associated with CDK4 activation is **Small Cell Lung Cancer (SCLC)**. CDK4 dysfunction is also implicated in other malignancies such as melanoma and breast cancer. \\boxed{Small Cell Lung Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 allele in this genomic pathway plays a critical role in cell cycle regulation by phosphorylating the retinoblastoma protein (RB1). This phosphorylation inactivates RB1, releasing E2F transcription factors to drive cells into S phase. Hyperactivation of CDK4, such as through amplification or mutation, leads to unchecked cell proliferation. This dysregulation is a hallmark of several cancers. Specifically, CDK4 overactivity is strongly associated with cancers like **retinoblastoma**, where RB1 inactivation is central. Additionally, CDK4 alterations contribute to **breast cancer**, **lung cancer**, and **prostate cancer**. The pathway's dysfunction promotes uncontrolled cell division, leading to tumor formation. Thus, the biological effect of the CDK4 allele is the promotion of **malignant cell growth**, most notably in **retinoblastoma** and other cancers. \n\n\\boxed{retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the interaction between cyclins (CCND1-3) and CDK4, leading to the phosphorylation of RB1, which in turn releases E2F transcription factors. This process drives cell cycle progression from G1 to S phase. The CDK4 allele, when mutated or overexpressed, can lead to aberrant phosphorylation of RB1, preventing its ability to inhibit E2F. This results in uncontrolled cell proliferation. Such dysregulation is a hallmark of several cancers, particularly those with defects in the Rb pathway. The most well-known disease associated with this pathway is **Retinoblastoma**, a childhood eye cancer. Mutations in CDK4 or loss of RB1 are frequently observed in retinoblastoma, promoting unchecked cell division and tumor formation. \\boxed{Retinoblastoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to constitutive activation of the PI3K-AKT-BAD signaling cascade. This leads to inhibition of BAD, a pro-apoptotic protein, thereby promoting cell survival and proliferation. Mutations in NRAS, like KRAS, result in uncontrolled signaling, driving cellular transformation. This pathway is critical in oncogenesis, particularly in cancers where RAS proteins are hyperactivated. The most common disease associated with NRAS mutations is **melanoma**, where activating mutations in NRAS are frequently observed. These mutations contribute to tumor initiation and progression by enhancing cell survival, proliferation, and resistance to apoptosis. Thus, NRAS mutations are strongly linked to **melanoma**. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT signaling cascade. Mutations in NRAS, like those in KRAS, lead to constitutive activation of downstream effectors, including AKT, which inhibits BAD, a pro-apoptotic protein. This results in resistance to apoptosis and uncontrolled cell proliferation. Such dysregulation is a hallmark of several cancers. Specifically, NRAS mutations are commonly found in melanoma, particularly in tumors arising from sun-damaged skin. They also contribute to other cancers such as bladder cancer, non-small cell lung cancer, and certain leukemias. The persistent activation of this pathway promotes tumor growth and progression by enhancing cell survival and proliferation. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT signaling cascade. This pathway is critical for cell survival, proliferation, and growth. Mutations in NRAS, like KRAS, lead to constitutive activation of downstream effectors, including AKT, which inhibits BAD, a pro-apoptotic protein. This results in resistance to apoptosis and uncontrolled cell growth. Such mutations are frequently observed in cancers where cell proliferation is dysregulated. The most well-known disease associated with NRAS mutations is **melanoma**, where activating mutations in NRAS drive tumor progression by enhancing cell survival and proliferation. These mutations are also implicated in other malignancies, including **non-small cell lung cancer** and **colorectal cancer**, depending on the tissue of origin. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene encodes a precursor protein essential for the proper folding and function of several lysosomal enzymes, including GBA, GBA2, and GALC. Mutations in PSAP can lead to impaired processing of these enzymes, resulting in their dysfunction. This contributes to the pathogenesis of metachromatic leukodystrophy (MLD), a rare inherited lysosomal storage disorder. MLD is characterized by the accumulation of sulfatides in the nervous system, leading to progressive neurological deterioration. The disease is caused by mutations in the GALC gene, but PSAP mutations can also play a role by affecting the activity of GBA and GBA2, which are involved in the breakdown of glycosphingolipids. Thus, PSAP mutations contribute to the biochemical and clinical manifestations of MLD.\n\n\\boxed{Metachromatic Leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene is involved in the biosynthesis of sphingolipids and is critical for the proper folding and function of lysosomal enzymes, including GBA, GBA2, and GALC. Mutations in PSAP can lead to impaired processing of these enzymes, resulting in their mislocalization and reduced activity. This dysfunction is particularly associated with Gaucher disease, where the absence or deficiency of GBA leads to the accumulation of glucosylceramide. PSAP deficiency can also cause metachromatic leukodystrophy (MLD), a neurodegenerative disorder caused by defects in GALC. However, PSAP is most notably linked to Gaucher disease, especially when combined with GBA mutations, contributing to a more severe phenotype. The PSAP allele's biological effect is thus central to the pathogenesis of Gaucher disease. \\boxed{Gaucher disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP allele is involved in lysosomal storage disorders due to its role in the biosynthesis of sphingolipid activator proteins. Mutations in PSAP lead to reduced production of enzymes like GBA, GBA2, and GALC, which are critical for lipid metabolism. This results in the accumulation of sphingolipids in lysosomes, causing cellular dysfunction. The most notable disease associated with PSAP mutations is metachromatic leukodystrophy (MLD). MLD is a rare, inherited neurodegenerative disorder characterized by the progressive loss of myelin in the central and peripheral nervous systems. The disease arises from the defective breakdown of glycosphingolipids, leading to inflammation and demyelination. The pathway involving PSAP, GBA, GBA2, and GALC is essential for maintaining proper lipid homeostasis, and disruptions in this pathway directly contribute to the pathogenesis of MLD.\n\n\\boxed{Metachromatic Leukodystrophy}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, starting from MET to BAD, plays a critical role in cell survival and proliferation. Activation of MET leads to the phosphorylation of GAB1, which in turn activates PI3K. PI3K generates PIP3, which recruits and activates AKT. AKT then inhibits BAD, preventing its pro-apoptotic function. This pathway promotes cell survival by suppressing apoptosis. Mutations or overactivation of MET, such as in PIK3CA or AKT genes, can lead to uncontrolled cell growth. This contributes to the development of cancers characterized by enhanced cell survival and resistance to apoptosis. The most significant disease associated with this pathway is non-small cell lung cancer (NSCLC), where MET amplification or mutation is commonly observed. \\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway drives cell proliferation, survival, and migration. Activation of MET leads to phosphorylation of GAB1, which activates PI3K. PI3K generates PIP3, which recruits and activates AKT. Activated AKT inhibits BAD, preventing apoptosis. This promotes cell survival and uncontrolled growth. Mutations or overactivation of MET, such as through amplification or mutations in PIK3CA/PIK3CB/PIK3CD, lead to constitutive pathway activation. This contributes to tumor progression. The pathway is frequently dysregulated in cancers, particularly in non-small cell lung cancer (NSCLC), gastric cancer, and renal cell carcinoma. The MET-driven signaling enhances oncogenesis by suppressing apoptosis and stimulating cell proliferation. The biological effect of MET allele activation is therefore a key contributor to cancer development. \\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GAB1; GRB2 associated binding protein 1 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway promotes cell survival and proliferation by activating downstream signaling through GAB1, PI3K, PIP3, and AKT, which inhibits BAD and prevents apoptosis. Mutations or amplifications in MET can lead to constitutive activation of this pathway, driving uncontrolled cell growth. This contributes to the development and progression of several cancers. Specifically, MET alterations are strongly associated with non-small cell lung cancer (NSCLC), particularly in patients with adenocarcinoma, and are also implicated in metastasis and resistance to therapy. Additionally, MET dysregulation is observed in renal cell carcinoma, gastric cancer, and other malignancies. The sustained activation of the PI3K-AKT axis due to MET aberrations results in enhanced cell survival, angiogenesis, and invasion, all of which are hallmarks of cancer. \\boxed{Non-small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or dysregulated, leads to the constitutive activation of the BCR-ABL oncoprotein. This activation drives the downstream signaling cascade involving CRKL, CBL, and CRK, which in turn activates PI3K. The PI3K pathway generates PIP3, which recruits and activates AKT. Activated AKT inhibits BAD, preventing apoptosis and promoting cell survival and proliferation. This pathway is central to the development of chronic myeloid leukemia (CML). The most well-known mutation is the Philadelphia chromosome translocation, t(9;22), which fuses BCR to ABL1, resulting in uncontrolled cell growth. This contributes to the pathogenesis of CML. \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or overactive, leads to the constitutive activation of the BCR-ABL oncoprotein. This activates downstream signaling through CRKL, CBL, and CRK, leading to the activation of PI3K and its product PIP3. This results in the activation of AKT, which inhibits BAD, preventing apoptosis. This pathway is critical for cell survival and proliferation. The uncontrolled activation of this pathway contributes to unregulated cell growth and resistance to apoptosis, hallmarks of cancer. This is most notably associated with Chronic Myeloid Leukemia (CML), where the Philadelphia chromosome results in the fusion of BCR and ABL1 genes, creating the BCR-ABL tyrosine kinase. The continuous activation of this pathway drives leukemic transformation. \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> (CRKL+CBL+CRK) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | CRKL; CRK proto-oncogene, adaptor protein | CBL; Cbl proto-oncogene | CRK; CRK proto-oncogene, adaptor protein | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or overactive, leads to the constitutive activation of the BCR-ABL oncoprotein. This results in the aberrant activation of downstream signaling pathways, including CRKL, CBL, and CRK, which in turn activate PI3K. The PI3K pathway produces PIP3, which recruits and activates AKT. Activated AKT inhibits BAD, preventing apoptosis and promoting cell survival and proliferation. This pathway is central to the development of chronic myeloid leukemia (CML), caused by the Philadelphia chromosome translocation (t(9;22)), which fuses BCR to ABL1. This fusion protein drives uncontrolled cell growth and is a hallmark of CML. The pathway also contributes to other diseases, but the most characteristic and well-defined is \\boxed{Chronic Myeloid Leukemia}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitochondrial quality control through the ubiquitination and degradation of damaged mitochondria via autophagy (mitophagy). Mutations in PRKN lead to impaired mitophagy, resulting in the accumulation of dysfunctional mitochondria and increased oxidative stress. This contributes to neurodegeneration. The most well-known disease associated with PRKN mutations is Parkinson's disease. Loss-of-function mutations in PRKN are linked to autosomal recessive early-onset Parkinson's disease. The disruption of the PRKN pathway leads to neuronal loss, particularly in the substantia nigra, a hallmark of Parkinson's disease. Therefore, the biological effect of this PRKN allele is the contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway involves the ubiquitination of PLCG1, which affects IP3 production and subsequent Ca\u00b2\u207a release via ITPR channels. Mutations in PRKN, a key E3 ubiquitin ligase, disrupt this pathway, leading to impaired regulation of intracellular calcium. This dysfunction is associated with neurodegeneration, particularly in Parkinson\u2019s disease. PRKN mutations cause loss of function, contributing to mitochondrial dysfunction, oxidative stress, and neuronal death. This pathway is crucial for mitophagy, the degradation of damaged mitochondria. Defects in this process lead to the accumulation of dysfunctional mitochondria, exacerbating neurodegeneration. PRKN mutations are linked to autosomal recessive early-onset Parkinsonism. Thus, the biological effect of this PRKN allele is the development of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway plays a critical role in regulating intracellular calcium levels through the PLCG1-IP3-ITPR cascade. PRKN, also known as parkin, functions as an E3 ubiquitin ligase, promoting the ubiquitination and degradation of proteins involved in this pathway. Mutations in PRKN lead to impaired calcium signaling, disrupting mitochondrial quality control and neuronal function. This disruption is strongly associated with Parkinson's disease, as PRKN mutations cause the accumulation of damaged mitochondria and neuronal death, particularly in dopaminergic neurons. The loss of PRKN function disrupts the ubiquitin-proteasome system, leading to oxidative stress and neurodegeneration. Thus, PRKN mutations contribute to the pathogenesis of Parkinson's disease by impairing calcium homeostasis and mitochondrial health. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to the formation of infectious prions. In the context of the pathway PRNP \u2192 NOTCH1, the interaction suggests a potential regulatory or signaling role of PRNP in NOTCH1 activity. Mutations in PRNP are most famously associated with prion diseases, such as Creutzfeldt-Jakob disease (CJD). These mutations can cause abnormal prion protein folding, leading to neurodegeneration through toxic gain-of-function. The pathway implication may highlight a role for NOTCH1 in modulating prion-related pathology. The most direct disease associated with PRNP mutations is \\boxed{Creutzfeldt-Jakob disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. The pathway PRNP \u2192 NOTCH1 suggests a regulatory interaction where PRNP may influence NOTCH1 signaling. Mutations in PRNP are most famously associated with Creutzfeldt-Jakob Disease (CJD), a rare, fatal brain disorder caused by abnormal prion proteins. These mutations can also contribute to other prion diseases, such as Gerstmann-Str\u00e4ussler-Scheinker syndrome (GSS) and fatal familial insomnia (FFI). The interaction with NOTCH1 may modulate cell proliferation and differentiation, and dysregulation of this pathway could contribute to neuronal dysfunction. Thus, the biological effect of this PRNP allele is the development of prion-related neurodegenerative disorders. \n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to the conversion of normal prion protein (PrP^C) into the pathological form (PrP^Sc). This misfolding triggers a cascade of protein aggregation and neuronal damage, leading to neurodegenerative diseases. The pathway PRNP \u2192 NOTCH1 suggests a potential interaction where PRNP may influence NOTCH1 signaling, which is critical for cell differentiation and neurogenesis. Dysregulation of this pathway is implicated in several neurodegenerative conditions. Specifically, mutations in PRNP are a well-known cause of **Creutzfeldt-Jakob Disease (CJD)**, a fatal prion disease characterized by rapid progressive dementia and neuronal loss. The interaction with NOTCH1 may further exacerbate neuronal dysfunction and disease progression. \\boxed{Creutzfeldt-Jakob Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the described pathway, plays a critical role in regulating hypoxia-inducible factors (HIFs) through the VHL-RBX1-Elongin C/B-CUL2 E3 ubiquitin ligase complex. Under normoxic conditions, VHL promotes the ubiquitination and degradation of HIF-1\u03b1. Mutations in VHL disrupt this process, leading to HIF-1\u03b1 stabilization and activation of downstream genes such as VEGFA, CXCL8, GLUT1, and EPO. This results in abnormal angiogenesis, erythropoiesis, and metabolic changes. These molecular alterations are hallmarks of a wide range of tumors, particularly those with hypoxic microenvironments. The most well-characterized disease associated with VHL mutations is **Von Hippel-Lindau disease**, a hereditary cancer syndrome characterized by the development of various tumors, including renal cell carcinomas, hemangioblastomas, and pheochromocytomas. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, plays a critical role in ubiquitin-mediated proteasomal degradation of hypoxia-inducible factors (HIFs), specifically HIF-1\u03b1 and HIF-2\u03b1. When VHL is mutated or inactivated, this degradation process is impaired, leading to the stabilization and accumulation of HIFs. This results in the aberrant activation of HIF target genes such as VEGFA, CXCL8, GLUT1, and EPO, which drive angiogenesis, cell survival, and erythropoiesis. This pathway is central to the pathogenesis of clear cell renal cell carcinoma (ccRCC), a common subtype of kidney cancer. VHL mutations are a hallmark of ccRCC, making it the most frequent hereditary cancer syndrome associated with VHL gene alterations. The loss of VHL function disrupts cellular responses to hypoxia and contributes to tumor progression through the dysregulation of angiogenic and metabolic pathways.\n\n\\boxed{Clear Cell Renal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, plays a critical role in the ubiquitin-mediated degradation of hypoxia-inducible factors (HIFs), such as EPAS1 and ARNT. When VHL is mutated, this degradation is impaired, leading to the stabilization and accumulation of HIFs. This results in the aberrant activation of HIF target genes, including VEGFA, CXCL8, GLUT1, and EPO. These genes drive angiogenesis, inflammation, and erythropoiesis, contributing to the development of hemangiomas and promoting tumor angiogenesis. Mutations in VHL are well-known for causing Von Hippel-Lindau (VHL) disease, a hereditary disorder characterized by the formation of benign and malignant tumors in various organs. The pathway described is central to the pathogenesis of this disease. \\boxed{Von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, specifically the expanded CAG repeat associated with Huntington's disease, contributes to neurodegeneration by disrupting normal synaptic function and calcium homeostasis. The pathway involves NMDA receptors (GRIN1, GRIN2A-D) and the mitochondrial calcium uniporter (MCU), which regulate mitochondrial calcium levels. Dysregulation leads to mitochondrial dysfunction, permeability transition pore (MPTP) opening, and release of cytochrome c (CYCS), activating APAF1 and downstream caspases (CASP9, CASP3), driving apoptosis. This results in neuronal loss, particularly in the striatum and cortex. The HTT mutation thus directly contributes to the pathogenesis of \\boxed{Huntington's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction is central to Huntington\u2019s disease. Mutations in HTT, specifically expansions of the CAG trinucleotide repeat, lead to the production of an aberrant huntingtin protein that forms toxic aggregates. This disrupts neuronal function, particularly in the striatum and cortex, leading to neurodegeneration. The described pathway highlights the role of NMDA receptors (GRIN1, GRIN2A-D), calcium influx through MCU, mitochondrial calcium overload, and subsequent activation of the mitochondrial permeability transition pore (MPTP), releasing cytochrome c and initiating apoptosis via APAF1, CASP9, and CASP3. These mechanisms underlie neuronal death in Huntington\u2019s disease. The HTT mutation thus directly contributes to the pathogenesis of this neurodegenerative disorder.\n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* // DLG4 -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: HTT; huntingtin | DLG4; discs large MAGUK scaffold protein 4 | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT (huntington disease) allele is associated with Huntington's disease. This genetic disorder is caused by an expansion of CAG repeats in the HTT gene, leading to the production of an abnormal huntingtin protein. The pathway described involves NMDA receptors (GRIN1, GRIN2A-D), calcium influx, mitochondrial calcium uptake via MCU and VDACs, release of cytochrome c (CYCS), activation of APAF1, and subsequent activation of caspase-9 (CASP9) and caspase-3 (CASP3), which mediate apoptosis. This apoptotic cascade contributes to neuronal degeneration, particularly in the striatum and cerebral cortex, which are hallmark features of Huntington's disease. The accumulation of mutant huntingtin disrupts calcium homeostasis and mitochondrial function, leading to neurotoxicity and progressive neurodegeneration. \n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit, critical for repolarizing cell membranes, particularly in neurons and cardiac tissue. Mutations in KCNC3 disrupt normal ion flow, leading to hyperexcitability and arrhythmias. Specifically, gain-of-function mutations in KCNC3 are associated with **severe early repolarization syndrome**, a proarrhythmic condition that increases the risk of ventricular tachycardia and sudden cardiac death. This genetic alteration affects the heart's electrical stability by altering action potential duration, contributing to life-threatening arrhythmias. Patients with such mutations may present with syncope, palpitations, or sudden cardiac arrest. KCNC3-related diseases highlight the critical role of potassium channels in maintaining cardiac rhythm and underscore the importance of genetic screening in high-risk populations. \\boxed{Early Repolarization Syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit, which plays a critical role in regulating neuronal excitability by modulating action potential duration. Mutations in KCNC3 can disrupt normal potassium channel function, leading to abnormal neuronal firing. This contributes to hyperexcitability and can result in neurological disorders. Specifically, pathogenic variants in KCNC3 are associated with **epilepsy**, particularly **early-onset epileptic encephalopathy**. These mutations impair repolarization of neurons, causing recurrent seizures and developmental delays. The altered ion flux disrupts normal brain activity, highlighting the gene's essential role in maintaining electrochemical balance in neurons. \\boxed{Epilepsy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: K+ // KCNC3* // K+(extracellular)\nGenes in the pathway: KCNC3; potassium voltage-gated channel subfamily C member 3\n\nGiven this context, what is the biological effect of this KCNC3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KCNC3 gene encodes a voltage-gated potassium channel subunit, which plays a critical role in repolarizing neurons and regulating action potential duration. Mutations in KCNC3 have been linked to neurological disorders. Specifically, variants in KCNC3 contribute to **epilepsy**, particularly **idiopathic generalized epilepsy (IGE)**. These mutations can lead to altered ion channel function, disrupting neuronal excitability and increasing susceptibility to seizures. KCNC3 is also implicated in **febrile seizures** and may contribute to **early-onset epileptic encephalopathies**. The genetic disruption affects neuronal membrane potential, leading to hyperexcitability and seizure generation. Thus, the biological effect of pathogenic KCNC3 alleles is the increased risk of developing **epilepsy**. \n\n\\boxed{Epilepsy}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves PRKN (parkin), which ubiquitinates PLCG1, leading to the regulation of IP3 receptors (ITPR1-3) and subsequent release of Ca\u00b2\u207a. Mutations in PRKN disrupt this ubiquitination, leading to accumulation of PLCG1 and increased IP3 receptor activity, causing excessive Ca\u00b2\u207a release. This dysregulation is associated with neuronal dysfunction and oxidative stress. The most well-known disease linked to PRKN mutations is Parkinson's Disease. Mutations in PRKN are a major cause of dominant-inherited Parkinson's, particularly in early-onset cases. These mutations impair mitochondrial quality control by preventing the ubiquitination and degradation of damaged mitochondria, leading to neurodegeneration. Therefore, the biological effect of a pathogenic PRKN allele is the disruption of mitochondrial homeostasis, contributing to the development of Parkinson's Disease.\n\n\\boxed{Parkinson's Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in the ubiquitination and degradation of proteins, including the regulation of calcium signaling through the PLCG1-IP3-ITPR cascade. Mutations in PRKN lead to impaired degradation of Parkin, disrupting mitochondrial quality control and calcium homeostasis. This results in mitochondrial dysfunction and neuronal death, particularly in the substantia nigra, a brain region critical for motor control. These effects are hallmarked by the accumulation of damaged mitochondria and the loss of dopaminergic neurons. This pathway is central to Parkinson's disease (PD), where PRKN mutations contribute to the pathogenesis by promoting neurodegeneration. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN allele, encoding parkin, is critical in mitochondrial quality control through ubiquitin-mediated degradation of damaged mitochondria. Mutations in PRKN disrupt this process, leading to the accumulation of dysfunctional mitochondria and increased oxidative stress. This contributes to neuronal loss, particularly in dopaminergic neurons, which is characteristic of Parkinson's disease. The pathway involving PLCG1, IP3, and ITPR receptors is involved in calcium signaling, which is essential for neuronal function and survival. Disruption of this pathway due to PRKN dysfunction exacerbates neurodegeneration. Therefore, PRKN mutations are a key genetic contributor to Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can cause neurodegenerative diseases. In the given pathway, PRNP is upstream of HSPA5, EIF2AK3, EIF2S1, ATF4, and DDIT3, suggesting a role in stress response and protein folding. Mutations in PRNP, particularly those leading to misfolded prion protein (PrP^Sc), are directly associated with Creutzfeldt-Jakob disease (CJD), a fatal neurodegenerative disorder. The pathway likely reflects the cellular stress response triggered by prion-related toxicity. The accumulation of abnormal prion proteins leads to neuronal damage and disease progression. This pathway is central to the pathogenesis of prion diseases. The biological effect of the PRNP allele, particularly pathogenic variants, is the development of Creutzfeldt-Jakob disease.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which plays a critical role in protein misfolding and aggregation. In the given pathway, PRNP negatively regulates BIP (HSPA5), which is involved in protein folding and the unfolded protein response. BIP modulates EIF2AK3, a kinase that phosphorylates EIF2S1, inhibiting protein translation. This inhibition leads to the activation of ATF4, which upregulates DDIT3, a gene involved in cellular stress responses and apoptosis. Mutations in PRNP can lead to misfolded prion proteins, triggering neurodegeneration. This pathway is central to prion diseases, where the accumulation of misfolded PRNP leads to neuronal damage. The biological effect of a pathogenic PRNP allele is the development of **Creutzfeldt-Jakob disease (CJD)**, a fatal neurodegenerative disorder caused by prion protein misfolding.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: PRNP; prion protein | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. In the given pathway, PRNP is upstream of BIP (HSPA5), which is involved in protein folding and stress response. The pathway continues through EIF2AK3, EIF2S1, ATF4, and finally DDIT3, all of which are implicated in the unfolded protein response and stress-induced gene regulation. Mutations in PRNP can cause prion diseases, such as Creutzfeldt-Jakob disease (CJD), through the formation of pathogenic prions. These misfolded proteins accumulate in the brain, leading to neuronal damage and progressive dementia. The pathway highlights the role of PRNP in protein homeostasis and its contribution to neurodegeneration when disrupted. \n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the \u03b11A subunit of the Cav1.1 calcium channel, which is critical for voltage-gated calcium entry in neurons. The pathway described involves extracellular calcium influx through this channel, contributing to intracellular calcium signaling. Mutations in CACNA1A are associated with impaired calcium homeostasis, leading to neurodevelopmental and neurodegenerative disorders. Specifically, this gene is implicated in familial hemiplegic migraine (FHM), a rare inherited condition characterized by severe migraines with hemiplegic symptoms. Additionally, CACNA1A mutations are linked to cerebellar ataxia, episodic ataxia type 2 (EA2), and certain forms of epilepsy. These conditions arise from disrupted calcium signaling in neurons, affecting synaptic transmission and neuronal excitability. The biological effect of the CACNA1A allele is thus a key contributor to calcium-dependent neurological disorders.\n\n\\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel. This channel is critical for calcium influx into neurons, playing a key role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with impaired calcium homeostasis, leading to hyperexcitability of neurons and disrupted synaptic transmission. This contributes to neurodevelopmental and neurological disorders. Specifically, CACNA1A mutations are a well-documented cause of familial hemiplegic migraine (FHM), a genetically inherited form of migraine with brainstem involvement and motor weakness. The altered calcium signaling disrupts normal neuronal function, leading to the characteristic clinical manifestations of FHM. \\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) -- CACNA1A* -> Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel. This channel is critical for neuronal excitability and neurotransmitter release. Mutations in CACNA1A are associated with impaired calcium influx, leading to disrupted neuronal signaling. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, mutations in CACNA1A are a known cause of familial hemiplegic migraine (FHM), a genetic disorder characterized by recurrent migraine attacks with aura and motor weakness. Additionally, CACNA1A mutations are linked to cerebellar ataxia and other neurological conditions. The altered calcium dynamics resulting from dysfunctional CACNA1A lead to hyperexcitability and impaired synaptic transmission, contributing to the pathophysiology of these diseases. \n\n\\boxed{Familial Hemiplegic Migraine}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 pathway is central to innate immune responses, particularly in the recognition of cytosolic DNA and the induction of antiviral states. TBK1 activates IRF3, leading to the production of type I interferons, and also plays a role in autophagy by interacting with proteins like OPTN, SQSTM1, and NBR1, which are involved in autophagosome formation and cargo recognition. Mutations in TBK1 disrupt these processes, impairing antiviral defense and autophagy. This contributes to chronic inflammatory conditions and susceptibility to viral infections. Specifically, TBK1 variants are associated with Crohn's disease, an inflammatory bowel disease, due to impaired regulation of immune responses and autophagy. These genetic defects lead to persistent inflammation and tissue damage. \\boxed{Crohn's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TBK1 gene is central to the autophagy pathway, interacting with proteins such as SQSTM1, OPTN, and NBR1, which are involved in the recruitment of autophagosomes. The pathway also involves LC3-II, a marker of autophagosome formation. Mutations in TBK1 disrupt this pathway, leading to impaired autophagy and the accumulation of damaged cellular components. This dysfunction is associated with neuroinflammation and neuronal loss. TBK1 mutations are linked to neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The loss of TBK1 function impairs the clearance of misfolded proteins and damaged mitochondria, contributing to neuronal toxicity. Thus, TBK1 mutations contribute to the pathogenesis of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: TBK1* // (SQSTM1,OPTN,NDP52,TAX1BP1,NBR1) == LC3-II\nGenes in the pathway: TBK1; TANK binding kinase 1 | SQSTM1; sequestosome 1 | OPTN; optineurin | CALCOCO2; calcium binding and coiled-coil domain 2 | TAX1BP1; Tax1 binding protein 1 | NBR1; NBR1 autophagy cargo receptor | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this TBK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves TBK1 and its interaction with proteins like SQSTM1, OPTN, NDP52, TAX1BP1, and NBR1, all of which are critical for autophagy and innate immune responses, particularly in response to viral infections and cellular stress. TBK1 plays a key role in the activation of IRF3, leading to the production of type I interferons. Mutations or dysfunction in this pathway impair antiviral defense and autophagy. This contributes to diseases characterized by chronic inflammation and impaired immune response. Specifically, mutations in TBK1 and its interacting partners are associated with **Autoinflammatory Disease**, including **Dyskeratosis Congenita** and other inflammatory conditions. The disruption of this pathway leads to defective clearance of pathogens and accumulation of damaged proteins, driving inflammation and cellular dysfunction. \\boxed{Autoinflammatory Disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA lead to the aggregation of alpha-synuclein into Lewy bodies, which are hallmark pathological features of Parkinson's disease. These aggregates disrupt neuronal function and contribute to the degeneration of dopaminergic neurons in the substantia nigra. The pathway also includes components of complex I of the electron transport chain, suggesting a link between mitochondrial dysfunction and neurodegeneration. This interplay between SNCA and mitochondrial complex I subunits underlines the role of oxidative stress and impaired energy metabolism in Parkinson's pathology. The cumulative effect of these genetic and metabolic disturbances results in progressive neurodegeneration. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA lead to the aggregation of alpha-synuclein, forming Lewy bodies, which are a hallmark of Parkinson's disease. These aggregations disrupt neuronal function and contribute to the progressive degeneration of dopaminergic neurons in the substantia nigra. The pathway listed includes genes involved in mitochondrial complex I, suggesting a link between mitochondrial dysfunction and neurodegeneration. This connection aligns with the role of alpha-synuclein in impairing mitochondrial function, further supporting its contribution to Parkinson's disease pathology. The interplay between SNCA and mitochondrial components highlights a critical mechanism in disease progression. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| CxI -> Q\nGenes in the pathway: SNCA; synuclein alpha | ND1; NADH dehydrogenase, subunit 1 (complex I) | ND2; MTND2 | ND3; NADH dehydrogenase, subunit 3 (complex I) | ND4; NADH dehydrogenase, subunit 4 (complex I) | ND5; NADH dehydrogenase, subunit 5 (complex I) | ND6; NADH dehydrogenase, subunit 6 (complex I) | NDUFS1; NADH:ubiquinone oxidoreductase core subunit S1 | NDUFS2; NADH:ubiquinone oxidoreductase core subunit S2 | NDUFS3; NADH:ubiquinone oxidoreductase core subunit S3 | NDUFS4; NADH:ubiquinone oxidoreductase subunit S4 | NDUFS5; NADH:ubiquinone oxidoreductase subunit S5 | NDUFS6; NADH:ubiquinone oxidoreductase subunit S6 | NDUFS7; NADH:ubiquinone oxidoreductase core subunit S7 | NDUFS8; NADH:ubiquinone oxidoreductase core subunit S8 | NDUFV1; NADH:ubiquinone oxidoreductase core subunit V1 | NDUFV2; NADH:ubiquinone oxidoreductase core subunit V2 | NDUFV3; NADH:ubiquinone oxidoreductase subunit V3 | NDUFA1; NADH:ubiquinone oxidoreductase subunit A1 | NDUFA2; NADH:ubiquinone oxidoreductase subunit A2 | NDUFA3; NADH:ubiquinone oxidoreductase subunit A3 | NDUFA4; NDUFA4 mitochondrial complex associated | NDUFA5; NADH:ubiquinone oxidoreductase subunit A5 | NDUFA6; NADH:ubiquinone oxidoreductase subunit A6 | NDUFA7; NADH:ubiquinone oxidoreductase subunit A7 | NDUFA8; NADH:ubiquinone oxidoreductase subunit A8 | NDUFA9; NADH:ubiquinone oxidoreductase subunit A9 | NDUFA10; NADH:ubiquinone oxidoreductase subunit A10 | NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1 | NDUFA11; NADH:ubiquinone oxidoreductase subunit A11 | NDUFA12; NADH:ubiquinone oxidoreductase subunit A12 | NDUFA13; NADH:ubiquinone oxidoreductase subunit A13 | NDUFB1; NADH:ubiquinone oxidoreductase subunit B1 | NDUFB2; NADH:ubiquinone oxidoreductase subunit B2 | NDUFB3; NADH:ubiquinone oxidoreductase subunit B3 | NDUFB4; NADH:ubiquinone oxidoreductase subunit B4 | NDUFB5; NADH:ubiquinone oxidoreductase subunit B5 | NDUFB6; NADH:ubiquinone oxidoreductase subunit B6 | NDUFB7; NADH:ubiquinone oxidoreductase subunit B7 | NDUFB8; NADH:ubiquinone oxidoreductase subunit B8 | NDUFB9; NADH:ubiquinone oxidoreductase subunit B9 | NDUFB10; NADH:ubiquinone oxidoreductase subunit B10 | NDUFB11; NADH:ubiquinone oxidoreductase subunit B11 | NDUFC1; NADH:ubiquinone oxidoreductase subunit C1 | NDUFC2; NADH:ubiquinone oxidoreductase subunit C2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or increased expression of SNCA lead to abnormal aggregation of alpha-synuclein, forming Lewy bodies, which are a hallmark of Parkinson's disease. These aggregates disrupt neuronal function, particularly in the substantia nigra, leading to the progressive loss of dopaminergic neurons. This results in motor symptoms such as tremors, rigidity, and bradykinesia. The pathway includes components of mitochondrial complex I, suggesting a link between energy metabolism and neurodegeneration. The presence of SNCA in this pathway highlights its role in mitochondrial dysfunction, which is a key factor in Parkinson's pathology. The accumulation of alpha-synuclein is both a cause and a consequence of mitochondrial dysfunction, amplifying neuronal damage. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1, plays a critical role in protecting cells from oxidative stress and maintaining mitochondrial function. Its interaction with DAXX and ASK1 activates the JNK signaling pathway, which is involved in apoptosis and cellular stress responses. Mutations in PARK7 are associated with impaired mitochondrial function and increased oxidative stress, leading to neuronal degeneration. This contributes to the pathogenesis of Parkinson's disease. Loss-of-function mutations in PARK7 disrupt its protective role, making neurons more susceptible to damage, particularly in the substantia nigra. As a result, PARK7 mutations are linked to early-onset Parkinson's disease. The dysfunction of this pathway impairs the clearance of misfolded proteins and increases susceptibility to neurotoxicity. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1, is part of a pathway involving DAXX and ASK1, which activates JNK. Mutations in PARK7 are associated with an increased risk of Parkinson's disease. The DJ1 protein plays a role in protecting neurons from oxidative stress and has chaperone-like functions. Loss-of-function mutations in PARK7 disrupt these protective mechanisms, leading to neuronal degeneration, a hallmark of Parkinson's disease. This pathway's disruption contributes to the pathogenesis of Parkinson's by promoting apoptosis and inflammation in dopaminergic neurons. Therefore, the biological effect of the PARK7 allele is its contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // (DAXX+ASK1) -> JNK\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | DAXX; death domain associated protein | MAP3K5; mitogen-activated protein kinase kinase kinase 5 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ-1, is involved in a pathway that includes DAXX and ASK1, leading to activation of JNK. This pathway is critical for cellular stress responses and apoptosis. Mutations in PARK7 are associated with impaired protein degradation and increased oxidative stress, contributing to neuronal damage. The specific allele in question is linked to Parkinson's disease. Loss-of-function mutations in PARK7 disrupt its protective role against oxidative stress and protein misfolding, leading to neurodegeneration, particularly in dopaminergic neurons. This contributes to the pathogenesis of Parkinson's disease. The biological effect of the PARK7 allele is therefore a key factor in the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele in the BRAF -> MEK -> ERK pathway contributes to the activation of the MAPK/ERK signaling cascade, which regulates cell proliferation, survival, and differentiation. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of this pathway, driving uncontrolled cell growth. This results in the development and progression of various cancers. Notably, BRAF mutations are strongly associated with melanoma, where they are found in approximately 50% of cases. Additionally, BRAF mutations contribute to other cancers, including colorectal, thyroid, and lung cancers. The sustained activation of ERK due to mutated BRAF leads to oncogenic transformation, making it a key target for therapeutic intervention in these diseases. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele, specifically mutations in the BRAF gene, contribute to the activation of the BRAF-MEK-ERK signaling pathway. This pathway plays a critical role in cell proliferation, differentiation, and survival. Mutations in BRAF, such as the V600E substitution, result in constitutive activation of the BRAF kinase, leading to uncontrolled cell growth and inhibition of apoptosis. This dysregulation is a key driver in several cancers. The most well-known disease associated with BRAF mutations is melanoma, particularly in cutaneous melanoma, where BRAF mutations are found in approximately 40-50% of cases. Additionally, BRAF mutations are also implicated in other malignancies, including thyroid, colon, and lung cancers. The persistent activation of the MAPK/ERK pathway due to BRAF mutations promotes tumor progression and resistance to therapy. Therefore, the biological effect of this BRAF allele is the activation of the MAPK/ERK pathway, which contributes to the development and progression of melanoma.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a critical signaling cascade involved in cell proliferation, differentiation, and survival. The BRAF gene encodes a serine/threonine kinase that activates MEK, which in turn phosphorylates ERK, leading to downstream effects on gene expression and cell cycle progression. Mutations in BRAF, particularly the V600E activating mutation, result in constitutive activation of the MAPK/ERK pathway, driving uncontrolled cell growth. This aberrant signaling is a key driver in several cancers. The most well-known disease associated with BRAF mutations is **melanoma**, where the V600E mutation is present in approximately 50% of cases. BRAF mutations also contribute to other malignancies, including colorectal, thyroid, and lung cancers. The persistent activation of the ERK pathway due to BRAF mutations promotes tumor initiation and progression by enhancing cell survival and angiogenesis. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT (adenine phosphoribosyltransferase) gene is involved in the purine salvage pathway, catalyzing the conversion of adenine to inosine monophosphate (IMP). Mutations in APRT can lead to a deficiency in this enzyme, resulting in the accumulation of adenine and its metabolites, which are toxic to cells. This accumulation primarily affects the kidneys, leading to the formation of adenine nucleotide crystals and subsequent kidney damage. The most common disease associated with APRT deficiency is Lesch-Nyhan syndrome, a rare X-linked recessive disorder characterized by neurological abnormalities, self-injurious behavior, and hyperuricemia. However, in cases where only one copy of the APRT gene is mutated (heterozygous state), the condition may manifest as a milder form of hyperuricemia and kidney stones. The specific biological effect of the APRT allele is therefore central to the pathogenesis of Lesch-Nyhan syndrome and related metabolic disorders. \\boxed{Lesch-Nyhan syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT (adenine phosphoribosyltransferase) gene plays a critical role in the purine salvage pathway, converting adenine to inosine monophosphate (IMP). Mutations in APRT can lead to reduced activity of the enzyme, resulting in the accumulation of adenine and its metabolites, such as 2,6-diaminopurine (DAP), which is toxic to cells. This accumulation is particularly harmful to the central nervous system, leading to neurodegeneration. The most well-documented disease associated with APRT deficiency is Lesch-Nyhan syndrome, an X-linked recessive disorder characterized by neurological abnormalities, self-harming behavior, and metabolic disturbances. The defective APRT allele disrupts purine metabolism, contributing to the pathophysiology of this rare genetic disorder. \\boxed{Lesch-Nyhan syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 16\nNetwork Definition of the pathway: Adenine // APRT*\nGenes in the pathway: APRT; adenine phosphoribosyltransferase\n\nGiven this context, what is the biological effect of this APRT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APRT (adenine phosphoribosyltransferase) gene is involved in the purine salvage pathway, catalyzing the conversion of adenine to inosine monophosphate (IMP). Mutations in APRT can lead to reduced activity of the enzyme, resulting in the accumulation of adenine and its derivatives, such as 2,6-diaminopurine, which can cause neurological damage. This genetic defect contributes to Lesch-Nyhan syndrome, a rare X-linked recessive disorder characterized by neurological abnormalities, self-injurious behaviors, and uric aciduria. The disease arises from mutations in the APRT gene, leading to impaired purine metabolism and subsequent toxic accumulation of adenine and related compounds. The most common mutation is a deletion in the APRT gene, which disrupts the enzyme's function. This condition primarily affects males due to X-linked inheritance. \\boxed{Lesch-Nyhan syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a key tumor suppressor that regulates cell cycle progression by inhibiting E2F transcription factors. The pathway definition RB1* // E2F suggests a regulatory interaction where RB1 modulates E2F activity. Loss-of-function mutations in RB1 lead to uncontrolled cell proliferation by allowing E2F-dependent genes to drive cell cycle entry. This dysregulation is a hallmark of retinoblastoma, a pediatric eye cancer. Additionally, RB1 mutations are implicated in various other cancers, including small cell lung cancer, osteosarcoma, and bladder cancer. The most directly associated disease with RB1 mutations is retinoblastoma, a bilateral intraocular malignancy primarily affecting children. Mutations in RB1 disrupt the cell cycle checkpoint, leading to genomic instability and tumor formation. \\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a key tumor suppressor that regulates cell cycle progression by inhibiting E2F transcription factors. The pathway RB1 // E2F illustrates the interaction between RB1 and E2F family members, which control the expression of genes involved in DNA replication and cell division. When RB1 is functional, it binds to and inactivates E2F, preventing cells from entering S phase. Mutations in RB1 disrupt this regulation, leading to unchecked cell proliferation. This is a hallmark of retinoblastoma, a childhood eye cancer. Loss of RB1 function also contributes to other cancers, including small cell lung cancer and bone tumors. The specific disease most directly associated with RB1 mutations is retinoblastoma. \n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: RB1* // E2F\nGenes in the pathway: RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this RB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RB1 gene encodes the retinoblastoma protein, a key tumor suppressor that regulates cell cycle progression by inhibiting E2F transcription factors. When RB1 is mutated or lost, it leads to uncontrolled cell proliferation. The pathway involving RB1 and E2F transcription factors is critical in preventing unregulated cell division. Loss of functional RB1 results in dysregulation of E2F activity, promoting excessive cell growth. This contributes to the development of retinoblastoma, a rare childhood eye cancer, and also increases the risk of other cancers, including small cell lung cancer and bone sarcomas. The most directly associated disease is retinoblastoma. \n\n\\boxed{Retinoblastoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nATXN3 is a key component of the poly-Q tract in the ataxin-3 protein. Mutations in ATXN3, particularly expansions of the poly-glutamine tract, lead to the formation of toxic protein aggregates, disrupting cellular function. This pathology is central to spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. In the provided pathway, ATXN3 is implicated in the calcium signaling cascade, where its dysfunction may perturb mitochondrial calcium homeostasis, contributing to neuronal damage. The interaction with ITPR1 and MCU suggests a role in calcium dysregulation, which is a common feature in neurodegenerative diseases. Therefore, the biological effect of the ATXN3 allele is the development of \\boxed{Spinocerebellar ataxia type 2}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein quality control and transcriptional regulation. Mutations in ATXN3, specifically expansions of the polyglutamine tract, lead to the formation of toxic protein aggregates, disrupting cellular function. This is the genetic cause of Spinocerebellar Ataxia Type 2 (SCA2), a neurodegenerative disorder characterized by progressive coordination difficulties, ataxia, and cognitive decline. In the context of the provided pathway, ATXN3 is linked to calcium signaling via its interaction with ITPR1 and other components, suggesting a role in mitochondrial calcium homeostasis. Dysregulation of this pathway contributes to neuronal dysfunction and cell death, which is central to the pathogenesis of SCA2. The expansion of the polyglutamine tract in ATXN3 is the primary genetic determinant of this disease. \\boxed{Spinocerebellar Ataxia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein degradation and transcriptional regulation. In the provided pathway, ATXN3 is linked to the IP3-Ca\u00b2+ signaling cascade, which regulates mitochondrial calcium levels and contributes to the mitochondrial permeability transition pore (MPTP) opening. Mutations in ATXN3 cause **spinocerebellar ataxia type 2 (SCA2)**, an inherited neurological disorder characterized by progressive loss of coordination. SCA2 is caused by expansions of the CAG trinucleotide repeat in the ATXN3 gene, leading to gain-of-function toxicity. The disease results in neurodegeneration, particularly in cerebellar and brainstem neurons, manifesting as ataxia, dysarthria, and ophthalmoplegia. The pathway highlights the role of calcium dysregulation and mitochondrial dysfunction in disease progression. \\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 inhibits BIP, which in turn inhibits ATF6, leading to reduced activation of DDIT3. SOD1 is a key enzyme that catalyzes the dismutation of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway described suggests a role for SOD1 in cellular stress response and protein folding, as BIP and ATF6 are involved in the unfolded protein response. Impaired function of SOD1 can lead to oxidative stress and neuronal damage, contributing to the pathogenesis of ALS. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway SOD1 \u2192 BIP \u2192 ATF6 \u2192 DDIT3 involves SOD1, a copper/zinc superoxide dismutase, which catalyzes the conversion of superoxide radicals into oxygen and hydrogen peroxide. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by the progressive loss of motor neurons. The pathway suggests a link between oxidative stress, endoplasmic reticulum (ER) stress, and cellular stress responses, all of which are implicated in ALS pathology. The activation of ATF6 and subsequent upregulation of DDIT3 (a stress-inducible gene) highlight the cell's attempt to manage proteotoxic stress. Therefore, the SOD1 allele contributes to the development of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 activates BIP, which in turn activates ATF6, leading to the expression of DDIT3. SOD1 encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. These mutations lead to the accumulation of misfolded proteins and cellular stress, contributing to neuronal death. The pathway described, involving SOD1, BIP, ATF6, and DDIT3, reflects the cellular stress response and protein quality control mechanisms that are disrupted in ALS. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene functions as a tumor suppressor by dephosphorylating PIP3, thereby inhibiting the activation of AKT. This pathway is critical for regulating cell growth, survival, and proliferation. Loss-of-function mutations in PTEN lead to increased PIP3 levels and sustained AKT activation, promoting uncontrolled cell growth. This dysfunction is strongly associated with the development of various cancers. Specifically, PTEN mutations are a key driver in the pathogenesis of Cowden syndrome, a hereditary disorder characterized by an increased risk of benign and malignant tumors, particularly in the breast, thyroid, and skin. Additionally, PTEN inactivation is frequently observed in cancers such as glioblastoma, endometrial cancer, and prostate cancer. The loss of PTEN function thus contributes to the hallmark features of these diseases by disrupting growth control mechanisms. \\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene functions as a tumor suppressor by inhibiting the PI3K-AKT signaling pathway. It dephosphorylates PIP3, converting it back to PIP2, thereby reducing AKT activation. Loss or mutation of PTEN leads to constitutive activation of AKT, promoting cell survival, proliferation, and resistance to apoptosis. This dysregulation is implicated in various cancers. Specifically, PTEN mutations are commonly associated with Cowden syndrome, a hereditary condition that increases the risk of developing certain cancers, including breast, thyroid, and endometrial cancers. Additionally, PTEN dysfunction is a key driver in glioblastoma multiforme and other malignancies. The loss of PTEN function disrupts normal cellular growth control, contributing to tumorigenesis. \\boxed{Cowden syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PTEN* // PIP3 -> AKT\nGenes in the pathway: PTEN; phosphatase and tensin homolog | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3\n\nGiven this context, what is the biological effect of this PTEN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PTEN gene encodes a tumor suppressor phosphatase that negatively regulates the PI3K-AKT signaling pathway by dephosphorylating PIP3, thereby inhibiting AKT activation. When PTEN is mutated or inactivated, PIP3 levels increase, leading to constitutive activation of AKT. This promotes cell survival, proliferation, and resistance to apoptosis. The loss of PTEN function is associated with a wide range of human cancers, most notably **Cowden syndrome** and **clear cell renal cell carcinoma ( RCC)**. It is also a key contributor to **breast cancer**, **prostate cancer**, and **glioblastoma multiforme**. Mutations in PTEN are frequently observed in multiple tumor types, making it one of the most significant tumor suppressor genes in oncogenesis. The loss of PTEN function disrupts cellular homeostasis, leading to uncontrolled cell growth and tumor formation.\n\n\\boxed{Cowden syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can trigger a cascade leading to neurodegeneration. In the given pathway, PRNP activates NMDARs, leading to increased mitochondrial Ca\u00b2+ influx via MCU, promoting the mitochondrial permeability transition pore (MPTP) opening. This results in the release of cytochrome c, activating APAF1 and CASP9, ultimately inducing apoptosis via CASP3. This pathway is central to neuronal death. Mutations in PRNP, particularly those causing misfolding, are directly linked to **Creutzfeldt-Jakob disease (CJD)**, a rare, rapidly progressive, and fatal neurodegenerative disorder. The pathway highlights how PRNP dysfunction disrupts calcium homeostasis and triggers apoptosis, contributing to the pathogenesis of CJD.\n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which plays a role in the pathway leading to neuronal damage through NMDA receptor activation, mitochondrial calcium dysregulation, and apoptosis. The pathway begins with PRNP, which interacts with NMDAR (via GRIN1, GRIN2A-D), leading to an influx of Ca2+. Excess calcium triggers the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channels (VDACs), causing mitochondrial calcium overload. This activates the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS), which activates APAF1 and initiates the intrinsic apoptotic pathway via CASP9 and CASP3. This process is central to neurodegeneration. Mutations in PRNP, particularly those promoting misfolding and prion formation, are directly linked to **Creutzfeldt-Jakob Disease (CJD)**, a fatal neurodegenerative disorder. \n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, leads to the formation of pathogenic prions. In the given pathway, PRNP is the initiating node, suggesting its role in triggering a cascade involving NMDA receptors, calcium influx, mitochondrial calcium uptake via MCU, and subsequent mitochondrial permeability transition pore (MPTP) opening. This leads to the release of cytochrome c, activation of APAF1, and initiation of apoptosis via CASP9 and CASP3. This pathway is central to neuronal damage and cell death. The misfolding and aggregation of PRNP are directly associated with Creutzfeldt-Jakob disease (CJD), a rapidly progressive and fatal neurodegenerative disorder caused by prion protein misfolding. The described pathway aligns with the neurodegenerative mechanisms observed in CJD. \\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, as part of the described genomic pathway, is involved in the regulation of apoptosis. SOD1, a copper/zinc superoxide dismutase, is primarily associated with the conversion of superoxide radicals into hydrogen peroxide. Mutations in SOD1 are well-documented as a major cause of amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by the progressive loss of motor neurons. In the context of the pathway, SOD1 mutations can lead to increased oxidative stress and mitochondrial dysfunction, promoting apoptotic pathways through the BCL2-BAX/BAK1-CYCS-APAF1-CASP9-CASP3 cascade. This results in neuronal death, contributing to the hallmark pathology of ALS. The accumulation of misfolded SOD1 proteins also disrupts cellular homeostasis, further exacerbating neurodegeneration. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, as part of the described apoptotic pathway, contributes to the regulation of cell death. SOD1, a copper/zinc superoxide dismutase, typically protects cells from oxidative stress by converting superoxide radicals into hydrogen peroxide. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. In the context of the pathway, SOD1 may influence mitochondrial function and apoptosis through its interaction with BCL2, BAX, BAK1, and the subsequent release of cytochrome c, leading to caspase activation and neuronal cell death. This pathway dysfunction is a key mechanism in the pathogenesis of ALS. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with the production of superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. In the provided pathway, SOD1 is upstream of BCL2, a key regulator of apoptosis. Mutations in SOD1, particularly in the context of its role in oxidative stress, are well-documented in amyotrophic lateral sclerosis (ALS). The pathway suggests that SOD1 may influence apoptosis through interactions with BCL2 and subsequent activation of the mitochondrial apoptotic cascade involving BAX, BAK1, CYCS, APAF1, CASP9, and CASP3. This indicates that dysfunctional SOD1 can lead to neurodegeneration by promoting apoptosis in motor neurons. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when activated, initiates a signaling cascade starting with MET, leading through GRB2, SOS, RAS, RAF, MEK, and ultimately ERK to CCND1. This pathway is critical for cell growth, survival, and proliferation. Activation of MET can lead to increased expression of cyclin D1 (CCND1), promoting cell cycle progression. Mutations or overexpression of MET can result in constitutive activation of this pathway, driving uncontrolled cell growth. This contributes to the development of various cancers, particularly those involving mesenchymal tissues. The most well-documented disease associated with MET activation is non-small cell lung cancer (NSCLC), where MET mutations or amplifications are frequently observed. Additionally, MET dysregulation is implicated in other malignancies, including colorectal, gastric, and hepatocellular carcinomas. Therefore, the biological effect of this MET allele is oncogenic, contributing to cancer development. \\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway is a key signaling cascade involved in cell proliferation, survival, and migration. Activation of the MET proto-oncogene leads to downstream activation of the RAS-RAF-MEK-ERK cascade, culminating in the upregulation of CCND1, a cyclin that drives cell cycle progression. Mutations or overexpression of MET can result in constitutive activation of this pathway, leading to uncontrolled cell growth. This dysregulation is associated with several cancers, including non-small cell lung cancer, gastric cancer, and hepatocellular carcinoma. The MET pathway is also implicated in metastasis and resistance to therapy. Specifically, MET-driven oncogenesis contributes to the development of **metastatic cancer**, particularly in the context of **liver and lung cancers**. The activation of this pathway through genetic alterations such as amplification or mutation of MET is a hallmark of these malignancies.\n\n\\boxed{Metastatic cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway is critical in cell growth, survival, and differentiation. When MET is altered, it can lead to constitutive activation of downstream signaling, including the RAS-RAF-MEK-ERK cascade, which promotes cell proliferation and inhibits apoptosis. This dysregulation is commonly associated with various cancers. Specifically, aberrant MET activation contributes to the development and progression of non-small cell lung cancer (NSCLC), gastric cancer, and other malignancies. MET-driven oncogenesis is often linked to poor prognosis and resistance to therapy. Mutations or amplifications in MET can drive tumor growth by enhancing downstream signaling through GRB2, SOS, RAS, and the RAF-MEK-ERK pathway, ultimately leading to uncontrolled cell proliferation and tumor formation. \\boxed{Non-small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase crucial for protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with Parkinson's disease (PD). These mutations lead to impaired ubiquitination and degradation of misfolded proteins, including alpha-synuclein, contributing to neurodegeneration. The pathway involving PRKN and monoamine oxidases (MAO A and B) suggests a role in dopamine metabolism, as MAO enzymes break down monoamines like dopamine. Dysregulation of this pathway may exacerbate oxidative stress and neuronal loss in PD. Therefore, the PRKN allele contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase involved in ubiquitin-dependent protein catabolism. Its role in the pathway MAO -> DOPAL suggests involvement in monoamine metabolism, particularly dopamine. Mutations in PRKN are associated with Parkinson's disease, as parkin dysfunction leads to the accumulation of damaged mitochondria and protein aggregates, contributing to neuronal degeneration. PRKN mutations impair the ubiquitination and degradation of proteins, including alpha-synuclein, exacerbating neurodegeneration. This genetic contribution is a key factor in the pathogenesis of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase involved in protein degradation via the ubiquitin-proteasome pathway. Mutations in PRKN are associated with impaired mitophagy, the selective degradation of damaged mitochondria. This dysfunction leads to the accumulation of dysfunctional mitochondria, oxidative stress, and neuronal loss. These processes are central to the pathogenesis of Parkinson's disease. The pathway described includes MAO enzymes (MAOA and MAOB), which metabolize monoamines like dopamine. Alterations in this pathway can affect dopamine metabolism, further contributing to neurodegeneration. The PRKN allele's biological effect is thus a key contributor to Parkinson's disease. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cellular response to DNA damage and stress, promoting apoptosis, cell cycle arrest, and DNA repair. Mutations in TP53 disrupt these functions, leading to genomic instability. The listed genes (CDKN1A, GADD45, BAX, BAK1, DDB2, POLK) are downstream effectors of p53, involved in cell cycle regulation, DNA repair, and apoptosis. When TP53 is mutated, these genes are not properly activated, impairing the cell's ability to respond to DNA damage. This results in unchecked cell proliferation and resistance to apoptosis, which are hallmarks of cancer. Consequently, TP53 mutations are strongly associated with a wide range of cancers, most notably \\boxed{Li-Fraumeni syndrome} and various solid tumors such as breast, ovarian, and lung cancers.", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cellular responses to DNA damage and stress, regulating cell cycle arrest, DNA repair, and apoptosis. The listed genes, including CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, are all downstream targets of p53, playing roles in cell cycle regulation, DNA repair, and programmed cell death. Mutations in TP53 disrupt this pathway, leading to loss of tumor suppression. This contributes to uncontrolled cell proliferation and genomic instability. TP53 mutations are among the most common genetic alterations in human cancers. The accumulation of these mutations leads to the development and progression of various malignancies. The most well-known disease associated with TP53 dysfunction is Li-Fraumeni syndrome, a hereditary cancer syndrome characterized by a high risk of multiple cancers, including sarcomas, breast cancer, and brain tumors. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cellular stress responses, DNA repair, and apoptosis. Mutations in TP53 disrupt its function, leading to impaired cell cycle regulation and failure to induce apoptosis in damaged cells. This results in genomic instability and unchecked cell proliferation. The listed genes\u2014CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK\u2014are all downstream effectors of TP53, involved in cell cycle arrest, DNA repair, and apoptosis. Dysregulation of this pathway is a hallmark of many cancers. Specifically, TP53 mutations are strongly associated with Li-Fraumeni syndrome and are found in a wide range of human malignancies, including osteosarcoma, breast cancer, and ovarian cancer. The cumulative effect of TP53 dysfunction is the promotion of tumorigenesis through loss of tumor suppression. \\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this genomic pathway is associated with the production of amyloid-beta (Abeta), which triggers a cascade leading to mitochondrial dysfunction, calcium dysregulation, and ultimately apoptosis. This pathway is central to neurodegenerative processes. Mutations in APP are well-documented in Alzheimer's disease, where they contribute to the accumulation of Abeta plaques, mitochondrial calcium overload, and cell death via the intrinsic apoptotic pathway involving cytochrome c release, APAF1, and caspase activation. The involvement of genes like GRM5, GNAQ, PLCB, ITPR, MCU, and the mitochondrial permeability transition pore (MPTP) further underscores the role of intracellular calcium homeostasis in neuronal damage. These molecular mechanisms are implicated in the pathogenesis of Alzheimer's disease. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes a cascade starting from the **APP** gene, leading to the production of **amyloid-beta (Abeta)**, which triggers a series of events culminating in **mitochondrial calcium uptake**, **mitochondrial permeability transition pore (MPTP) opening**, and ultimately **apoptosis via caspase activation**. This pathway is central to **neurodegeneration**. The accumulation of **amyloid-beta** is a hallmark of **Alzheimer's disease**, where it leads to mitochondrial dysfunction, oxidative stress, and neuronal death. The involvement of **GRM5**, **GNAQ**, **PLCB**, **IP3**, **MCU**, and the **mitochondrial cascade** underscores its role in **neurodegeneration**. The downstream activation of **CASP9** and **CASP3** further confirms the apoptotic pathway. Therefore, mutations or dysregulation in this **APP-dependent pathway** are strongly associated with **Alzheimer's disease**.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> GRM5 -> GNAQ -> PLCB -> IP3 -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this pathway is the production of amyloid-beta (Abeta), which initiates a cascade leading to mitochondrial dysfunction, calcium dysregulation, and ultimately apoptosis. This pathway is central to neurodegenerative processes. The accumulation of Abeta disrupts calcium homeostasis by increasing mitochondrial calcium uptake via MCU, leading to the opening of the mitochondrial permeability transition pore (MPTP). This triggers the release of cytochrome c, activating the apoptotic cascade via APAF1 and caspases 9 and 3. This mechanism is strongly associated with Alzheimer's disease. Mutations in APP that enhance Abeta production or aggregation are known to contribute to the pathogenesis of Alzheimer's. The pathway reflects the link between amyloid pathology and neuronal death in this disease. \n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, leads to the formation of infectious prions. These misfolded proteins trigger a cascade of events starting with the activation of RYR/ITPR receptors, leading to calcium release from the endoplasmic reticulum. Excess calcium enters mitochondria via MCU, inducing mitochondrial permeability transition pore (MPTP) opening. This results in cytochrome c release, activating APAF1 and CASP9, which ultimately activate CASP3, causing apoptosis. This pathway is critical in prion diseases. The PRNP allele associated with disease leads to misfolding and aggregation of the prion protein, disrupting calcium homeostasis and triggering apoptosis. This contributes to the development of **Creutzfeldt-Jakob disease (CJD)**, a rare, fatal neurodegenerative disorder. \n\n\\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can trigger neurodegenerative processes. In the given pathway, PRNP initiates a cascade involving ryanodine receptors (RYR1-3) and inositol 1,4,5-trisphosphate receptors (ITPR1-3), leading to the release of calcium ions (Ca2+). This calcium influx activates the mitochondrial calcium uniporter (MCU), increasing mitochondrial calcium levels. Excess mitochondrial calcium can lead to the opening of the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS) and activating APAF1 and caspase-9, ultimately triggering apoptosis via caspase-3. This pathway is closely associated with neuronal cell death. Mutations in PRNP, particularly those causing misfolding of the prion protein, are linked to **Creutzfeldt-Jakob Disease (CJD)**, a rare, fatal neurodegenerative disorder.\n\n\\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> (RYR,ITPR) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PRNP; prion protein | RYR1; ryanodine receptor 1 | RYR2; ryanodine receptor 2 | RYR3; ryanodine receptor 3 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can trigger neurodegenerative processes. In the given pathway, PRNP is linked to ryanodine receptors (RYR) and inositol 1,4,5-trisphosphate receptors (ITPR), which regulate calcium release from the endoplasmic reticulum. This calcium then enters mitochondria via the mitochondrial calcium uniporter (MCU), leading to mitochondrial permeability transition pore (MPTP) opening. This disrupts mitochondrial function, causing cytochrome c release, activation of apoptotic factors like APAF1, CASP9, and ultimately CASP3, leading to cell death. This pathway is central to neuronal apoptosis. The PRNP allele, particularly when harboring pathogenic mutations, contributes to the misfolding and aggregation of prion protein, initiating this cascade. This is a hallmark of **Creutzfeldt-Jakob disease (CJD)**, a fatal neurodegenerative disorder. \n\n\\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is implicated in amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally detoxifies superoxide radicals. Mutations in SOD1 lead to the production of toxic protein aggregates, which contribute to motor neuron degeneration. The pathway described involves the ubiquitin-proteasome system, where SOD1 is ubiquitinated and directed to the proteasome for degradation. Dysfunction in this pathway, including impaired proteasomal degradation of misfolded SOD1, results in protein accumulation and neurotoxicity. This process is central to the pathogenesis of ALS. Mutations in SOD1 account for approximately 10-20% of familial ALS cases. The involvement of proteasome subunits (e.g., PSMA and PSMB) underscores the role of proteasomal dysfunction in disease progression. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes protein ubiquitination and proteasomal degradation. SOD1, a copper/zinc superoxide dismutase, when mutated, leads to the production of misfolded proteins that accumulate and cause neurodegeneration. This pathway is central to protein quality control. Mutations in SOD1 are a well-documented cause of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease characterized by the progressive loss of motor neurons. The aberrant protein aggregation and dysfunction in the ubiquitin-proteasome system contribute to neuronal death. Therefore, the biological effect of the SOD1 allele in this context is the pathogenesis of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes ubiquitination and proteasomal degradation. SOD1, when misfolded or mutated, can lead to the accumulation of toxic protein aggregates. This is a key mechanism in neurodegenerative diseases. The pathway described involves the ubiquitin-proteasome system (UPS), where SOD1 is ubiquitinated and targeted for degradation by the 26S proteasome. Mutations in SOD1 are known to cause Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disorder characterized by the progressive loss of motor neurons. The dysfunction in the UPS contributes to the accumulation of mutant SOD1, leading to neuronal toxicity. Therefore, the biological effect of this SOD1 allele is the development of a neurodegenerative disease due to protein misfolding and impaired degradation. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cellular processes such as proliferation, differentiation, and survival. It is activated by ligands from the neuregulin (NRG) family, including NRG1-4. Mutations or dysregulation of ERBB4 can lead to aberrant signaling, contributing to oncogenic processes. ERBB4 is frequently amplified or overexpressed in various cancers, including breast, ovarian, and non-small cell lung cancer. Additionally, ERBB4 has been implicated in neurodevelopmental disorders, such as autism spectrum disorder, due to its role in brain development. However, the most well-documented disease associated with ERBB4 dysfunction is breast cancer. \\boxed{Breast Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cell growth, differentiation, and survival. It is activated by ligands such as neuregulins (NRG1\u20134). Mutations or dysregulation of ERBB4 can lead to aberrant signaling, contributing to various diseases. Specifically, ERBB4 has been implicated in the development and progression of cancers, including non-small cell lung cancer (NSCLC), breast cancer, and glioblastoma. Additionally, ERBB4 has been associated with neurodevelopmental disorders, such as autism spectrum disorder (ASD), due to its role in neuronal development. However, the most well-documented disease linked to ERBB4 dysregulation is breast cancer, where it contributes to tumorigenesis and metastasis. \\boxed{Breast Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in signal transduction pathways, particularly those involving neuregulins (NRG1-4). Activation of ERBB4 by its ligands leads to cellular processes such as proliferation, differentiation, and survival. Dysregulation of ERBB4, such as through gain-of-function mutations or overexpression, can disrupt normal developmental and physiological processes. This contributes to the pathogenesis of several diseases, including certain types of cancer. Specifically, ERBB4 alterations are associated with non-small cell lung cancer (NSCLC), where they can promote tumor growth and resistance to therapy. Additionally, ERBB4 has been implicated in neurological disorders, though its most well-documented pathological contribution is in cancer. The biological effect of aberrant ERBB4 is therefore primarily linked to oncogenic processes. \\boxed{Non-small cell lung cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, through its pathway HTT \u2192 MLK2 \u2192 MKK7 \u2192 JNK, is involved in the mitogen-activated protein kinase (MAPK) signaling cascade. Mutations in HTT are associated with Huntington's disease, a neurodegenerative disorder caused by expansion of CAG repeats in the HTT gene. The mutant huntingtin protein disrupts cellular processes, including protein degradation and transcription, leading to neuronal death. The pathway described contributes to neuronal stress and apoptosis, which exacerbates the progression of the disease. The activation of JNK, a stress-activated kinase, is implicated in neurotoxicity and is a key pathway in the pathogenesis of Huntington's disease. Therefore, the biological effect of the HTT allele in this pathway is central to the development and progression of \\boxed{Huntington's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, through its interaction with MLK2, MKK7, and downstream JNK activation, contributes to neurodegenerative processes. Mutations in HTT, particularly expansions of the CAG repeat, lead to the production of mutant huntingtin protein, which disrupts cellular signaling pathways, including the JNK cascade. This disruption is implicated in neuronal death and the progressive loss of motor function. The most well-characterized disease associated with this pathway is Huntington's disease. The accumulation of toxic huntingtin protein interferes with protein clearance and disrupts synaptic function, ultimately leading to neurodegeneration. This pathway's involvement highlights the role of aberrant signaling in disease progression. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -> MLK2 -> MKK7 -> JNK\nGenes in the pathway: HTT; huntingtin | MAP3K10; mitogen-activated protein kinase kinase kinase 10 | MAP2K7; mitogen-activated protein kinase kinase 7 | MAPK8; mitogen-activated protein kinase 8 | MAPK9; mitogen-activated protein kinase 9 | MAPK10; mitogen-activated protein kinase 10\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, through its interaction with the pathway HTT \u2192 MLK2 \u2192 MKK7 \u2192 JNK, is implicated in neurodegenerative processes. Mutations in HTT, particularly those leading to expanded CAG repeats, cause Huntington's disease. This expansion results in the production of a toxic form of the huntingtin protein, which disrupts cellular functions, including protein degradation and mitochondrial health. The downstream pathway involving MLK2, MKK7, and JNK is involved in stress response and apoptosis, contributing to neuronal death. The accumulation of mutant huntingtin leads to progressive degeneration of neurons, particularly in the striatum and cerebral cortex. This results in motor, cognitive, and psychiatric symptoms. The pathway highlights the role of aberrant protein signaling in disease progression. \n\n\\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cell proliferation, differentiation, and survival. It is activated by ligands such as NRG1-4, which are members of the neuregulin family. Mutations or dysregulation of ERBB4 can lead to aberrant signaling, contributing to various diseases. One notable condition associated with ERBB4 dysfunction is **schizophrenia**. Genetic studies have linked variants in ERBB4 to an increased risk of schizophrenia, likely due to its role in neural development and synaptic plasticity. Additionally, ERBB4 has been implicated in certain cancers, such as non-small cell lung cancer and breast cancer, where its overactivation can drive tumor growth. However, based on the pathway definition and the focus on NRG ligands, the most direct association is with **schizophrenia**. \n\n\\boxed{Schizophrenia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a crucial role in cell growth, differentiation, and survival. It is activated by neuregulins (NRG1\u20134), which bind to its ligand-binding domain. Mutations or dysregulation of ERBB4 can disrupt these signaling pathways, leading to abnormal cellular processes. ERBB4 is implicated in several diseases, including cancer. Specifically, aberrant ERBB4 signaling contributes to the development and progression of non-small cell lung cancer (NSCLC), where it promotes tumor growth and resistance to therapy. Additionally, ERBB4 has been associated with neurological disorders, such as schizophrenia, due to its role in synaptic plasticity. However, its most well-documented pathological contribution is in oncogenesis. \\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cell signaling, particularly in neural development, myelination, and cell survival. The NRG (neuregulin) family of ligands binds to ERBB4, activating downstream signaling pathways such as ERK and AKT, which are essential for normal tissue development and function. Mutations or dysregulation of ERBB4 can lead to aberrant signaling, contributing to disease. Specifically, alterations in ERBB4 have been implicated in various cancers, including breast cancer, glioblastoma, and non-small cell lung cancer, where it promotes cell proliferation and survival. Additionally, ERBB4 dysfunction has been associated with neurological disorders, such as schizophrenia and autism spectrum disorders. However, one of the most well-documented diseases linked to ERBB4 is \\boxed{breast cancer}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase involved in ubiquitin-mediated protein degradation. Mutations in PRKN are associated with impaired protein quality control and mitochondrial dysfunction. This contributes to the pathogenesis of Parkinson's disease (PD). Loss-of-function variants in PRKN lead to the accumulation of misfolded proteins and dysfunctional mitochondria, resulting in neuronal death, particularly in dopamine-producing neurons in the substantia nigra. This process is linked to the hallmark pathology of PD, including Lewy body formation. Additionally, the pathway involving MAO A and B, which metabolize monoamines like dopamine, is perturbed in PD, further supporting neurodegeneration. Therefore, PRKN mutations contribute to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase involved in mitophagy and the degradation of damaged mitochondria. Mutations in PRKN lead to impaired mitophagy, resulting in the accumulation of dysfunctional mitochondria and oxidative stress. This contributes to neuronal degeneration. PRKN is a key gene in Parkinson's disease, where loss-of-function mutations are associated with autosomal recessive Parkinsonism. The pathway also involves monoamine oxidases (MAO-A and MAO-B), which metabolize dopamine and other monoamines. Dysregulation of this pathway may exacerbate neurodegeneration by increasing oxidative stress and dopamine metabolism. Therefore, the PRKN allele contributes to Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MAO -> DOPAL\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MAOA; monoamine oxidase A | MAOB; monoamine oxidase B\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin protein ligase that plays a critical role in ubiquitin-mediated protein degradation, particularly in the clearance of damaged mitochondria through mitophagy. Mutations in PRKN are associated with impaired mitophagy and the accumulation of dysfunctional mitochondria, leading to oxidative stress and neuronal dysfunction. This contributes to the pathogenesis of Parkinson's disease. Specifically, PRKN mutations are a known cause of autosomal recessive Parkinson's disease, characterized by the loss of dopaminergic neurons in the substantia nigra. The pathway also involves monoamine oxidases (MAO-A and MAO-B), which metabolize dopamine and other monoamines, further linking mitochondrial dysfunction to dopaminergic neuron loss. Thus, the biological effect of the PRKN allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes SOD1 \u2192 BIP \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3. SOD1 encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-established in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway described suggests a role in cellular stress response and protein folding, with SOD1 mutations leading to protein misfolding and aggregation, which contributes to neuronal death. This pathway's dysregulation due to mutant SOD1 is central to the pathogenesis of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes SOD1 \u2192 BIP \u2192 EIF2AK3 \u2192 EIF2S1 \u2192 ATF4 \u2192 DDIT3. SOD1 encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disorder characterized by progressive loss of motor neurons. The pathway involving SOD1, BIP, and other genes is linked to endoplasmic reticulum (ER) stress and unfolded protein response, which are implicated in neuronal dysfunction and cell death in ALS. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| EIF2AK3 -> EIF2S1 -> ATF4 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3 | EIF2S1; eukaryotic translation initiation factor 2 subunit alpha | ATF4; activating transcription factor 4 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is central to a pathway involving protein folding and stress response. SOD1 encodes superoxide dismutase 1, which catalyzes the conversion of superoxide radicals into hydrogen peroxide. Mutations in SOD1 are directly linked to amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The pathway involving SOD1, HSPA5 (binding immunoglobulin protein), EIF2AK3 (PERK), EIF2S1 (eIF2\u03b1), ATF4, and DDIT3 (CHOP) reflects the unfolded protein response (UPR) and stress-induced apoptosis. Mutant SOD1 disrupts protein homeostasis, leading to neuronal toxicity and cell death. This contributes to the pathogenesis of ALS. \\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. The pathway involves UBCH7/8 (E2 conjugating enzymes) and SYPH1, which are related to ubiquitination processes. Dysfunction in this pathway leads to impaired degradation of misfolded proteins, including alpha-synuclein, contributing to neuronal toxicity. PRKN mutations result in loss of parkin function, disrupting mitophagy and leading to mitochondrial dysfunction and neurodegeneration. This contributes to the progression of Parkinson's disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for proteasomal degradation of misfolded or damaged proteins. Mutations in PRKN lead to impaired ubiquitin-mediated proteolysis, resulting in the accumulation of toxic proteins and mitochondrial dysfunction. This contributes to neurodegeneration. PRKN haploinsufficiency or loss-of-function mutations are strongly associated with Parkinson\u2019s disease (PD), a neurodegenerative disorder characterized by dopaminergic neuron loss and Lewy body formation. PRKN mutations disrupt the ubiquitin-proteasome system, leading to the accumulation of proteins such as alpha-synuclein, which further exacerbates neuronal damage. This pathway is central to maintaining protein homeostasis and mitochondrial health, and its dysfunction is a key driver in the pathogenesis of Parkinson\u2019s disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // SYPH1\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCAIP; synuclein alpha interacting protein\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase that plays a critical role in protein quality control by promoting ubiquitin-mediated degradation of faulty or misfolded proteins. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. These mutations impair parkin's ability to ubiquitinate target proteins, leading to the accumulation of damaged proteins and mitochondrial dysfunction, which contributes to neuronal loss in the substantia nigra. PRKN mutations are one of the most common genetic causes of inherited Parkinson's disease. The pathway involving UBCH7/8 (E2 conjugating enzymes) and SYPH1 (synuclein alpha interacting protein) further supports the role of ubiquitin-mediated protein degradation in neurodegeneration. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase that plays a critical role in ubiquitin-mediated protein degradation, particularly in the removal of misfolded or damaged proteins. Mutations in PRKN are a major cause of autosomal recessive Parkinson's disease (PD). The pathway involving PRKN, along with UBCH7/8 and PAELR, is implicated in protein quality control and mitochondrial homeostasis. Loss-of-function mutations in PRKN impair the degradation of damaged mitochondria, leading to impaired neuronal function and neurodegeneration. This contributes to the pathogenesis of Parkinson's disease by disrupting the ubiquitin-proteasome system and mitochondrial function, ultimately leading to dopaminergic neuron loss. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for protein quality control and mitochondrial function. Mutations in PRKN lead to loss of function, disrupting ubiquitin-mediated protein degradation. This contributes to the accumulation of damaged proteins and mitochondrial dysfunction, which is closely linked to neurodegeneration. PRKN mutations are a major cause of autosomal recessive Parkinson's disease. The pathway involving UBCH7/8 (E2 conjugating enzymes) and PAELR supports ubiquitin ligase activity, essential for proper protein turnover. Impaired PRKN function disrupts this pathway, leading to neuronal loss. This genetic disruption is a key factor in the pathogenesis of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in protein degradation via the ubiquitin-proteasome system. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. The pathway involving PRKN, along with UBCH7/8 and PAELR, is critical for mitochondrial quality control and synaptic function. Dysfunction in this pathway leads to the accumulation of damaged proteins and impaired mitochondrial function, contributing to neurodegeneration. PRKN mutations disrupt this process, leading to the selective degeneration of dopaminergic neurons in the substantia nigra, a hallmark of Parkinson's disease. Thus, PRKN mutations are a key genetic contributor to Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele, specifically mutations in the BRAF gene, contribute to the activation of the MAPK/ERK signaling pathway by constitutively activating MEK and ERK. This leads to uncontrolled cell proliferation and survival, promoting tumor growth. The BRAF-V600E mutation is a well-known driver in several cancers. This pathway is critical in melanoma, where BRAF mutations are found in approximately 50% of cases. Additionally, BRAF mutations are implicated in other malignancies such as colorectal, lung, and thyroid cancers. The aberrant activation of this pathway disrupts normal cellular regulation, leading to oncogenic transformation. Therefore, the biological effect of this BRAF allele is the promotion of tumorigenesis, most notably in melanoma. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF allele, specifically mutations in the BRAF gene, contribute to the activation of the MAPK/ERK signaling pathway through the BRAF -> MEK -> ERK cascade. This pathway is critical for cell proliferation, differentiation, and survival. Mutations in BRAF, such as the V600E hotspot mutation, lead to constitutive activation of the pathway, driving uncontrolled cell growth. This dysregulation is a key driver in several cancers, most notably melanoma. BRAF mutations are found in approximately 50% of melanomas and are associated with more aggressive tumor behavior and poorer prognosis. Additionally, BRAF mutations can contribute to other cancers, including colorectal, lung, and thyroid cancers. The persistent activation of the ERK pathway due to BRAF mutations promotes tumor progression and resistance to apoptosis. Therefore, the biological effect of this BRAF allele is the promotion of malignancy, most notably in melanoma. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a key signaling cascade involved in cell proliferation and survival. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of the BRAF-MEK-ERK signaling pathway. This results in uncontrolled cell growth and resistance to apoptosis, contributing to tumorigenesis. The pathway includes genes such as BRAF, MAP2K1, MAP2K2, MAPK1, and MAPK3, all of which are critical for signal transduction. The constitutive activation of this pathway is commonly observed in melanoma, where BRAF mutations are present in approximately 50% of cases. This aberrant signaling promotes cancer cell proliferation, survival, and metastasis. The BRAF V600E mutation is a hallmark of melanoma and is a target for therapeutic interventions such as BRAF inhibitors. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP allele is involved in the metabolism of sphingolipids and is part of a pathway that includes GBA, GBA2, and GALC. PSAP, or prosaposin, is a precursor protein that is processed into saposins, which are essential for the activity of lysosomal enzymes like GBA (beta-glucosidase) and GALC (galactosylceramidase). Mutations in PSAP can lead to reduced production of functional saposins, impairing lysosomal enzyme activity and causing the accumulation of sphingolipids in cells. This contributes to the pathogenesis of metachromatic leukodystrophy (MLD), a rare inherited disorder characterized by the progressive degeneration of the central nervous system due to the accumulation of unmetabolized sphingolipids. The involvement of PSAP in this pathway underscores its critical role in maintaining lysosomal function and preventing neurodegeneration. \n\n\\boxed{Metachromatic Leukodystrophy}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene encodes a precursor protein essential for the proper glycosylation and activation of lysosomal enzymes involved in sphingolipid metabolism. Mutations in PSAP lead to reduced levels of functional enzyme substrates, including GBA, GBA2, and GALC, which are critical for breaking down sphingolipids. This disruption results in the accumulation of toxic lipid derivatives in lysosomes, leading to neurodegeneration. The most notable disease associated with PSAP mutations is **Fabry disease**, a X-linked lysosomal storage disorder. However, PSAP mutations can also contribute to **Gaucher disease** through impaired GBA function, as PSAP is required for proper GBA maturation. The primary disease linked to PSAP dysfunction is \\boxed{Fabry disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: PSAP* // (GBA,GALC)\nGenes in the pathway: PSAP; prosaposin | GBA; glucosylceramidase beta | GBA2; glucosylceramidase beta 2 | GALC; galactosylceramidase\n\nGiven this context, what is the biological effect of this PSAP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSAP (prosaposin) gene encodes a precursor protein essential for the biosynthesis of sphingolipids and the proper functioning of lysosomal enzymes, including GBA, GBA2, and GALC. Mutations in PSAP can lead to reduced production of these enzymes, resulting in the accumulation of toxic lipids in cells, particularly in the nervous system. This contributes to the pathogenesis of metachromatic leukodystrophy (MLD), a rare inherited neurological disorder. MLD is characterized by progressive demyelination of the central and peripheral nervous systems, leading to severe motor and cognitive decline. The involvement of PSAP in this pathway highlights its critical role in lysosomal function and myelin maintenance. \\boxed{Metachromatic Leukodystrophy}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein degradation and stress responses. In the given pathway, ATXN3 is linked to the IP3-Ca\u00b2+ signaling cascade, which regulates mitochondrial calcium levels and contributes to mitochondrial dysfunction. Mutations in ATXN3 are associated with spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination. These mutations lead to the production of an abnormal ataxin-3 protein that accumulates in neurons, disrupting cellular function and leading to neuronal death, particularly in the cerebellum. The resulting mitochondrial dysfunction further exacerbates the disease by impairing energy production and increasing susceptibility to oxidative stress. Thus, the ATXN3 allele contributes to spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a polyglutamine-containing protein involved in protein degradation and neurodegeneration. Mutations in ATXN3 lead to expanded polyglutamine tracts, resulting in the formation of toxic protein aggregates. This is the hallmark of spinocerebellar ataxia type 2 (SCA2), a hereditary neurodegenerative disorder characterized by progressive degeneration of the cerebellum and motor incoordination. The pathway involving ATXN3 contributes to mitochondrial dysfunction, calcium dysregulation, and cell death, all of which are critical in the pathogenesis of SCA2. The interaction with ITPR1, MCU, and other components of the pathway further supports its role in calcium homeostasis disruption, a key factor in neuronal damage. Thus, the ATXN3 allele is directly linked to the development of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein quality control and transcriptional regulation. In the provided pathway, ATXN3 is implicated in the IP3-Ca2+ signaling cascade, contributing to mitochondrial calcium homeostasis. Mutations in ATXN3 are a well-established cause of spinocerebellar ataxia type 2 (SCA2), an autosomal dominant neurodegenerative disorder characterized by progressive cerebellar atrophy and motor incoordination. These mutations lead to the production of an abnormally long polyglutamine tract in ataxin-3, resulting in protein misfolding, aggregation, and neuronal dysfunction. The disruption of calcium signaling through the MCU and MPTP pathways likely exacerbates mitochondrial dysfunction and neuronal death. Thus, pathogenic variants in ATXN3 primarily contribute to \\boxed{Spinocerebellar Ataxia Type 2}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is a critical regulator of cell cycle arrest, DNA repair, and apoptosis in response to genotoxic stress. Mutations in TP53 disrupt its ability to activate downstream genes such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, which are essential for maintaining genomic stability. Loss of TP53 function leads to unchecked cell proliferation, resistance to apoptosis, and accumulation of genetic damage, all of which contribute to tumorigenesis. This pathway is particularly important in preventing cancer. Mutations in TP53 are frequently observed in a variety of cancers, most notably in sarcomas, osteosarcomas, and certain types of lymphomas. However, the most well-documented and common disease associated with TP53 mutations is **Li-Fraumeni syndrome**, a hereditary cancer predisposition disorder. \n\n\\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cell cycle regulation, DNA repair, and apoptosis. Mutations in TP53 disrupt these functions, leading to unchecked cell proliferation and genomic instability. The listed genes\u2014CDKN1A, GADD45A/B/G, BAX, BAK1, DDB2, and POLK\u2014are downstream targets of p53, involved in cell cycle arrest, DNA repair, and apoptosis. When TP53 is mutated, these genes are dysfunctional, impairing the cell's ability to respond to DNA damage. This contributes to tumorigenesis by allowing damaged cells to survive and divide. The most well-known disease associated with TP53 mutations is Li-Fraumeni syndrome, a hereditary disorder characterized by a high risk of multiple cancers, including sarcomas, breast cancer, brain tumors, and osteosarcoma. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is a critical regulator of cell cycle arrest, DNA repair, and apoptosis. Mutations in TP53, the * tumor protein p53*, lead to loss of these functions, allowing damaged cells to survive and proliferate. This contributes to genomic instability and tumor progression. Genes such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK are downstream targets of p53 and play roles in cell cycle regulation, DNA repair, and apoptosis. When TP53 is mutated, these genes are dysregulated, impairing the cell's ability to respond to DNA damage. This pathway dysfunction is a hallmark of several cancers. The most well-known disease associated with TP53 mutations is **Li-Fraumeni syndrome**, a hereditary condition characterized by a high risk of multiple cancers, including sarcomas, breast cancer, and brain tumors. \\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are among the most common genetic causes of early-onset familial Alzheimer's disease (AD). The pathway involving PSEN1 \u2192 GSK3B and the kinesin family proteins (KIF5 and KLC) suggests a role in intracellular transport and protein clearance, both of which are disrupted in AD. Altered GSK3B activity and disrupted kinesin-mediated transport contribute to neurodegeneration by impairing synaptic function and waste clearance. Therefore, mutations in PSEN1 primarily contribute to \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), leading to the production of amyloid-\u03b2 peptides. Mutations in PSEN1 are a primary cause of early-onset familial Alzheimer's disease (FAD). The pathway described, involving PSEN1 \u2192 GSK3B -| (KIF5+KLC), reflects the involvement of PSEN1 in regulating GSK3B, a kinase implicated in neurodegeneration and tau pathology. The interaction with kinesin family members (KIF5A/B/C) and kinesin light chains (KLC1-4) suggests a role in axonal transport, which is disrupted in Alzheimer's disease. Impaired axonal transport contributes to neuronal dysfunction and the accumulation of pathological proteins. Thus, the PSEN1 allele contributes to the development of Alzheimer's disease. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a crucial component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating \u03b2-amyloid peptides. Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease. The pathway described involves PSEN1 regulating GSK3B, a kinase involved in multiple cellular processes, including neurogenesis and tau phosphorylation. The interaction with KIF5 (kinesin family member 5) and KLC (kinesin light chain) suggests involvement in intracellular transport, which is disrupted in neurodegenerative diseases. Collectively, these interactions support a role in neuronal dysfunction and protein misfolding. The biological effect of pathogenic PSEN1 alleles is thus the disruption of normal \u03b3-secretase activity, leading to increased \u03b2-amyloid production and plaque formation, hallmark features of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS allele is central to the cAMP signaling pathway, which plays a key role in hormone regulation and cellular responses. Mutations in GNAS can lead to dysregulation of cAMP levels, disrupting downstream signaling through ADCY and PKA to CREB and ultimately affecting hormone production, such as ACTH and POMC. This pathway is crucial in the pituitary and adrenal glands. GNAS mutations are well-known contributors to **McCune-Albright syndrome**, a disorder characterized by fibrous dysplasia of bone, endocrine overactivity (e.g., precocious puberty, hypercorticism), and skin pigmentation. These mutations are typically somatic, leading to mosaic expression and variable clinical manifestations. The disruption of GNAS impairs normal cellular responses, leading to the hallmark features of this syndrome. \\boxed{McCune-Albright syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS allele plays a central role in the cAMP signaling pathway, initiating a cascade involving adenylate cyclases (ADCY), cAMP, PKA, and CREB family transcription factors, ultimately influencing POMC expression. Mutations in GNAS can lead to dysregulation of this pathway, affecting adrenal cortisol production and pituitary hormone secretion. This contributes to a group of disorders known as **pseudo-pseudohypoparathyroidism** and **primary osteoporosis**, characterized by end-organ resistance to parathyroid hormone (PTH) and altered adrenal function. GNAS mutations are also implicated in **McCune-Albright syndrome**, a condition marked by fibrous dysplasia, endocrinopathy, and skin pigmentation. These mutations disrupt normal signaling, leading to hormonal imbalances and developmental abnormalities. The specific disease associated with GNAS mutations, particularly those affecting the pathway from GNAS to ACTH, is **McCune-Albright syndrome**.\n\n\\boxed{McCune-Albright syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: GNAS* -> ADCY -> cAMP -> PKA -> CREB -> ACTH\nGenes in the pathway: GNAS; GNAS complex locus | ADCY1; adenylate cyclase 1 | ADCY2; adenylate cyclase 2 | ADCY3; adenylate cyclase 3 | ADCY4; adenylate cyclase 4 | ADCY5; adenylate cyclase 5 | ADCY6; adenylate cyclase 6 | ADCY7; adenylate cyclase 7 | ADCY8; adenylate cyclase 8 | ADCY9; adenylate cyclase 9 | PRKACA; protein kinase cAMP-activated catalytic subunit alpha | PRKACB; protein kinase cAMP-activated catalytic subunit beta | PRKACG; protein kinase cAMP-activated catalytic subunit gamma | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | POMC; proopiomelanocortin\n\nGiven this context, what is the biological effect of this GNAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe GNAS allele plays a critical role in the cAMP signaling pathway, influencing the activation of PKA and downstream transcription factors like CREB, which regulate genes such as POMC. Mutations in GNAS can lead to altered cAMP levels, disrupting hormone production and secretion. This is particularly significant for ACTH and melanocortin pathways, which are essential for adrenal function and pigmentation. GNAS mutations are well-documented in conditions such as pseudohypoparathyroidism, where there is resistance to parathyroid hormone, and in primary Albright hereditary osteodystrophy (AHO), characterized by skeletal abnormalities and endocrine dysfunction. Additionally, GNAS mutations are linked to pituitary adenomas and Cushing's disease due to aberrant ACTH production. The most specific disease associated with GNAS mutations is \\boxed{Pseudohypoparathyroidism}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex. Mutations in PSEN1 are well-established as the most common cause of early-onset familial Alzheimer's disease (FAD). The pathway described involves PSEN1 regulating GSK3B, a kinase involved in multiple cellular processes, including neurogenesis and synaptic plasticity. The interactions with KIF5 (kinesin family member 5) and KLC (kinesin light chain) suggest roles in intracellular transport, which is disrupted in neurodegenerative conditions. These molecular pathways are perturbed in Alzheimer's disease, contributing to amyloid-beta production, tau pathology, and neuronal dysfunction. Therefore, the biological effect of the PSEN1 allele is the increased risk of developing Alzheimer's disease due to impaired proteolytic processing and transport mechanisms. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is critical for the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (FAD). The pathway involving PSEN1 \u2192 GSK3B and the kinesin family proteins (KIF5+KLC) suggests a role in neurodegenerative processes, including tau pathology and neuronal transport. Impaired function of these proteins disrupts cellular homeostasis, contributing to synaptic dysfunction and neurodegeneration. These molecular alterations directly link PSEN1 mutations to the pathogenesis of Alzheimer's disease. The biological effect of this PSEN1 allele is therefore the increased risk and early onset of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is involved in the cleavage of amyloid precursor protein (APP), leading to the production of \u03b2-amyloid peptides. Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease. The pathway involving PSEN1 \u2192 GSK3B and the kinesin proteins (KIF5 and KLC) suggests a role in neurodegenerative processes, including protein trafficking and amyloidogenesis. GSK3B is implicated in tau hyperphosphorylation and neuronal dysfunction, both of which are hallmarks of Alzheimer's disease. The interaction with kinesins indicates involvement in axonal transport, which is disrupted in neurodegeneration. Therefore, the PSEN1 allele contributes to the pathogenesis of Alzheimer's disease by promoting amyloid accumulation and neurotoxicity through these molecular pathways.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a potent inhibitor of cyclin D-dependent kinases CDK4 and CDK6. In the given pathway, CDKN2A negatively regulates MDM2, which normally ubiquitinates and destabilizes TP53. By inhibiting MDM2, CDKN2A enhances TP53 stability, leading to cell cycle arrest and apoptosis. Mutations or loss of CDKN2A disrupt this regulatory mechanism, allowing unchecked cell proliferation. This contributes to the progression of cancers characterized by inactivation of the p53 pathway. CDKN2A mutations are strongly associated with melanoma and pancreatic cancer. The loss of CDKN2A function is a key driver in these malignancies due to the consequent inactivation of TP53 and dysregulation of the cell cycle. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a key inhibitor of CDK4/6, which regulates the cell cycle by preventing the phosphorylation of RB1. In the given pathway, CDKN2A negatively regulates MDM2, which normally promotes the degradation of TP53. By inhibiting MDM2, CDKN2A stabilizes TP53, enhancing its tumor suppressor function. Loss or mutation of CDKN2A leads to reduced TP53 activity, allowing unchecked cell proliferation. This dysfunction is strongly associated with uncontrolled cell growth and tumorigenesis. CDKN2A mutations are a hallmark of many cancers, particularly melanoma, pancreatic cancer, and small cell lung cancer. The loss of CDKN2A disrupts the p53-CDK4/6-RB1-E2F pathway, promoting the expression of E2F-driven genes involved in cell cycle progression. This contributes to the development and progression of cancer. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a key inhibitor of CDK4/6, which are enzymes that phosphorylate RB1. By inhibiting CDK4/6, CDKN2A prevents RB1 phosphorylation, maintaining RB1 in an active state that suppresses E2F-driven cell cycle progression. Loss or mutation of CDKN2A disrupts this inhibitory mechanism, leading to RB1 inactivation and uncontrolled cell proliferation. This contributes to genomic instability and tumor formation. CDKN2A mutations are strongly associated with retinoblastoma, a childhood eye cancer, and are also implicated in melanoma and other cancers. The loss of CDKN2A allows for unchecked cell cycle progression, promoting oncogenesis. \\boxed{Retinoblastoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CTNNB1 allele in this genomic pathway is central to the WNT signaling cascade. CTNNB1 (\u03b2-catenin) is a key mediator of WNT signaling, and its stabilization and nuclear translocation activate TCF/LEF transcription factors, driving the expression of downstream genes such as BIRC5, MYC, and CCND1. Mutations in CTNNB1 that lead to its constitutive activation are associated with uncontrolled cell proliferation and inhibit apoptosis, contributing to oncogenesis. This pathway is frequently dysregulated in cancers characterized by aberrant WNT signaling. The most well-known disease linked to CTNNB1 mutations is colorectal cancer, where activating mutations in CTNNB1 are commonly found in the absence of APC mutations. Such mutations drive the progression of adenomas to carcinomas by promoting cell cycle progression and survival. \\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CTNNB1 allele in this genomic pathway is central to the WNT signaling cascade. CTNNB1 encodes \u03b2-catenin, a key transcriptional co-activator that, when stabilized, translocates to the nucleus and activates target genes such as BIRC5, MYC, and CCND1. Mutations in CTNNB1 that lead to its stabilization and constitutive activation drive aberrant cell proliferation and survival, contributing to uncontrolled growth. This dysregulation is a hallmark of several cancers. Specifically, CTNNB1 mutations are frequently observed in colorectal cancer, where they disrupt the WNT/\u03b2-catenin pathway, leading to oncogenic transformation. The activation of downstream targets like MYC and CCND1 further promotes cell cycle progression and tumor formation. Thus, the biological effect of this CTNNB1 allele is oncogenic, and it contributes to \\boxed{Colorectal Cancer}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (GSK3B+AXIN+APC) // CTNNB1* -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this CTNNB1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CTNNB1 allele, as part of the WNT signaling pathway, plays a critical role in regulating cell proliferation and differentiation. When mutated or overactive, CTNNB1 leads to the stabilization and nuclear translocation of beta-catenin, enhancing the transcription of downstream genes like BIRC5, MYC, and CCND1. This dysregulation promotes uncontrolled cell growth and survival, contributing to the development of cancer. Specifically, mutations in CTNNB1 are commonly associated with colorectal cancer, where it drives the activation of oncogenic pathways. The abnormal activation of the WNT/CTNNB1 pathway is a key driver in tumor progression, making it a significant factor in the pathogenesis of colorectal adenocarcinoma. \\boxed{Colorectal cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 pathway is involved in intracellular calcium signaling, linking mitochondrial calcium uptake to the release of cytochrome c, which plays a key role in apoptosis. Mutations in SIGMAR1 disrupt this pathway, leading to impaired calcium homeostasis and increased mitochondrial permeability. This contributes to cellular stress and apoptosis, particularly in neurons. SIGMAR1 is implicated in neurodegenerative diseases due to its role in maintaining mitochondrial integrity and preventing excessive calcium influx. Altered SIGMAR1 function has been linked to Parkinson's disease, where mitochondrial dysfunction and oxidative stress are key features. The disruption of this pathway results in neuronal loss, a hallmark of Parkinson's. Therefore, the biological effect of the SIGMAR1 allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 pathway is involved in intracellular calcium signaling, linking mitochondrial calcium uptake via MCU to the release of cytochrome c through the MPTP. SIGMAR1 modulates ITPR-mediated calcium release from the endoplasmic reticulum, influencing mitochondrial calcium levels. Altered SIGMAR1 function disrupts calcium homeostasis, leading to mitochondrial dysfunction and apoptosis. This contributes to neurodegenerative diseases. Mutations in SIGMAR1 are associated with Parkinson's disease, where it promotes alpha-synuclein aggregation and neuronal death. The pathway's role in calcium signaling and mitochondrial integrity makes it critical in disease progression. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: SIGMAR1* -> ITPR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: SIGMAR1; sigma non-opioid intracellular receptor 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this SIGMAR1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SIGMAR1 pathway plays a critical role in calcium signaling by regulating the release of calcium from the endoplasmic reticulum (via ITPR) and its uptake into mitochondria through the MCU. This process is essential for mitochondrial function and apoptosis. Mutations in SIGMAR1 can disrupt calcium homeostasis, leading to mitochondrial dysfunction and the release of cytochrome c (CYCS), which promotes apoptosis. This pathway is implicated in neurodegenerative diseases where mitochondrial stress and apoptosis are key features. Specifically, alterations in SIGMAR1 contribute to Parkinson's disease, as they are associated with impaired neuronal survival, mitochondrial dysfunction, and dopaminergic neuron loss. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is central to mitochondrial function and apoptosis. PINK1, a serine threonine kinase, localizes to mitochondria and plays a key role in maintaining mitochondrial health. It phosphorylates HTRA2, preventing its translocation to the cytosol, and interacts with TRAP1, a mitochondrial chaperone. Under stress, PINK1 promotes the release of cytochrome c (CYCS) by facilitating HTRA2 translocation, which activates APAF1, leading to caspase-9 (CASP9) and caspase-3 (CASP3) activation, driving apoptosis. Mutations in PINK1 disrupt this pathway, leading to impaired mitochondrial function and increased apoptosis. This is associated with Parkinson\u2019s disease, as PINK1 mutations are a known cause of inherited Parkinsonism. The disruption of this pathway contributes to neurodegeneration by promoting neuronal death. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is central to mitochondrial function and apoptosis. PINK1, a mitochondrial kinase, works with HTRA2 and TRAP1 to regulate cytochrome c release, which activates APAF1, leading to caspase-9 and caspase-3 activation, ultimately resulting in apoptosis. Mutations in PINK1 disrupt this process, impairing mitochondrial quality control and increasing apoptosis. This contributes to neurodegeneration. The most well-documented disease associated with PINK1 mutations is Parkinson's disease. Loss-of-function mutations in PINK1 are linked to familial and sporadic Parkinson's, characterized by dopaminergic neuron loss. The pathway's role in maintaining mitochondrial health and preventing excessive apoptosis makes it critical for neuronal survival. Therefore, the biological effect of PINK1 allele dysfunction is neurodegeneration, specifically contributing to \\boxed{Parkinson's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // (HTRA2,TRAP1) // CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | HTRA2; HtrA serine peptidase 2 | TRAP1; TNF receptor associated protein 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is central to mitochondrial quality control and apoptosis. PINK1, a serine/threonine kinase, plays a key role in maintaining mitochondrial integrity by phosphorylating TOMM20 and stabilizing the mitochondrial membrane. When mitochondria are damaged, PINK1 localizes to the outer membrane, initiating recruitment of PARK2 (PRKN), leading to mitophagy. The pathway also involves HTRA2 and TRAP1, which are involved in mitochondrial stress response, and cytochrome c (CYCS), which activates APAF1 to trigger caspase cascades (CASP9 \u2192 CASP3), leading to apoptosis. Mutations in PINK1 disrupt mitochondrial homeostasis and apoptosis regulation, contributing to neurodegeneration. This pathway is implicated in Parkinson's disease, where PINK1 mutations cause impaired mitophagy and neuronal loss. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein degradation and cellular stress responses. Its involvement in the network with genes like BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 suggests a role in autophagy, a critical process for maintaining cellular homeostasis. Mutations in ATXN3 are specifically associated with spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination and motor control. The disease results from expansions of polyglutamine repeats in the ataxin-3 protein, leading to protein misfolding, aggregation, and neuronal dysfunction. These pathological changes disrupt autophagic clearance, exacerbating neuronal damage. Thus, the ATXN3 allele contributes to the development of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and proteasomal function. Mutations in ATXN3 lead to the expansion of glutamine repeats, resulting in the formation of toxic protein aggregates. This contributes to the pathogenesis of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive degeneration of the cerebellum and brainstem, leading to ataxia and motor coordination defects. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy, a cellular process that clears misfolded proteins and damaged organelles. Impaired autophagy due to ATXN3 dysfunction exacerbates protein aggregation and neuronal toxicity. Thus, the ATXN3 allele contributes to the development of spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in protein degradation and transcriptional regulation. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, resulting in the formation of toxic protein aggregates. This contributes to neurodegeneration by disrupting cellular homeostasis and impairing protein clearance. The pathway includes genes involved in autophagy, such as BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1, which are critical for the degradation of misfolded proteins. Impaired autophagy exacerbates the accumulation of toxic ataxin-3 aggregates, leading to neuronal loss. This process is central to the pathogenesis of spinocerebellar ataxia type 2 (SCA2), a hereditary neurodegenerative disorder characterized by progressive cerebellar atrophy and motor dysfunction. The interplay between ATXN3 and autophagy-related pathways underscores the role of protein quality control in maintaining neuronal health. \\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET pathway, when activated, drives cell proliferation and survival. The MET gene encodes a receptor tyrosine kinase that, when mutated or overexpressed, leads to constitutive activation of downstream signaling, including the RAS-RAF-MEK-ERK cascade. This results in uncontrolled cell growth and inhibition of apoptosis. Such alterations are commonly associated with increased cell proliferation and tumor formation. Specifically, MET-driven oncogenic signaling contributes to the development of various cancers, including non-small cell lung cancer (NSCLC), gastric cancer, and metastatic breast cancer. In particular, MET amplification or mutations are linked to metastatic disease and poor prognosis. The activation of this pathway also promotes angiogenesis and epithelial-mesenchymal transition (EMT), enhancing tumor invasiveness. Therefore, the biological effect of MET activation is the promotion of oncogenic processes that contribute to the progression of cancer. \\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when mutated or overactive, drives the MET signaling pathway, leading to aberrant activation of downstream effectors such as GRB2, SOS, RAS, RAF, MEK, and ERK. This results in increased expression of CCND1, a protein that promotes cell cycle progression. The dysregulation of this pathway is closely associated with uncontrolled cell proliferation and inhibition of apoptosis, contributing to the development of various cancers. Specifically, MET activation is implicated in the progression of metastatic disease, particularly in cancers such as non-small cell lung cancer (NSCLC), papillary renal cell carcinoma, and hepatocellular carcinoma. It also plays a role in the aggressiveness and poor prognosis of these cancers by promoting tumor growth, invasion, and metastasis. The MET pathway is a key driver in oncogenesis and is often targeted in cancer therapy. \\boxed{Metastatic Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: MET* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: MET; MET proto-oncogene, receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this MET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MET allele, when mutated or overexpressed, activates the MET receptor tyrosine kinase, initiating a signaling cascade through GRB2, SOS, RAS, RAF, MEK, and ERK, ultimately leading to the upregulation of CCND1. This pathway is central to cell proliferation and survival. Dysregulation of MET contributes to uncontrolled cell growth and tumor formation. Specifically, activation of this pathway is implicated in the development of various cancers, including non-small cell lung cancer (NSCLC), renal cell carcinoma, and hepatocellular carcinoma. MET-driven oncogenic signaling promotes tumor growth, angiogenesis, and metastasis by enhancing cell cycle progression and inhibiting apoptosis. Mutations or amplifications in MET are commonly observed in cancers where this pathway is aberrantly activated. Therefore, the biological effect of this MET allele is the promotion of cancer, particularly contributing to \\boxed{Non-small cell lung cancer}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a tumor suppressor protein that inhibits the cyclin D-CDK4/6 complex, preventing phosphorylation of the retinoblastoma protein (RB1). This inhibition blocks the release of E2F transcription factors, which drive cell cycle progression. In the given pathway, CDKN2A acts upstream of the cyclin D (CCND) and CDK4/6 complex, regulating the G1/S phase transition. Loss or mutation of CDKN2A leads to uncontrolled cell proliferation by removing this checkpoint, allowing RB1 to remain hypophosphorylated and E2F to remain active. This dysregulation is a key driver in various cancers. The most well-documented disease associated with CDKN2A dysfunction is melanoma, specifically in the context of neurocristic tumors. Additionally, CDKN2A mutations are prominent in cancers such as lung, pancreatic, and prostate cancers. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes p16INK4a, a key inhibitor of CDK4 and CDK6, which are involved in the progression of the cell cycle by phosphorylating and inactivating the retinoblastoma protein (RB1). In the given pathway, CDKN2A inhibits the CDK4/6-cyclin D complex, preventing phosphorylation of RB1. When RB1 remains unphosphorylated, it binds to E2F transcription factors, suppressing the expression of genes required for DNA replication and cell cycle progression. Loss or inactivation of CDKN2A disrupts this checkpoint, leading to unchecked cell proliferation. This dysregulation is a hallmark of several cancers, particularly those involving the cell cycle. The most well-known disease associated with CDKN2A dysfunction is melanoma, as well as pancreatic cancer. Mutations in CDKN2A are also linked to familial melanoma syndromes. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nCDKN2A encodes the protein p16INK4a, which inhibits CDK4 and CDK6, preventing the phosphorylation of the retinoblastoma protein (RB1). This inhibition blocks the release of E2F transcription factors, which are essential for cell cycle progression. In the given pathway, CDKN2A acts as a tumor suppressor by suppressing cyclin D (CCND) and CDK4/6, thereby preventing RB1 phosphorylation and E2F activation. Loss or mutation of CDKN2A disrupts this regulatory mechanism, leading to uncontrolled cell proliferation. This contributes to the development of cancers characterized by dysregulated cell cycle control. CDKN2A mutations are strongly associated with melanoma and various cancers, including pancreatic, prostate, and bladder cancers. The loss of CDKN2A function is a key driver in these malignancies. \n\n\\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS-RAF-MEK-ERK signaling pathway, plays a critical role in cell proliferation and differentiation. Mutations in NRAS, such as gain-of-function mutations, lead to constitutive activation of the pathway, resulting in uncontrolled cell growth. This dysregulation is a hallmark of several cancers. Specifically, NRAS mutations are strongly associated with melanoma, where they drive tumor initiation and progression by promoting cell cycle progression through the upregulation of cyclin D1 (CCND1). Additionally, NRAS mutations can contribute to other malignancies, including certain leukemias and lung cancers. The persistent activation of the MAPK pathway due to NRAS mutations disrupts normal cellular homeostasis, leading to oncogenic transformation. Therefore, the biological effect of this NRAS allele is the promotion of malignant transformation, most notably in melanoma.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS-RAF-MEK-ERK signaling pathway, drives cell proliferation and survival by activating downstream effectors such as MEK and ERK. This leads to increased expression of CCND1, a key regulator of the cell cycle. Mutations in NRAS, particularly activating mutations, result in constitutive activation of the MAPK pathway, promoting uncontrolled cell growth. This dysregulation is a hallmark of several cancers. The most common disease associated with NRAS mutations is **melanoma**, where activating mutations in NRAS are frequently observed. These mutations contribute to tumor initiation and progression by enhancing cellular proliferation and resistance to apoptosis. Additionally, NRAS mutations are also implicated in other malignancies such as non-small cell lung cancer, bladder cancer, and certain leukemias. The persistent activation of the pathway leads to oncogenic transformation, making it a key driver in these diseases.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> RAF -> MEK -> ERK -> CCND1\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS-RAF-MEK-ERK signaling pathway, contributes to uncontrolled cell proliferation by activating downstream effectors such as MEK and ERK. This leads to increased expression of CCND1, a key regulator of the cell cycle. Mutations in NRAS, particularly gain-of-function mutations, result in constitutive activation of the MAPK pathway, driving cellular proliferation and inhibiting apoptosis. This dysregulated signaling is a hallmark of several cancers. The most common disease associated with NRAS mutations is **melanoma**, where activating mutations in NRAS are frequently observed. These mutations are also implicated in other malignancies, including non-small cell lung cancer, bladder cancer, and certain leukemias. The persistent activation of the pathway promotes tumor growth and resistance to therapy, making NRAS mutations a significant contributor to oncogenesis. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or overactive, contributes to the constitutive activation of the BCR-ABL oncoprotein. This leads to uncontrolled signaling through the downstream pathway: BCR-ABL \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK. This aberrant signaling promotes cell proliferation, survival, and resistance to apoptosis. The most well-known disease associated with this pathway is chronic myeloid leukemia (CML), caused by the Philadelphia chromosome translocation (t(9;22)), which fuses BCR to ABL1, creating the BCR-ABL fusion protein. This fusion protein acts as a constitutively active tyrosine kinase, driving leukemogenesis. Additionally, ABL1 mutations can contribute to other cancers, including some solid tumors. The hallmark of this pathway activation is its role in sustaining oncogenic signaling, leading to malignant transformation. \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that plays a critical role in the BCR-ABL oncogenic pathway. This pathway is central to the activation of downstream signaling cascades, including the RAS-RAF-MEK-ERK cascade, which promotes cell proliferation, survival, and differentiation. Mutations leading to the constitutive activation of BCR-ABL, such as the Philadelphia chromosome translocation (t(9;22)), result in uncontrolled kinase activity. This leads to the aberrant activation of downstream effectors, driving uncontrolled cell growth and genomic instability. The most well-known disease associated with this pathway is chronic myeloid leukemia (CML). The persistent activation of ABL1 through BCR-ABL fusion causes malignant transformation of hematopoietic cells, leading to the hallmark features of CML. \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 allele, when mutated or overactive, leads to the constitutive activation of the BCR-ABL oncoprotein. This results in uncontrolled tyrosine kinase activity, which drives the continuous activation of downstream signaling molecules in the RAS-MAPK pathway, including GRB2, SOS, RAS, RAF, MEK, and ERK. This persistent activation promotes cell proliferation, survival, and resistance to apoptosis, leading to uncontrolled cell growth. This pathway is central to the development of chronic myeloid leukemia (CML), a type of blood cancer characterized by the presence of the Philadelphia chromosome, which arises from a reciprocal translocation between chromosomes 9 and 22, resulting in the BCR-ABL fusion gene. The constitutive activation of this pathway is a hallmark of CML and drives its pathogenesis. \\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN allele, encoding parkin, is critical for mitochondrial quality control. Mutations in PRKN disrupt mitophagy, the process by which damaged mitochondria are removed. This dysfunction leads to the accumulation of dysfunctional mitochondria, oxidative stress, and neuronal damage. PRKN interacts with MFN1 and MFN2, which are essential for mitochondrial fusion. Impaired PRKN function impairs this interaction, disrupting mitochondrial dynamics and contributing to neurodegeneration. This pathway is central to Parkinson's disease, where PRKN mutations are a known cause. Loss of PRKN function leads to the accumulation of toxic proteins and impaired cellular function, particularly in dopamine-producing neurons. The resulting neuronal death is a hallmark of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitochondrial dynamics and quality control. PRKN, also known as parkin, is an E3 ubiquitin ligase that mediates the ubiquitination and degradation of mitochondrial fusion proteins MFN1 and MFN2. Loss-of-function mutations in PRKN disrupt mitochondrial fusion, leading to impaired mitophagy and accumulation of dysfunctional mitochondria. This contributes to neuronal loss and is a key factor in Parkinson's disease. Mutations in PRKN are among the most common genetic causes of early-onset Parkinson's disease. The pathway's dysfunction impairs the removal of damaged mitochondria, leading to oxidative stress and neurodegeneration. Therefore, the biological effect of this PRKN allele is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* // MFN1/2\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase critical for mitochondrial quality control. Its interaction with MFN1 and MFN2, which mediate mitochondrial fusion, highlights its role in maintaining mitochondrial integrity. Mutations in PRKN lead to impaired mitophagy, allowing dysfunctional mitochondria to accumulate. This disruption contributes to neuronal damage and is a key factor in neurodegenerative diseases. The most well-characterized disease associated with PRKN mutations is Parkinson's disease. Loss-of-function mutations in PRKN are linked to autosomal recessive Parkinson's, characterized by dopaminergic neuron loss. Thus, the biological effect of this PRKN allele is the disruption of mitochondrial homeostasis, leading to neuronal degeneration and the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose mutant form leads to the accumulation of abnormal protein aggregates. This is the primary cause of Huntington's disease, a neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and behavioral changes. The pathway involving HTT, CREB family members, and ATF4 suggests a role in transcriptional regulation, which is disrupted in the disease. Mutations in HTT result in toxic gain-of-function effects, including mitochondrial dysfunction, oxidative stress, and neuronal death. The involvement of PPARGC1A, a coactivator of nuclear receptors, indicates potential dysregulation of metabolic pathways. Overall, this pathway is central to the pathogenesis of Huntington's disease. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose normal function is not fully understood, but its mutation leads to the expansion of CAG repeats, resulting in the production of an abnormally long polyglutamine tract. This mutation is the causal genetic factor in Huntington's disease, a neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. The pathway involving HTT, CREB family proteins, and ATF4 suggests a role in transcriptional regulation, which is disrupted in the disease. The accumulation of mutant huntingtin protein disrupts cellular processes, leading to neuronal death, particularly in the striatum and cerebral cortex. This genetic mutation is inherited in an autosomal dominant manner, and the severity of the disease correlates with the length of the CAG repeat expansion. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| (CREB+TAF4) => PPARGC1A\nGenes in the pathway: HTT; huntingtin | CREB3; cAMP responsive element binding protein 3 | CREB1; cAMP responsive element binding protein 1 | ATF2; activating transcription factor 2 | ATF6B; activating transcription factor 6 beta | CREB3L4; cAMP responsive element binding protein 3 like 4 | ATF4; activating transcription factor 4 | CREB3L2; cAMP responsive element binding protein 3 like 2 | CREB3L3; cAMP responsive element binding protein 3 like 3 | CREB3L1; cAMP responsive element binding protein 3 like 1 | CREB5; cAMP responsive element binding protein 5 | TAF4; TATA-box binding protein associated factor 4 | PPARGC1A; PPARG coactivator 1 alpha\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT allele, as part of a pathway involving CREB and ATF family transcription factors leading to PPARGC1A, is implicated in modulating gene expression related to energy metabolism and transcriptional regulation. Mutations in HTT are most notably associated with Huntington's disease, a neurodegenerative disorder caused by an expanded CAG repeat in the HTT gene, leading to the production of a toxic huntingtin protein. This protein disrupts cellular functions, including transcriptional regulation, mitochondrial function, and protein degradation, ultimately causing neuronal death. The involvement of PPARGC1A, a key regulator of mitochondrial biogenesis and energy metabolism, suggests that HTT dysfunction may impair metabolic processes in neurons, exacerbating disease progression. Therefore, the biological effect of the HTT allele in this pathway contributes to the development of \\boxed{Huntington's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is central to mitochondrial quality control and apoptosis. PINK1, a serine/threonine kinase, is critical for stabilizing the mitochondrial membrane and activating parkin (PRKN), an E3 ubiquitin ligase. When mitochondria are damaged, PINK1 accumulates on the outer membrane, recruiting parkin to initiate mitophagy. This process removes dysfunctional mitochondria, preventing cellular damage. Mutations in PINK1 disrupt this pathway, leading to impaired mitophagy, accumulation of damaged mitochondria, and subsequent apoptosis. This dysfunction contributes to neurodegeneration. The most well-documented disease associated with PINK1 mutations is Parkinson\u2019s disease. Loss-of-function variants in PINK1 are linked to an increased risk of Parkinson\u2019s, characterized by dopaminergic neuron loss. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 pathway is central to mitochondrial quality control and apoptosis. PINK1, when mutated, impairs mitochondrial function by preventing the recruitment of PRKN (parkin) to damaged mitochondria, which disrupts the ubiquitination and degradation of dysfunctional mitochondria. This leads to the accumulation of damaged mitochondria, oxidative stress, and neuronal dysfunction. The pathway also involves BAX-mediated release of cytochrome c, activation of APAF1, and subsequent activation of caspase-9 and caspase-3, promoting apoptosis. Mutations in PINK1 are strongly associated with Parkinson's disease, as they contribute to neurodegeneration by impairing mitochondrial health and increasing apoptosis in dopaminergic neurons. Thus, the biological effect of a pathogenic PINK1 allele is the disruption of mitochondrial homeostasis and increased neuronal death, which contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // BAX -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | BAX; BCL2 associated X, apoptosis regulator | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is central to mitochondrial quality control and apoptosis. PINK1 phosphorylates PRKN (parkin), initiating ubiquitin-mediated degradation of damaged mitochondria. This process is crucial for maintaining cellular energy homeostasis and preventing the accumulation of dysfunctional mitochondria. When PINK1 is mutated, this pathway is impaired, leading to mitochondrial dysfunction and neuronal death. This dysfunction is a key factor in Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons. Mutations in PINK1 are one of the known genetic causes of inherited Parkinsonism. The disruption of the PINK1-PRKN axis impairs mitophagy, contributing to the pathogenesis of Parkinson's disease. Thus, the biological effect of this PINK1 allele is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene encodes nucleoredoxin, a protein involved in redox regulation and mitochondrial function. Its interaction with DVL proteins (dishevelled segment polarity proteins) suggests a role in Wnt signaling, which is critical for development and cellular homeostasis. Mutations in NXN may disrupt this pathway, leading to impaired cellular redox balance and aberrant Wnt signaling. This has been implicated in neurodegenerative diseases. Specifically, alterations in NXN have been associated with Parkinson's disease, where mitochondrial dysfunction and oxidative stress play key roles. The disruption of NXN-DVL interactions may contribute to neuronal death by compromising mitochondrial integrity and Wnt signaling, both of which are critical for neuronal survival. Therefore, the biological effect of the NXN allele is linked to the development and progression of \\boxed{Parkinson's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene, also known as nucleoredoxin, is involved in redox regulation and cellular stress response. Its interaction with DVL proteins, which are key components of the Wnt signaling pathway, suggests a role in developmental processes and cellular homeostasis. Mutations in NXN may disrupt this regulatory network, leading to impaired signaling and potential disease. Dysregulation of the Wnt pathway is implicated in various cancers and developmental disorders. Specifically, alterations in NXN have been associated with neurodevelopmental conditions and certain types of cancer, including gliomas and breast cancer. The disruption of the NXN-DVL interaction may contribute to tumor progression by affecting cell proliferation and differentiation. Based on these associations, the biological effect of the NXN allele is most closely linked to \\boxed{Glioblastoma}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: NXN* -| DVL\nGenes in the pathway: NXN; nucleoredoxin | DVL1; dishevelled segment polarity protein 1 | DVL2; dishevelled segment polarity protein 2 | DVL3; dishevelled segment polarity protein 3\n\nGiven this context, what is the biological effect of this NXN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NXN gene, also known as nucleoredoxin, is involved in redox regulation and plays a role in maintaining cellular homeostasis. Mutations in NXN have been associated with oxidative stress and impaired cellular responses to DNA damage. The pathway involving NXN and DVL proteins (Dishevelled segment polarity proteins) is implicated in Wnt signaling, which is critical for development and tissue homeostasis. Dysregulation of this pathway has been linked to various diseases. Specifically, mutations in NXN have been associated with neurodegenerative disorders, particularly Parkinson's disease, due to its role in mitochondrial function and protein quality control. Impaired NXN function contributes to increased oxidative stress and neuronal death, hallmark features of Parkinson's disease. Thus, the biological effect of the NXN allele is a contribution to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, as part of the pathway SOD1 \u2192 BIP \u2192 ATF6 \u2192 DDIT3, is implicated in oxidative stress response and endoplasmic reticulum (ER) stress signaling. Mutations in SOD1 are well-known to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive degeneration of motor neurons. SOD1 encodes superoxide dismutase 1, an enzyme that detoxifies superoxide radicals. Mutant SOD1 proteins misfold and aggregate, leading to ER stress and activation of the unfolded protein response (UPR), involving ATF6 and DDIT3. This pathway disruption contributes to neuronal toxicity and disease progression. Thus, the biological effect of the SOD1 allele is the induction of neurodegeneration through ER stress and oxidative damage.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 negatively regulates BIP, which in turn affects ATF6, ultimately influencing DDIT3. SOD1 encodes superoxide dismutase 1, an enzyme that detoxifies superoxide radicals. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive loss of motor neurons. The pathway suggests SOD1 may influence endoplasmic reticulum (ER) stress and transcriptional regulation through ATF6 and DDIT3, which are involved in cellular stress responses. This connection aligns with the role of SOD1 in oxidative stress and protein folding, both critical in ALS pathogenesis. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway SOD1 \u2192 BIP \u2192 ATF6 \u2192 DDIT3 involves SOD1, a gene associated with protein misfolding and oxidative stress. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway likely reflects SOD1's role in endoplasmic reticulum (ER) stress and unfolded protein response, with ATF6 and DDIT3 mediating downstream cellular responses. SOD1's dysfunction leads to neuronal toxicity, contributing to ALS pathogenesis. This connection highlights SOD1's critical role in maintaining protein homeostasis and its link to neurodegeneration. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein degradation. In the given pathway, ATXN3 is linked to the IP3-Ca2+ signaling cascade, which regulates mitochondrial calcium levels and apoptosis. Mutations in ATXN3 are well-documented in spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination. The expansion of the polyglutamine tract in ataxin-3 leads to protein misfolding, aggregation, and neuronal dysfunction, particularly in the cerebellum. This contributes to the hallmark symptoms of SCA2, including gait instability, slurred speech, and cognitive decline. The involvement of ATXN3 in this pathway underscores its role in maintaining calcium homeostasis and preventing cell death, and its dysfunction directly links to the pathogenesis of SCA2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a key component of the polyQ tract that, when expanded, leads to the development of spinocerebellar ataxia type 2 (SCA2). This expansion causes protein misfolding and aggregation, disrupting neuronal function, particularly in the cerebellum, which results in progressive coordination defects and ataxia. In the provided pathway, ATXN3 is part of the IP3-mediated calcium signaling cascade, where it may modulate calcium dynamics in neurons. Mutations in ATXN3 disrupt this pathway, leading to mitochondrial calcium dysregulation and oxidative stress, contributing to neurodegeneration. The accumulation of mutant ataxin-3 also promotes the formation of toxic protein aggregates, further impairing cellular homeostasis. These molecular disturbances underlie the pathogenesis of SCA2, a hereditary neurodegenerative disorder characterized by motor incoordination and cognitive decline.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: \"Glutamate -> GRM1 -> GNAQ -> PLCB -> IP3 -> (ITPR1+(ATXN2*,ATXN3*)) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\"\nGenes in the pathway: GRM1; glutamate metabotropic receptor 1 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ATXN2; ataxin 2 | ATXN3; ataxin 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves glutamate signaling leading to calcium influx through the mitochondrial calcium uniporter (MCU), contributing to mitochondrial dysfunction. ATXN3, an E3 ubiquitin ligase, is part of the calcium-regulated complex that influences protein degradation. Mutations in ATXN3 cause spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of coordination. The allele's role in modulating calcium homeostasis and ubiquitination pathways implicates it in neuronal dysfunction. Impaired calcium regulation and protein quality control due to ATXN3 mutations lead to neuronal death, particularly in cerebellar circuits. This contributes to the pathogenesis of SCA2. \\boxed{Spinocerebellar ataxia type 2}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, is critical for ubiquitin ligase activity targeting hypoxia-inducible factors (HIFs), such as EPAS1 and ARNT. When VHL is mutated, this complex fails to degrade HIFs under normoxic conditions, leading to constitutive HIF activation. This results in overexpression of HIF target genes like VEGFA, CXCL8, GLUT1, and EPO, promoting angiogenesis, inflammation, and erythropoiesis. This dysregulation is a hallmark of VHL hemangioblastoma and clear cell renal cell carcinoma. The loss of VHL function disrupts cellular responses to oxygen levels, contributing to tumor formation and progression. The disease associated with this VHL allele is von Hippel-Lindau disease, a hereditary disorder characterized by the development of cysts and tumors in multiple organs. \n\n\\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, is central to the ubiquitin ligase pathway that targets hypoxia-inducible factors (HIFs) for degradation. When VHL is mutated, this degradation pathway is disrupted, leading to the stabilization of HIF-1\u03b1. This results in the activation of HIF-1\u03b1 target genes such as VEGFA, CXCL8, GLUT1, and EPO, promoting angiogenesis, inflammation, and erythropoiesis. These molecular changes are hallmarks of hypoxia and are critical in tumor progression. Mutations in VHL are most commonly associated with von Hippel-Lindau (VHL) disease, a hereditary disorder characterized by the development of benign and malignant tumors in various organs, including the retina, brain, kidneys, and adrenal glands. The biological effect of the VHL allele mutation is therefore the development of VHL disease. \\boxed{Von Hippel-Lindau disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: (VHL*+RBX1+ELOC+ELOB+CUL2) // EPAS1 == ARNT => (VEGFA,CXCL8,GLUT1,EPO)\nGenes in the pathway: VHL; von Hippel-Lindau tumor suppressor | RBX1; ring-box 1 | ELOC; elongin C | ELOB; elongin B | CUL2; cullin 2 | EPAS1; endothelial PAS domain protein 1 | ARNT; aryl hydrocarbon receptor nuclear translocator | VEGFA; vascular endothelial growth factor A | CXCL8; C-X-C motif chemokine ligand 8 | SLC2A1; solute carrier family 2 member 1 | EPO; erythropoietin\n\nGiven this context, what is the biological effect of this VHL allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe VHL allele, as part of the VHL-RBX1-ELOC-ELOB-CUL2 complex, is crucial for ubiquitin ligase activity, targeting hypoxia-inducible factors (HIFs) like EPAS1 and ARNT for degradation. In the absence of functional VHL, this degradation is impaired, leading to stabilization of HIFs. This results in the upregulation of HIF-target genes such as VEGFA, CXCL8, GLUT1, and EPO, promoting angiogenesis, inflammation, and erythropoiesis. These effects are central to the pathogenesis of hemangioblastomas and clear cell renal cell carcinomas. Mutations in VHL are a hallmark of von Hippel-Lindau disease, a hereditary disorder characterized by the development of multiple tumors, including those in the kidneys, brain, and adrenal glands. The VHL pathway is thus directly linked to the development of von Hippel-Lindau disease.\n\n\\boxed{Von Hippel-Lindau disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT-BAD signaling cascade. Mutations in NRAS lead to constitutive activation of downstream effectors, including AKT, which inhibits BAD, a pro-apoptotic protein. This inhibition prevents apoptosis, promoting cell survival and proliferation. Such dysregulation is a hallmark of several cancers. Specifically, activating mutations in NRAS are commonly found in melanoma, particularly in cases arising from sun-damaged skin (senescent keratinocytes). These mutations drive uncontrolled cell growth and resistance to apoptosis, contributing to tumor formation and progression. Thus, the biological effect of this NRAS allele is the promotion of melanoma.\n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the RAS-PI3K-AKT-BAD signaling cascade, where NRAS and KRAS activate PI3K, leading to PIP3 production and subsequent activation of AKT. AKT then inhibits BAD, preventing apoptosis. Mutations in NRAS, such as activating mutations, result in constitutive activation of this pathway, promoting cell survival and proliferation. This contributes to uncontrolled cell growth and inhibition of programmed cell death, hallmark features of cancer. Specifically, NRAS mutations are strongly associated with **melanoma**, particularly in the context of **nevus melanocytic** and **uveal melanoma**, as well as **non-small cell lung cancer** and **colorectal cancer**. These mutations drive tumorigenesis by sustaining pro-survival signals and disrupting apoptotic mechanisms. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the RAS signaling pathway, activates PI3K, leading to the production of PIP3 and subsequent activation of AKT. This inhibits BAD, preventing apoptosis and promoting cell survival and proliferation. Mutations in NRAS, such as gain-of-function mutations, lead to constitutive activation of this pathway, driving uncontrolled cell growth. This contributes to the development of cancers characterized by sustained RAS signaling. The most common disease associated with activating NRAS mutations is **melanoma**, particularly in the context of BRAFV600E mutations. NRAS mutations are also found in other malignancies, including non-small cell lung cancer, colorectal cancer, and certain leukemias. However, melanoma is the most clinically significant disease linked to NRAS activation. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this pathway is the production of A\u03b2 (amyloid beta), which is a key component in the pathogenesis of Alzheimer's disease. The pathway involves the processing of APP into A\u03b2, which then interacts with PPID and other mitochondrial proteins, leading to mitochondrial dysfunction and the accumulation of MPTP (mitochondrial permeability transition pore). This contributes to neuronal damage and cell death. The involvement of VDACs and SLC25A genes highlights the role of mitochondrial permeability and energy metabolism in this process. The accumulation of A\u03b2 and subsequent mitochondrial dysfunction are strongly associated with the progression of Alzheimer's disease. Therefore, this pathway is central to the development of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this pathway is the production of amyloid beta (Abeta), which is a key component in the formation of amyloid plaques. This pathway leads to the disruption of mitochondrial function through interactions with PPID, VDACs, and SLC25A family members, ultimately affecting CYCS. These disruptions are strongly associated with neurodegeneration. The accumulation of Abeta and mitochondrial dysfunction are central features of Alzheimer's disease. Therefore, this pathway contributes directly to the pathogenesis of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> PPID -> MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | PPID; peptidylprolyl isomerase D | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele in this pathway is the production of amyloid-beta (Abeta), which is a key component in the pathogenesis of Alzheimer's disease. The pathway involving APP -> Abeta -> PPID -> MPTP -> CYCS highlights the role of Abeta in mitochondrial dysfunction and oxidative stress, leading to neuronal damage. Abnormal accumulation of Abeta leads to the formation of plaques in the brain, a hallmark of Alzheimer's. The involvement of VDACs and SLC25A genes suggests a disruption in mitochondrial homeostasis, further contributing to cell death. This pathway is strongly associated with the progression of Alzheimer's disease, making it a critical component in understanding the molecular basis of this neurodegenerative disorder. \\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). Mutations in the SOD1 gene lead to the production of a misfolded and toxic superoxide dismutase 1 protein, which aggregates and disrupts neuronal function. This protein dysfunction triggers oxidative stress, mitochondrial damage, and neuroinflammation, ultimately leading to the degeneration of motor neurons. The pathway described involves the ubiquitination and proteasomal degradation of misfolded proteins, including SOD1. Impaired proteasomal function, as indicated by the involvement of multiple proteasome subunits (PSMA and PSMB), contributes to the accumulation of toxic protein aggregates, exacerbating neurodegeneration. This pathway is central to the molecular mechanisms underlying SOD1-mediated ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, specifically in the context of this genomic pathway, contributes to amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is a key enzyme involved in antioxidant defense. Mutations in SOD1 are one of the most common genetic causes of familial ALS. The pathway described involves the ubiquitin-proteasome system, which is crucial for protein degradation. Misfolded or aggregated SOD1 proteins, particularly due to pathogenic mutations, resist degradation and accumulate, leading to neuronal toxicity. This accumulation disrupts proteostasis, impairs mitochondrial function, and triggers neurodegeneration. The involvement of proteasomal subunits like PSMA and PSMC highlights the role of the proteasome in clearing misfolded SOD1. Overall, dysfunctional SOD1 and impaired proteasomal degradation are central to the pathogenesis of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes protein ubiquitination and proteasomal degradation. SOD1 (superoxide dismutase 1) is an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-known to cause amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease characterized by the loss of motor neurons. The pathway involving SOD1, DERL1, and the proteasome complex is critical for protein quality control, and dysfunction in this pathway can lead to the accumulation of misfolded proteins, including mutant SOD1, which contributes to neuronal toxicity. Mutant SOD1 forms aggregates and disrupts cellular processes, leading to motor neuron death. This directly links the SOD1 allele to the development of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which plays a critical role in the processing of amyloid precursor protein (APP), leading to the production of \u03b2-amyloid peptides. Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (AD). These mutations disrupt normal \u03b3-secretase function, leading to increased production of toxic \u03b2-amyloid species, which aggregate into plaques in the brain. This pathological accumulation is associated with neuronal toxicity, synaptic dysfunction, and neuroinflammation, ultimately contributing to cognitive decline and dementia. The pathway described involves calcium dysregulation and mitochondrial dysfunction, which are downstream consequences of PSEN1 mutations, further exacerbating neuronal damage. Therefore, PSEN1 mutations primarily contribute to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex involved in the processing of amyloid precursor protein (APP). Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease (FAD). These mutations lead to increased production of amyloid-\u03b2 plaques, a hallmark of Alzheimer's pathology. The pathway described involves calcium signaling through the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channel (VDAC), leading to mitochondrial dysfunction, cytochrome c release, and activation of the mitochondrial apoptosis pathway via APAF1 and caspases 3 and 7. This cascade contributes to neuronal death, a key feature of Alzheimer's disease. Thus, the PSEN1 allele contributes to the development of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves the interaction between presenilins (PSEN1 and PSEN2), which are integral to gamma-secretase activity, and their role in regulating intracellular calcium levels via the ryanodine receptor (RYR3) and mitochondrial calcium uptake through MCU. This disruption leads to the release of cytochrome c (CYCS) from mitochondria, activating the apoptotic cascade via APAF1, CASP9, and subsequent activation of CASP3 and CASP7. Mutations in PSEN1 are well-documented in early-onset Alzheimer's disease (AD), as they contribute to amyloid-beta peptide production and neuronal dysfunction. The resulting calcium dyshomeostasis and mitochondrial damage drive neurodegeneration. Therefore, the biological effect of this PSEN1 allele is the promotion of neurodegeneration associated with Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 allele in this pathway drives oncogenic signaling through its activation of STAT5A/B, which in turn activates PIM1/2. This cascade promotes cell proliferation, survival, and resistance to apoptosis. Mutations in FLT3, particularly internal tandem duplication (ITD) or kinase domain mutations, are commonly found in acute myeloid leukemia (AML). These mutations lead to constitutive activation of the pathway, contributing to leukemogenesis. FLT3 mutations are associated with poor prognosis in AML patients due to their role in promoting tumor growth and resistance to therapy. Therefore, the biological effect of this FLT3 allele is the promotion of leukemic transformation. \n\n\\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 allele, specifically activating mutations in FLT3, leads to constitutive activation of the FMS-like tyrosine kinase 3 receptor. This results in persistent signaling through downstream pathways, including STAT5 and PIM1/2. This uncontrolled signaling promotes cell proliferation, survival, and resistance to apoptosis. The activation of these pathways is strongly associated with the development and progression of leukemia, particularly acute myeloid leukemia (AML). FLT3 mutations are among the most common genetic alterations in AML, contributing to disease aggressiveness and poor prognosis. These mutations are frequently found in patients with secondary AML, often arising from prior clonal hematopoiesis. Therefore, the biological effect of this FLT3 allele is the promotion of leukemic transformation, specifically contributing to acute myeloid leukemia.\n\n\\boxed{Acute Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 13\nNetwork Definition of the pathway: FLT3* -> STAT5 => PIM1/2\nGenes in the pathway: FLT3; fms related tyrosine kinase 3 | STAT5A; signal transducer and activator of transcription 5A | STAT5B; signal transducer and activator of transcription 5B | PIM1; Pim-1 proto-oncogene, serine/threonine kinase | PIM2; Pim-2 proto-oncogene, serine/threonine kinase\n\nGiven this context, what is the biological effect of this FLT3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FLT3 allele, specifically when mutated or overactive, contributes to the development of acute myeloid leukemia (AML). FLT3 is a receptor tyrosine kinase that, when constitutively activated, leads to continuous signaling through downstream pathways such as STAT5 and PIM1/2. This results in uncontrolled cell proliferation and inhibition of apoptosis, promoting leukemic transformation. Mutations in FLT3, particularly internal tandem duplications (ITDs) or point mutations, are frequently observed in AML and are associated with a poor prognosis. The activation of STAT5 and PIM1/2 further enhances cell survival and differentiation block, reinforcing the malignant phenotype. Thus, aberrant FLT3 signaling is a key driver in the pathogenesis of AML.\n\n\\boxed{Acute Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nLRRK2 is a key protein involved in cellular processes such as autophagy and apoptosis. In the given pathway, LRRK2 activates CYCS, which is involved in mitochondrial function, and through APAF1, leads to the activation of CASP9 and ultimately CASP3, promoting apoptosis. Mutations in LRRK2 are well-documented in Parkinson's disease. These mutations disrupt normal cellular functions, including mitochondrial homeostasis and protein degradation, leading to neuronal dysfunction and death, particularly in dopaminergic neurons. This contributes to the neurodegeneration observed in Parkinson's disease. Therefore, the biological effect of this LRRK2 allele is the promotion of apoptosis and neurodegeneration, directly contributing to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe LRRK2 pathway described involves the activation of cytochrome c (CYCS) through APAF1, leading to the activation of caspase-9 (CASP9) and subsequently caspase-3 (CASP3), which drives apoptosis. This pathway is critical for programmed cell death, particularly in response to mitochondrial damage. Mutations in LRRK2 are well-documented in Parkinson's disease (PD), where they contribute to neuronal death by disrupting mitochondrial function and promoting apoptosis. The involvement of CYCS, APAF1, CASP9, and CASP3 highlights a mechanism by which LRRK2 dysfunction leads to excessive apoptosis in dopaminergic neurons, a hallmark of PD. Thus, the biological effect of this LRRK2 allele is the promotion of neuronal apoptosis, contributing to the pathogenesis of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: LRRK2* -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: LRRK2; leucine rich repeat kinase 2 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this LRRK2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe LRRK2 pathway described represents a apoptotic cascade initiated by LRRK2, leading to the release of cytochrome c (CYCS), activation of APAF1, and subsequent activation of caspase-9 (CASP9) and caspase-3 (CASP3), resulting in programmed cell death. Mutations in LRRK2 are well-documented in Parkinson's disease. This particular pathway contributes to neuronal apoptosis, a key feature of Parkinson's. LRRK2 mutations disrupt normal cellular processes, including mitochondrial function and autophagy, leading to increased oxidative stress and neuronal death. The activation of the intrinsic apoptotic pathway via cytochrome c release and caspase activation is a mechanism by which LRRK2 mutations contribute to neurodegeneration. Thus, the biological effect of this LRRK2 allele is the promotion of apoptosis in neurons, specifically contributing to Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with impaired calcium influx, leading to disrupted neuronal function. This contributes to neurodevelopmental and neurodegenerative disorders. Specifically, pathogenic variants in CACNA1A are a known cause of spinocerebellar ataxia type 2 (SCA2), a hereditary disorder characterized by progressive loss of coordination and cerebellar atrophy. The dysfunction of calcium signaling through this channel disrupts synaptic transmission and leads to neuronal loss, particularly in the cerebellum. Therefore, the biological effect of this CACNA1A allele is the contribution to \\boxed{Spinocerebellar Ataxia Type 2}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CACNA1A gene encodes the alpha1A subunit of the P/Q-type voltage-gated calcium channel, which plays a critical role in neurotransmitter release and neuronal excitability. Mutations in CACNA1A are associated with a range of neurological disorders, including familial hemiplegic migraine (FHM), a form of migraine with aura characterized by severe headaches and temporary neurological deficits. These mutations often lead to altered calcium influx in neurons, disrupting normal synaptic function and contributing to hyperexcitability. CACNA1A mutations are also linked to ataxia and cerebellar degeneration, as seen in certain hereditary ataxias. The pathway involving extracellular calcium and the CACNA1A subunit highlights the gene's role in maintaining calcium homeostasis in neurons. Disruption of this pathway can lead to excessive neuronal activity and neurodegeneration. \\boxed{Familial Hemiplegic Migraine}", "user\nSolve the following genomic pathway question:\nChromosome Number: 19\nNetwork Definition of the pathway: Ca2+(extracellular) // CACNA1A* // Ca2+\nGenes in the pathway: CACNA1A; calcium voltage-gated channel subunit alpha1 A\n\nGiven this context, what is the biological effect of this CACNA1A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe **CACNA1A** gene encodes the alpha-1A subunit of the P/Q-type voltage-gated calcium channel. This subunit is critical for calcium influx into neurons, playing a key role in neurotransmitter release and neuronal excitability. Mutations in **CACNA1A** are associated with **familial hemiplegic migraine (FHM)**, a rare inherited form of migraine with aura. These mutations disrupt calcium homeostasis, leading to hyperexcitability of neurons and impaired regulation of synaptic transmission. The altered calcium signaling contributes to the pathophysiology of migraine attacks, including neuroinflammation and cortical spreading depression. Additionally, **CACNA1A** mutations have been linked to other neurological disorders, such as **spinocerebellar ataxia type 2 (SCA2)** and **central precocious puberty**. However, the most well-characterized condition directly linked to **CACNA1A** is **familial hemiplegic migraine**.\n\n\\boxed{Familial Hemiplegic Migraine}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. In the given pathway, SNCA is upstream of BIP and ERN1, which are involved in the unfolded protein response (UPR) in the endoplasmic reticulum (ER). ERN1 activates XBP1, a transcription factor that regulates ER function and stress responses. Mutations or overexpression of SNCA lead to the accumulation of misfolded alpha-synuclein, disrupting ER homeostasis and triggering UPR activation. This contributes to neuronal dysfunction and death, hallmarks of Parkinson's disease. Thus, the SNCA allele is a key contributor to the development of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function and aggregation in neurodegenerative diseases. In the given pathway, SNCA is upstream of HSPA5 (a chaperone protein) and ERN1 (a key sensor of endoplasmic reticulum (ER) stress). ERN1 activates XBP1, a transcription factor critical for ER stress response. Mutations or overexpression of SNCA lead to misfolded alpha-synuclein, triggering ER stress and activating this pathway. This contributes to neuronal damage and neurodegeneration. Notably, SNCA mutations are a major genetic cause of Parkinson's disease, where alpha-synuclein aggregation leads to Lewy body formation and dopaminergic neuron loss. Thus, the SNCA allele is strongly associated with Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SNCA; synuclein alpha | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function and aggregation in neurodegenerative diseases. In the provided pathway, SNCA is upstream of BIP (Binding Immunoglobulin Protein), a chaperone involved in ER stress response, which then activates ERN1 (ER stress sensor PERK), leading to XBP1 splicing. This pathway is central to the unfolded protein response (UPR). Mutations or overexpression of SNCA, particularly in Parkinson's disease, lead to the accumulation of misfolded alpha-synuclein, triggering ER stress and neuronal dysfunction. The activation of this pathway contributes to neurodegeneration by promoting ER stress and impairing protein homeostasis. Therefore, the SNCA allele is strongly associated with Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase involved in ubiquitin-mediated protein degradation. Mutations in PRKN lead to loss of function, impairing the ubiquitin-proteasome system and accumulating damaged proteins. This pathway includes UBCH7/8 (E2 conjugating enzymes) and PAELR, which are involved in ubiquitin conjugation. The dysfunction of PRKN is a key factor in Parkinson's disease, where it contributes to mitochondrial dysfunction, oxidative stress, and neurodegeneration. PRKN mutations are one of the most common genetic causes of early-onset Parkinson's disease. The loss of parkin function disrupts quality control mechanisms in neurons, leading to neuronal death. Therefore, the biological effect of PRKN allele mutations is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for ubiquitin-mediated proteasome degradation. Mutations in PRKN lead to impaired protein quality control and mitochondrial function. This contributes to the accumulation of misfolded proteins and damaged mitochondria, triggering cellular stress and neurodegeneration. PRKN is a key gene in the ubiquitin-proteasome system and is essential for maintaining neuronal health. Loss-of-function mutations in PRKN are a well-established cause of Parkinson's disease (PD), specifically autosomal recessive early-onset PD. These mutations disrupt the clearance of damaged mitochondria and protein aggregates, leading to dopaminergic neuron loss. Therefore, the biological effect of PRKN allele mutations is the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase involved in ubiquitin-mediated protein degradation. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. In the context of the provided pathway, PRKN interacts with UBCH7/8 (E2 conjugating enzymes) and PAELR, which are involved in ubiquitination processes. Dysfunction in this pathway leads to impaired protein quality control and mitochondrial maintenance, contributing to neuronal degeneration. The loss of functional PRKN results in the accumulation of misfolded proteins and damaged mitochondria, ultimately leading to the progressive loss of dopaminergic neurons. This genetic disruption is a key factor in the development of Parkinson's disease. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA lead to the aggregation of alpha-synuclein, which is a hallmark of Lewy body formation in Parkinson's. The pathway includes genes involved in the proteasome system, which is responsible for degrading misfolded or damaged proteins. Dysfunction in this system, including components of the 20S and 26S proteasomes, contributes to the accumulation of toxic alpha-synuclein. This accumulation disrupts neuronal function and leads to neurodegeneration. Therefore, the SNCA allele contributes to Parkinson's disease through the disruption of proteasomal degradation, resulting in the accumulation of misfolded proteins and neuronal damage. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of neurodegenerative diseases. Mutations or overexpression of SNCA are strongly associated with Parkinson\u2019s disease (PD), where misfolded alpha-synuclein aggregates into Lewy bodies, a hallmark of PD. The pathway includes genes involved in proteasomal function, such as PSMA and PSMB subunits, which are critical for protein degradation. Impaired proteasomal degradation of alpha-synuclein contributes to its accumulation, leading to neuronal toxicity. Additionally, the 26S proteasome subunits (e.g., PSMC, PSMD) are essential for the ubiquitin-proteasome system, which is disrupted in PD. Thus, SNCA dysfunction and proteasome impairment are interconnected in PD pathology. The biological effect of the SNCA allele is the contribution to the development and progression of Parkinson\u2019s disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| 26S\nGenes in the pathway: SNCA; synuclein alpha | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in the pathogenesis of Parkinson's disease. Mutations or overexpression of SNCA lead to the accumulation of misfolded alpha-synuclein, which forms toxic aggregates such as Lewy bodies. These aggregates disrupt neuronal function and contribute to the degeneration of dopaminergic neurons in the substantia nigra, a hallmark of Parkinson's disease. The pathway includes genes related to the proteasome, which is responsible for protein degradation. Dysfunction in proteasome subunits, as seen in this pathway, can impair the clearance of misfolded proteins, exacerbating the accumulation of toxic species like alpha-synuclein. This interplay between SNCA and proteasome dysfunction is central to the molecular mechanisms underlying Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene encodes presenilin 2, a key component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN2 are associated with early-onset familial Alzheimer's disease (FAD). These mutations lead to increased production of toxic amyloid-beta species, which aggregate into plaques in the brain, contributing to neuronal dysfunction and death. The pathway described involves the propagation of calcium dysregulation and mitochondrial stress, ultimately leading to apoptosis via the intrinsic mitochondrial pathway, further exacerbating neurodegeneration. This underscores the central role of PSEN2 in Alzheimer's disease pathology. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene encodes presenilin 2, a component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP). Mutations in PSEN2 are associated with early-onset familial Alzheimer's disease (FAD). In the provided pathway, PSEN2 is part of the upstream regulatory network leading to mitochondrial calcium dysregulation via MCU and VDACs, ultimately resulting in cytochrome c release, activation of APAF1, and caspase cascades that drive apoptosis. This aligns with the pathophysiology of Alzheimer's disease, where mitochondrial dysfunction and apoptosis contribute to neuronal loss. Thus, the biological effect of PSEN2 mutations is the disruption of normal calcium homeostasis and promotion of cell death, leading to neurodegeneration. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN2 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN2 gene encodes presenilin 2, a critical component of the gamma-secretase complex. Mutations in PSEN2 are associated with early-onset familial Alzheimer's disease (FAD). In the provided pathway, PSEN2 is part of the upstream regulatory network that influences calcium signaling through the ryanodine receptor 3 (RYR3) and mitochondrial calcium uptake via MCU. Dysregulation of this pathway leads to mitochondrial dysfunction, increased reactive oxygen species, and apoptosis via the intrinsic pathway involving cytochrome c (CYCS), APAF1, and caspases (CASP9, CASP3, CASP7). These events contribute to neuronal death and the pathogenesis of Alzheimer's disease. Thus, the PSEN2 allele contributes to the development of \\boxed{Alzheimer's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction leads to the accumulation of mutant protein aggregates. In the provided pathway, HTT is part of the calcium signaling cascade initiated by glutamate through the metabotropic receptor GRM5. Mutations in HTT, such as the CAG trinucleotide repeat expansion, result in the production of an abnormally long huntingtin protein, leading to neuronal dysfunction and cell death. This is the hallmark of Huntington\u2019s disease, a neurodegenerative disorder characterized by progressive motor, cognitive, and psychiatric impairments. The pathogenic mechanism involves disrupted calcium homeostasis, mitochondrial dysfunction, and activation of apoptotic pathways via the release of cytochrome c and subsequent caspase activation. Thus, the HTT allele contributes to Huntington\u2019s disease. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose dysfunction is central to Huntington's disease. In the given pathway, HTT is part of the calcium regulation cascade initiated by glutamate signaling. Mutations in HTT, particularly the CAG trinucleotide repeat expansion, lead to the production of an abnormally long huntingtin protein, which disrupts cellular processes, including calcium homeostasis and mitochondrial function. This disruption contributes to neuronal damage and apoptosis via the mitochondrial permeability transition pore (MPTP) and subsequent activation of caspases. The accumulation of misfolded huntingtin also impairs protein clearance and neurotransmission, leading to progressive neurodegeneration. These mechanisms are central to the pathogenesis of Huntington's disease, a genetic disorder characterized by motor dysfunction, cognitive decline, and behavioral changes. \n\n\\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: Glutamate -> GRM5 -> GNAQ -> PLCB -> IP3 -> (ITPR+HTT*) -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: GRM5; glutamate metabotropic receptor 5 | GNAQ; G protein subunit alpha q | PLCB1; phospholipase C beta 1 | PLCB2; phospholipase C beta 2 | PLCB3; phospholipase C beta 3 | PLCB4; phospholipase C beta 4 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3 | HTT; huntingtin | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein whose mutation leads to the accumulation of an abnormal protein aggregate. This is the primary genetic cause of Huntington's disease, a neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. The mutation involves an expansion of CAG trinucleotide repeats in the HTT gene, resulting in a toxic gain-of-function effect due to the formation of polyglutamine repeats. This leads to neuronal dysfunction and death, particularly in the striatum and cerebral cortex. The pathway involving HTT intersects with calcium signaling and apoptosis, contributing to neuronal damage. The presence of the mutant HTT allele is sufficient to cause the disease, making it a monogenetic disorder. \\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can lead to neurodegenerative diseases. The pathway PRNP \u2192 NOTCH1 suggests a potential interaction or regulatory role between the prion protein and the NOTCH1 receptor. Mutations in PRNP are most famously associated with Creutzfeldt-Jakob disease (CJD), a lethal transmissible spongiform encephalopathy caused by prion protein misfolding. This disease is characterized by rapid cognitive decline, neuronal loss, and\u6d77\u7ef5\u8111 (spongiform encephalopathy). The involvement of NOTCH1 may indicate a broader role in neurodevelopment or cell survival, but the primary disease linked to PRNP is Creutzfeldt-Jakob disease. \\boxed{Creutzfeldt-Jakob disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can trigger prion diseases. The pathway PRNP \u2192 NOTCH1 suggests a regulatory interaction where PRNP may modulate NOTCH1 signaling. Mutations in PRNP, particularly those leading to misfolding or aggregation of the prion protein, are directly associated with transmissible spongiform encephalopathies (TSEs). These include Creutzfeldt-Jakob Disease (CJD) in humans, bovine spongiform encephalopathy (BSE) in cattle, and scrapie in sheep. The misfolded prion protein (PrP^Sc) accumulates in the brain, causing neuronal damage and leading to progressive neurodegeneration. This pathway's disruption contributes to the pathogenesis of these fatal neurodegenerative disorders. \\boxed{Creutzfeldt-Jakob Disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 20\nNetwork Definition of the pathway: PRNP* -> NOTCH1\nGenes in the pathway: PRNP; prion protein | NOTCH1; notch receptor 1\n\nGiven this context, what is the biological effect of this PRNP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRNP gene encodes the prion protein, which, when misfolded, can induce conformational changes in normal prion proteins, leading to the formation of infectious prion aggregates. This process is central to prion diseases, a group of rare, fatal neurodegenerative disorders. The pathway PRNP \u2192 NOTCH1 suggests a potential regulatory interaction, though the exact mechanism remains under investigation. Mutations in PRNP are most famously associated with Creutzfeldt-Jakob disease (CJD), a rapidly progressive and almost always fatal brain disorder. These mutations can result in the abnormal folding of the prion protein, triggering misfolding of other prion proteins and leading to neuronal damage. This contributes to the hallmark spongiform encephalopathy observed in CJD. The interaction with NOTCH1 may further modulate cellular responses to prion-induced stress. \\boxed{Creutzfeldt-Jakob disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in ubiquitin homeostasis. Its role in protein degradation and quality control is critical. Mutations in UCHL1 disrupt this process, leading to the accumulation of misfolded proteins. This dysfunction is implicated in neurodegenerative diseases. Specifically, UCHL1 mutations contribute to Parkinson's disease by promoting alpha-synuclein aggregation and neuronal toxicity. Additionally, UCHL1 has been associated with Alzheimer's disease through its involvement in protein clearance pathways. The pathway involving UCHL1, along with ubiquitin-related genes like UBA52, UBB, and UBC, underscores its role in maintaining proteostasis. Impairment in this network leads to disease progression. The biological effect of the UCHL1 allele is therefore linked to neurodegeneration. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in the degradation of ubiquitin and ubiquitin-like proteins. Mutations in UCHL1 are associated with the accumulation of ubiquitinated proteins, leading to neurodegeneration. This gene is implicated in Parkinson's disease, where UCHL1 dysfunction contributes to the pathological accumulation of alpha-synuclein and other proteins, exacerbating neuronal loss. UCHL1 also plays a role in the ubiquitin-proteasome system, which is critical for protein quality control. Impaired UCHL1 function disrupts this system, leading to the accumulation of misfolded proteins and oxidative stress, both of which are hallmarks of Parkinson's disease. Therefore, the biological effect of the UCHL1 allele is the contribution to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: UB(chain) // UCHL1* // UB(free)\nGenes in the pathway: RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | UCHL1; ubiquitin C-terminal hydrolase L1\n\nGiven this context, what is the biological effect of this UCHL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe UCHL1 gene encodes ubiquitin C-terminal hydrolase L1, an enzyme involved in ubiquitin proteasome system regulation. Mutations in UCHL1 are associated with impaired protein degradation, leading to neurodegeneration. This gene is prominently linked to Parkinson's disease, where reduced UCHL1 activity contributes to the accumulation of misfolded proteins and neurotoxicity. The pathway involving UB(chain), UCHL1, and UB(free) reflects ubiquitin processing and turnover, critical for maintaining cellular homeostasis. Dysfunction in this pathway disrupts protein quality control, exacerbating neuronal damage. Therefore, the biological effect of the UCHL1 allele is a key contributor to the pathogenesis of Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). Mutations in the SOD1 gene lead to the production of a misfolded and toxic superoxide dismutase 1 enzyme, which accumulates in motor neurons. This accumulation causes oxidative stress, protein aggregation, and ultimately neuronal death. The pathway involving SOD1 and its interacting proteins, including dynactin subunits and dynein-related proteins, is critical for cellular processes such as protein transport and RNA processing. Dysfunction in this pathway disrupts axonal transport and leads to motor neuron degeneration. The involvement of multiple dynein and dynactin subunits suggests a broader role in neurodegeneration. This pathway is central to the pathogenesis of ALS, making SOD1 a key contributor to the disease. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented as a cause of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive degeneration of motor neurons. The pathway involving SOD1 and related genes such as DCTN1\u20136, ACTR1A/B, and various DNAH and DNAI genes suggests a role in cellular processes like axonal transport and mitochondrial function, which are disrupted in ALS. These genes are part of the cytoskeleton and motor protein complexes essential for neuronal function. Mutant SOD1 proteins can disrupt these pathways, leading to neuronal toxicity and cell death. Therefore, the SOD1 allele contributes to the pathogenesis of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally detoxifies superoxide radicals. Mutations in SOD1 disrupt its function, leading to the accumulation of toxic reactive oxygen species and subsequent neuronal damage, particularly in motor neurons. This results in the progressive degeneration of motor neurons in the brain and spinal cord, causing muscle weakness, atrophy, and ultimately paralysis. The pathway involving SOD1 and related genes such as DCTN1\u20136, ACTR1A/B, and various DNAH/DNAI/DNAL genes highlights a network involved in axonal transport and mitochondrial function, which are critical for neuronal health. Dysfunction in this pathway contributes to the pathogenesis of ALS. \\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involving SOD1 \u2192 BIP \u2192 ATF6 \u2192 DDIT3 highlights a stress response mechanism. SOD1, a copper/zinc superoxide dismutase, catalyzes the conversion of superoxide radicals into hydrogen peroxide. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by motor neuron loss. The pathway suggests SOD1's role in oxidative stress and endoplasmic reticulum (ER) stress, both of which are implicated in ALS pathology. The downstream activation of ATF6 and DDIT3 indicates a cellular response to proteotoxic stress, further supporting SOD1's contribution to neuronal dysfunction and death in ALS. Thus, this SOD1 allele is associated with the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway SOD1 \u2192 BIP \u2192 ATF6 \u2192 DDIT3 involves SOD1, which encodes superoxide dismutase 1. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway suggests SOD1\u2019s involvement in stress response mechanisms, likely through the unfolded protein response (via BIP and ATF6) and DDIT3, which is associated with cellular stress and apoptosis. The connection between SOD1 dysfunction and ALS is supported by both genetic and functional studies. Mutant SOD1 proteins gain toxic gain-of-function properties, leading to motor neuron death. Thus, this SOD1 allele contributes to the development of ALS.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ATF6 => DDIT3\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ATF6; activating transcription factor 6 | DDIT3; DNA damage inducible transcript 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway where SOD1 inhibits BIP, which in turn inhibits ATF6, leading to decreased expression of DDIT3. SOD1 is a copper/zinc superoxide dismutase enzyme that normally detoxifies superoxide radicals. Mutations in SOD1 are well-known to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway described suggests a role for SOD1 in cellular stress responses, particularly through the endoplasmic reticulum (ER) stress pathway involving ATF6 and DDIT3. Impaired regulation of this pathway due to mutant SOD1 contributes to neuronal dysfunction and death. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that plays a critical role in the BCR-ABL fusion protein, which is a hallmark of chronic myeloid leukemia (CML). The BCR-ABL fusion results from a reciprocal translocation between chromosomes 9 and 22, forming the Philadelphia chromosome. This fusion protein exhibits constitutive tyrosine kinase activity, leading to uncontrolled cell proliferation and survival by activating downstream signaling pathways, including the RAS-MAPK pathway. This aberrant signaling promotes leukemic transformation and resistance to apoptosis. The ABL1 allele, when fused to BCR, drives the transformation of hematopoietic cells, contributing directly to the development of CML. \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that plays a key role in the BCR-ABL pathway. When ABL1 is constitutively activated, as in the case of the Philadelphia chromosome translocation (t(9;22)), it leads to the formation of the BCR-ABL fusion protein. This fusion protein is a constitutively active tyrosine kinase that continuously activates downstream signaling pathways, including the RAS-RAF-MEK-ERK cascade. This uncontrolled signaling promotes cell proliferation, survival, and resistance to apoptosis, leading to uncontrolled cell growth. The hallmark disease associated with this genetic alteration is chronic myeloid leukemia (CML). The persistent activation of the BCR-ABL oncogene drives the transformation of hematopoietic cells, resulting in the clonal expansion of myeloid cells. \\boxed{Chronic Myeloid Leukemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: BCR-ABL -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this ABL1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ABL1 gene encodes a non-receptor tyrosine kinase that plays a critical role in the BCR-ABL pathway. When ABL1 is constitutively active, such as through the formation of the BCR-ABL fusion protein (commonly due to the Philadelphia chromosome translocation t(9;22)), it leads to continuous activation of downstream signaling molecules, including GRB2, SOS, RAS, RAF, MEK, and ERK. This persistent activation drives uncontrolled cell proliferation and inhibits apoptosis, leading to the development of chronic myeloid leukemia (CML). The BCR-ABL fusion protein is a key oncogenic driver in CML, making it a critical target for therapies like tyrosine kinase inhibitors. \\boxed{Chronic Myeloid Leukemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT pathway is critical for cell survival, proliferation, and differentiation. Mutations in KIT, particularly activating mutations in the KIT proto-oncogene, lead to constitutive activation of the KIT receptor tyrosine kinase. This results in uncontrolled signaling through downstream effectors such as GRB2, SOS, RAS, and the MAPK/ERK cascade. This aberrant signaling drives uncontrolled cell growth and survival, contributing to oncogenic transformation. This pathway is frequently dysregulated in diseases characterized by increased cell proliferation and survival. One such disease is **GIST (Gastrointestinal Stromal Tumor)**, where KIT mutations are among the most common genetic alterations. These mutations are often gain-of-function mutations that lead to continuous activation of the KIT receptor, promoting tumor growth. \\boxed{GIST}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, when mutated, leads to constitutive activation of the KIT receptor tyrosine kinase. This results in continuous signaling through the downstream pathway: KIT \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK. This aberrant signaling promotes uncontrolled cell proliferation, survival, and migration. The activation of this pathway is implicated in several diseases, including gastrointestinal stromal tumors (GISTs), which are the most common tumor type associated with KIT mutations. Additionally, KIT mutations can contribute to mast cell disorders such as mastocytosis and certain leukemias. The most characteristic disease linked to KIT mutations is gastrointestinal stromal tumor. \\boxed{GIST}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, specifically when mutated, leads to constitutive activation of the KIT receptor tyrosine kinase. This results in uncontrolled signaling through the downstream pathway: KIT \u2192 GRB2 \u2192 SOS \u2192 RAS \u2192 RAF \u2192 MEK \u2192 ERK. This aberrant signaling promotes cell proliferation, survival, and migration. Such dysregulation is a hallmark of several diseases. Notably, KIT mutations are commonly associated with gastrointestinal stromal tumors (GISTs), where activating mutations in KIT drive tumor growth. Additionally, KIT mutations can contribute to other malignancies, including certain leukemias and mast cell disorders. The most well-characterized disease linked to KIT mutations is gastrointestinal stromal tumor. \\boxed{Gastrointestinal Stromal Tumor}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDK4 allele in this genomic pathway plays a critical role in cell cycle regulation by phosphorylating the retinoblastoma protein (RB1). This phosphorylation inactivates RB1, releasing it from its inhibitory effect on E2F transcription factors. E2F then drives the expression of genes required for DNA replication and cell division, promoting cell proliferation. Dysregulation of this pathway, such as through amplification or mutation of CDK4, leads to unchecked cell growth. This contributes to the development of cancers characterized by uncontrolled cell division. The most well-known disease associated with this pathway alteration is **retinoblastoma**, a childhood eye cancer, but CDK4 overactivation is also implicated in other cancers such as breast, lung, and melanoma. The pathway's disruption is a key driver in tumor progression. \n\n\\boxed{Retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the interaction between cyclins (CCND1-3) and CDK4, leading to the phosphorylation of RB1, which in turn releases E2F transcription factors. This process drives cell cycle progression from G1 to S phase. Mutations or overexpression of CDK4 can lead to constitutive activation of this pathway, resulting in uncontrolled cell proliferation. This contributes to the development of cancers characterized by dysregulated cell cycle control. Specifically, alterations in CDK4 are strongly associated with **retinoblastoma** when combined with RB1 inactivation, and are also implicated in other malignancies such as breast, lung, and melanoma. The hallmark of this pathway dysfunction is the loss of RB1 tumor suppressor function, allowing unchecked cell division. Therefore, the biological effect of CDK4 alterations is the promotion of cell proliferation, contributing to **retinoblastoma** and other cancers. \n\n\\boxed{retinoblastoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 12\nNetwork Definition of the pathway: (CCND+CDK4*) -> RB1 // E2F\nGenes in the pathway: CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDK4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the interaction between cyclins (CCND1-3) and CDK4, leading to the phosphorylation of RB1, which in turn releases E2F transcription factors. This process promotes cell cycle progression from G1 to S phase. The CDK4 allele, when mutated or overactive, enhances this phosphorylation, leading to the inactivation of RB1 and uncontrolled cell proliferation. This dysregulation is a hallmark of several cancers. Specifically, alterations in CDK4 are strongly associated with retinoblastoma, a childhood eye cancer. Mutations in CDK4 or its regulatory genes, such as CDKN2A, contribute to the loss of cell cycle control, driving tumor formation. Therefore, the biological effect of the CDK4 allele in this pathway is the promotion of uncontrolled cell division, contributing to retinoblastoma.\n\n\\boxed{Retinoblastoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a key component in the ubiquitin-proteasome system and is involved in autophagy and the degradation of damaged proteins. In the context of the provided pathway, SQSTM1 is highlighted as a critical node connecting PINK1 and PRKN, which are implicated in mitochondrial quality control. Mutations in SQSTM1 can disrupt this pathway, leading to the accumulation of damaged proteins and mitochondrial dysfunction. This contributes to neurodegenerative processes. Specifically, SQSTM1 mutations are associated with Parkinson's disease, as they impair the clearance of aggregated proteins and mitochondrial dysfunction, both of which are central to the pathogenesis of Parkinson's. Therefore, the biological effect of this SQSTM1 allele is linked to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a key component in the ubiquitin-proteasome system and is involved in autophagy. In the given pathway, SQSTM1 is linked to PINK1 and PRKN, which are critical in mitochondrial quality control. Mutations in SQSTM1 disrupt this pathway, leading to impaired mitophagy and accumulation of damaged mitochondria. This dysfunction is associated with neurodegeneration. Specifically, SQSTM1 mutations contribute to Parkinson's disease by promoting neuronal loss and synaptic dysfunction. The gene's role in autophagy and its connection to mitochondrial health make it a key player in Parkinson's pathology. Therefore, the biological effect of this SQSTM1 allele is the contribution to \\boxed{Parkinson's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: PINK1 -> PRKN -> (CISD1,CISD2,FAF2,FKBP8,TOMM70,HK1) // SQSTM1* // LC3\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | CISD1; CDGSH iron sulfur domain 1 | CISD2; CDGSH iron sulfur domain 2 | FAF2; Fas associated factor family member 2 | FKBP8; FKBP prolyl isomerase 8 | TOMM70; translocase of outer mitochondrial membrane 70 | HK1; hexokinase 1 | SQSTM1; sequestosome 1 | MAP1LC3A; microtubule associated protein 1 light chain 3 alpha | MAP1LC3B; microtubule associated protein 1 light chain 3 beta | MAP1LC3B2; microtubule associated protein 1 light chain 3 beta 2 | MAP1LC3C; microtubule associated protein 1 light chain 3 gamma\n\nGiven this context, what is the biological effect of this SQSTM1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SQSTM1 (sequestosome 1) gene is a key component of the autophagy pathway, functioning as a ubiquitin-binding adaptor that facilitates the recruitment of damaged proteins and ubiquitinated substrates to autophagosomes. In the context of the provided pathway, SQSTM1 is positioned downstream of PINK1 and PRKN, which are critical in mitochondrial quality control. Mutations in SQSTM1 disrupt autophagy and mitochondrial homeostasis, leading to the accumulation of damaged mitochondria and protein aggregates. This dysfunction is strongly associated with neurodegeneration. Specifically, SQSTM1 mutations contribute to Parkinson's disease by impairing the clearance of damaged mitochondria and ubiquitinated proteins in neurons. The loss of SQSTM1 function exacerbates oxidative stress and neuronal death, making it a key player in the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele involves the accumulation of amyloid-beta (Abeta) through the cleavage of the amyloid beta precursor protein. This leads to the activation of the Fas-mediated apoptotic pathway, initiating a cascade that includes FADD, caspase-8, and downstream effector caspases such as caspase-3. This pathway also intersects with the mitochondrial apoptotic pathway via BID, BAX, BAK1, and the release of cytochrome c, which activates APAF1 and caspase-9. This apoptotic signaling contributes to neuronal death. The accumulation of Abeta and subsequent apoptosis are central to the pathogenesis of Alzheimer\u2019s disease. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the extrinsic apoptosis route initiated by the amyloid beta precursor protein (APP). The cleavage of APP leads to the production of amyloid beta, which is a key factor in neuronal toxicity. This pathway involves the activation of FAS, FADD, CASP8, and subsequent caspases like CASP9 and CASP3, ultimately leading to mitochondrial damage through BID, BAX, and BAK1, and the release of cytochrome c via APAF1. This process promotes apoptosis. The accumulation of amyloid beta and the activation of this apoptotic pathway are strongly associated with neurodegeneration. The biological effect of this APP allele is the promotion of neuronal apoptosis, contributing to the development of Alzheimer's disease. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> FAS -> FADD -> CASP8 -> BID -> (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: APP; amyloid beta precursor protein | FAS; Fas cell surface death receptor | FADD; Fas associated via death domain | CASP8; caspase 8 | BID; BH3 interacting domain death agonist | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway illustrates the extrinsic apoptosis pathway initiated by the amyloid beta precursor protein (APP). The cleavage of APP produces amyloid beta (Abeta), a key protein in the pathogenesis of Alzheimer's disease. Abeta triggers Fas receptor (FAS) activation, leading to the recruitment of FADD and the subsequent activation of caspase 8 (CASP8). This induces the release of cytochrome c (CYCS) via BID, BAX, and BAK1, promoting the activation of APAF1 and caspase 9 (CASP9), which ultimately activates caspase 3 (CASP3), leading to apoptosis. Accumulation of Abeta and subsequent apoptosis contribute to neuronal loss in Alzheimer's disease. Therefore, the biological effect of this APP allele is the promotion of apoptosis and neurodegeneration associated with Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves the KIT receptor tyrosine kinase, which activates PI3K (encoded by PIK3CA, PIK3CB, PIK3CD), leading to the production of PIP3 and subsequent activation of AKT (AKT1, AKT2, AKT3). AKT inhibits BAD, preventing apoptosis. Mutations in KIT or PI3K genes enhance this signaling, promoting cell survival and proliferation. This contributes to uncontrolled cell growth. The KIT allele, particularly mutations in KIT, are associated with mast cell disorders. The most well-known disease linked to KIT mutations is **mast cell leukemia** and **systemic mastocytosis**, characterized by the overproduction of mast cells. Mutations in KIT, such as activating mutations in exons 17, 18, or 21, drive the pathogenesis of these diseases by constitutively activating downstream pathways. \\boxed{systemic mastocytosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, when mutated, leads to constitutive activation of the KIT receptor tyrosine kinase, which initiates downstream signaling through PI3K and AKT. This pathway promotes cell survival by inhibiting BAD, a pro-apoptotic protein. The dysregulated survival signals result in uncontrolled cell proliferation and resistance to apoptosis. This mechanism is central to several cancers. Notably, mutations in KIT are strongly associated with gastrointestinal stromal tumors (GISTs), where activating mutations in KIT drive tumor growth. Additionally, KIT mutations are implicated in other malignancies such as leukemia and certain melanomas. The persistent activation of the PI3K/AKT pathway due to KIT dysfunction contributes to tumor progression and therapeutic resistance. Thus, the biological effect of this KIT allele is the promotion of cell survival and proliferation, leading to the development of \\boxed{GIST}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: KIT* -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KIT; KIT proto-oncogene receptor tyrosine kinase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this KIT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe KIT allele, through its activation of the PI3K-AKT-BAD signaling pathway, promotes cell survival by inhibiting BAD, a pro-apoptotic protein. This leads to resistance to programmed cell death, uncontrolled cell proliferation, and tumor formation. Mutations or overactivation of KIT, such as those found in PIK3CA, PIK3CB, PIK3CD, or AKT1-3 genes, enhance this pathway, contributing to oncogenesis. This pathway is critically involved in the development and progression of cancers characterized by KIT overactivation. The most prominent disease associated with this pathway is Gastrointestinal Stromal Tumor (GIST), where KIT mutations or amplifications are common. These genetic alterations drive tumorigenesis by promoting cell survival and growth. \\boxed{Gastrointestinal Stromal Tumor}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, as part of the described pathway, is involved in the regulation of apoptosis. SOD1 is upstream of BCL2, which modulates the balance between cell survival and apoptosis by controlling the release of cytochrome c from mitochondria. The pathway leads to the activation of CASP9 and subsequently CASP3, resulting in apoptosis. Mutations in SOD1, particularly in the context of misfolded protein aggregation, are well-documented in amyotrophic lateral sclerosis (ALS). These mutations lead to toxic gain-of-function, disrupting mitochondrial homeostasis and promoting neuronal death. Therefore, the biological effect of the SOD1 allele in this pathway is the induction of apoptosis, contributing to the pathogenesis of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele, as part of the described pathway, is involved in apoptosis regulation. SOD1 (superoxide dismutase 1) is an antioxidant enzyme that converts superoxide radicals into hydrogen peroxide. Mutations in SOD1 are well-known to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. In the given pathway, SOD1 is upstream of BCL2, which regulates mitochondrial outer membrane permeabilization. Mutant SOD1 can disrupt this regulation, leading to mitochondrial dysfunction and apoptosis via the BAX/BAK1-CYCS-APAF1-CASP9-CASP3 pathway. This promotes neuronal cell death, contributing to the pathogenesis of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BCL2 -| (BAX,BAK1) -> CYCS == APAF1 -> CASP9 -> CASP3\nGenes in the pathway: SOD1; superoxide dismutase 1 | BCL2; BCL2 apoptosis regulator | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that links oxidative stress to apoptosis. SOD1, a copper/zinc superoxide dismutase, normally detoxifies superoxide radicals. Mutations in SOD1 lead to the production of misfolded proteins that aggregate, disrupting cellular function and promoting neuronal death. This pathway involves BCL2, which regulates apoptosis by controlling mitochondrial outer membrane permeabilization. BAX and BAK1 mediate mitochondrial outer membrane permeabilization, releasing cytochrome c (CYCS), which activates APAF1 and CASP9, leading to CASP3 activation and apoptosis. Mutations in SOD1 are a well-documented cause of amyotrophic lateral sclerosis (ALS). The accumulation of toxic SOD1 proteins disrupts mitochondrial function and triggers apoptotic pathways, contributing to motor neuron degeneration. \\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MEN1 allele, when mutated, leads to the loss of function of the MEN1 gene, which encodes the tumor suppressor protein menin. This protein is critical for the regulation of cell proliferation and apoptosis. The pathway defined includes KMT2A, a histone methyltransferase, and CDKN1B and CDKN2C, which are cyclin-dependent kinase inhibitors. The disruption of MEN1 results in the dysregulation of these genes, promoting uncontrolled cell growth. This contributes to the development of multiple endocrine neoplasia type 1 (MEN1), a genetic disorder characterized by tumors in multiple endocrine glands. The loss of MEN1 function impairs the normal control of cell cycle progression and tumor suppression, leading to the hallmark features of MEN1 syndrome. \\boxed{Multiple Endocrine Neoplasia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MEN1 gene encodes menin, a tumor suppressor protein involved in transcriptional regulation and cell cycle control. When mutated, it disrupts these functions, leading to uncontrolled cell proliferation. The interaction with KMT2A, a histone methyltransferase, suggests altered chromatin structure and gene expression. CDKN1B and CDKN2C are cyclin-dependent kinase inhibitors that regulate cell cycle progression. Loss of function in these genes due to mutations or epigenetic changes can result in cell cycle deregulation. Together, this pathway is implicated in the development of tumors. Specifically, mutations in MEN1 are a well-known cause of **multiple endocrine neoplasia type 1 (MEN1)**, a hereditary syndrome characterized by tumors in multiple endocrine glands. The biological effect of the MEN1 allele is thus the initiation and progression of **MEN1 syndrome**.\n\n\\boxed{Multiple Endocrine Neoplasia Type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 11\nNetwork Definition of the pathway: (MEN1*+KMT2A) // (CDKN1B,CDKN2C)\nGenes in the pathway: MEN1; menin 1 | KMT2A; lysine methyltransferase 2A | CDKN1B; cyclin dependent kinase inhibitor 1B | CDKN2C; cyclin dependent kinase inhibitor 2C\n\nGiven this context, what is the biological effect of this MEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe MEN1 allele, when mutated, leads to the loss of function of the MEN1 gene, which encodes the tumor suppressor protein menin. Menin plays a critical role in regulating cell growth and apoptosis by interacting with various proteins, including KMT2A and CDKN1B/CDKN2C, which are involved in cell cycle control. The dysregulation of this pathway contributes to uncontrolled cell proliferation. Mutations in MEN1 are well-established as a cause of **Multiple Endocrine Neoplasia type 1 (MEN1)**. This condition is characterized by the development of tumors in multiple endocrine glands, including parathyroid, pancreatic, and pituitary glands. The disruption of the tumor suppressor function due to the MEN1 mutation leads to increased risk of endocrine tumors. Therefore, the biological effect of the MEN1 allele is the promotion of tumor formation, contributing to **Multiple Endocrine Neoplasia type 1**.\n\n\\boxed{Multiple Endocrine Neoplasia type 1}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APC allele plays a critical role in the WNT signaling pathway. The pathway described involves the inhibition of \u03b2-catenin degradation by APC, leading to its accumulation and activation of TCF/LEF transcription factors. This results in the upregulation of downstream genes such as BIRC5, MYC, and CCND1, which drive cell proliferation and inhibit apoptosis. Mutations in APC, particularly loss-of-function mutations, disrupt this regulation, leading to uncontrolled cell growth. This is a hallmark of colorectal cancer, where APC mutations are among the most common genetic alterations. The loss of APC function results in \u03b2-catenin stabilization and aberrant activation of WNT target genes, promoting tumor formation and progression. Thus, the biological effect of this APC allele is the promotion of colorectal cancer.\n\n\\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APC allele plays a critical role in the WNT signaling pathway. The pathway described involves the degradation of CTNNB1 (\u03b2-catenin) through a complex including APC, GSK3B, AXIN1/2, and ultimately prevents its nuclear accumulation. When APC is mutated or inactivated, this degradation is impaired, leading to stabilization and nuclear accumulation of \u03b2-catenin. This aberrant activation of \u03b2-catenin/TCF/LEF transcriptional activity drives the expression of oncogenes such as MYC, CCND1, and BIRC5, promoting uncontrolled cell proliferation and survival. This dysregulation is a hallmark of colorectal cancer. The inactivation of APC is one of the most common genetic alterations in colorectal carcinogenesis. \\boxed{Colorectal Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 5\nNetwork Definition of the pathway: (GSK3B+AXIN) // APC* // CTNNB1 -> TCF/LEF => (BIRC5,MYC,CCND1)\nGenes in the pathway: GSK3B; glycogen synthase kinase 3 beta | AXIN1; axin 1 | AXIN2; axin 2 | APC; APC, WNT signaling pathway regulator | CTNNB1; catenin beta 1 | TCF7; transcription factor 7 | TCF7L1; transcription factor 7 like 1 | TCF7L2; transcription factor 7 like 2 | LEF1; lymphoid enhancer binding factor 1 | BIRC5; baculoviral IAP repeat containing 5 | MYC; MYC proto-oncogene, bHLH transcription factor | CCND1; cyclin D1\n\nGiven this context, what is the biological effect of this APC allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe APC allele plays a central role in the WNT signaling pathway. The pathway described involves the degradation of \u03b2-catenin (CTNNB1) by a complex including APC, GSK3B, AXIN1/AXIN2, which prevents its accumulation. When APC is mutated or inactivated, this degradation is impaired, leading to \u03b2-catenin stabilization and nuclear translocation. This activates TCF/LEF transcription factors, promoting the expression of oncogenes such as MYC, CCND1, and BIRC5. This dysregulated signaling contributes to uncontrolled cell proliferation and survival. Mutations in APC are a hallmark of colorectal cancer, where loss of function in APC leads to persistent WNT activation and tumor progression. Therefore, the biological effect of the APC allele is the promotion of colorectal cancer through aberrant WNT signaling.\n\n\\boxed{Colorectal Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally detoxifies reactive oxygen species. However, mutations in SOD1 can lead to its misfolding and aggregation, which contributes to neuronal toxicity. This pathological process is central to the degeneration of motor neurons in ALS. The pathway described involves the ubiquitination of SOD1, leading to its degradation via the ubiquitin-proteasome system, which is impaired in disease. The involvement of proteasomal subunits (e.g., PSMA and PSMB) highlights the proteasome's role in the clearance of misfolded SOD1. Mutant SOD1 disrupts this system, leading to protein accumulation and neurodegeneration. Therefore, the biological effect of the SOD1 allele is the contribution to the development of amyotrophic lateral sclerosis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is involved in a pathway that includes ubiquitination and proteasomal degradation. SOD1, when misfolded or mutated, can aggregate and resist degradation, leading to the accumulation of toxic protein species. This is a hallmark of neurodegenerative diseases. Specifically, mutations in SOD1 are well-documented as a cause of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder characterized by the loss of motor neurons. The pathway involving DERL1, ubiquitin (UBA52, UBB, UBC), and proteasomal subunits (PSMA and PSMB) reflects the cellular attempt to degrade misfolded SOD1. Impairment in this pathway contributes to the accumulation of toxic SOD1 aggregates, driving disease progression. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| DERL1 -> (Protein+UB) -- 26S -> Peptide\nGenes in the pathway: SOD1; superoxide dismutase 1 | DERL1; derlin 1 | RPS27A; ribosomal protein S27a | UBA52; ubiquitin A-52 residue ribosomal protein fusion product 1 | UBB; ubiquitin B | UBC; ubiquitin C | PSMA6; proteasome 20S subunit alpha 6 | PSMA2; proteasome 20S subunit alpha 2 | PSMA4; proteasome 20S subunit alpha 4 | PSMA7; proteasome 20S subunit alpha 7 | PSMA8; proteasome 20S subunit alpha 8 | PSMA5; proteasome 20S subunit alpha 5 | PSMA1; proteasome 20S subunit alpha 1 | PSMA3; proteasome 20S subunit alpha 3 | PSMB6; proteasome 20S subunit beta 6 | PSMB7; proteasome 20S subunit beta 7 | PSMB3; proteasome 20S subunit beta 3 | PSMB2; proteasome 20S subunit beta 2 | PSMB5; proteasome 20S subunit beta 5 | PSMB1; proteasome 20S subunit beta 1 | PSMB4; proteasome 20S subunit beta 4 | PSMC2; proteasome 26S subunit, ATPase 2 | PSMC1; proteasome 26S subunit, ATPase 1 | PSMC4; proteasome 26S subunit, ATPase 4 | PSMC6; proteasome 26S subunit, ATPase 6 | PSMC3; proteasome 26S subunit, ATPase 3 | PSMC5; proteasome 26S subunit, ATPase 5 | PSMD2; proteasome 26S subunit, non-ATPase 2 | PSMD1; proteasome 26S subunit, non-ATPase 1 | PSMD3; proteasome 26S subunit, non-ATPase 3 | PSMD9; proteasome 26S subunit, non-ATPase 9 | PSMD12; proteasome 26S subunit, non-ATPase 12 | PSMD11; proteasome 26S subunit, non-ATPase 11 | PSMD6; proteasome 26S subunit, non-ATPase 6 | PSMD7; proteasome 26S subunit, non-ATPase 7 | PSMD13; proteasome 26S subunit, non-ATPase 13 | PSMD4; proteasome 26S subunit, non-ATPase 4 | PSMD14; proteasome 26S subunit, non-ATPase 14 | PSMD8; proteasome 26S subunit, non-ATPase 8 | ADRM1; adhesion regulating molecule 1 | SEM1; SEM1 26S proteasome complex subunit\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that normally neutralizes superoxide radicals. Mutations in SOD1 lead to the production of dysfunctional or toxic SOD1 proteins, which aggregate and disrupt cellular processes, particularly in motor neurons. These aggregates contribute to neuronal death, leading to the progressive degeneration of motor neurons responsible for controlling voluntary muscles. This results in the clinical features of ALS, including muscle weakness, atrophy, and eventual paralysis. The pathway involving SOD1, DERL1, and the proteasome components highlights the role of protein misfolding and degradation in disease progression. Mutant SOD1 is misfolded and is targeted for degradation via the ubiquitin-proteasome system, but impaired proteasome function exacerbates the accumulation of toxic protein aggregates. \\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is associated with amyotrophic lateral sclerosis (ALS). SOD1, or superoxide dismutase 1, is an enzyme that catalyzes the conversion of superoxide radicals into less harmful molecules. Mutations in the SOD1 gene lead to the production of abnormal SOD1 proteins that aggregate and cause toxic effects in motor neurons. These aggregates disrupt cellular processes, leading to neuronal death. The pathway includes genes involved in cytoskeletal dynamics and transport, such as dynactin subunits and dynein-related proteins, which are essential for intracellular transport. Dysfunction in these processes contributes to neurodegeneration. Mutations in SOD1 are a well-documented cause of familial ALS, and they are linked to the clinical features of the disease, including progressive muscle atrophy and paralysis. The involvement of these genes highlights the role of protein misfolding and transport defects in ALS pathogenesis.\n\n\\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by the progressive loss of motor neurons. The pathway involving SOD1 and associated genes like DCTN1-6, ACTR1A/B, and various DNAH and DNAI genes suggests involvement in cytoskeletal dynamics, axonal transport, and mitochondrial function\u2014key processes disrupted in ALS. These genes collectively support neuronal structure and function, and their dysfunction contributes to motor neuron death. Therefore, the biological effect of pathogenic SOD1 alleles is the disruption of these essential cellular processes, leading to neurodegeneration. \\boxed{Amyotrophic Lateral Sclerosis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| (DCTN+DNAH+DNAI+DNALI1+DNAL)\nGenes in the pathway: SOD1; superoxide dismutase 1 | DCTN1; dynactin subunit 1 | DCTN2; dynactin subunit 2 | DCTN3; dynactin subunit 3 | DCTN4; dynactin subunit 4 | DCTN5; dynactin subunit 5 | DCTN6; dynactin subunit 6 | ACTR1A; actin related protein 1A | ACTR1B; actin related protein 1B | ACTR10; actin related protein 10 | DNAH1; dynein axonemal heavy chain 1 | DNAH2; dynein axonemal heavy chain 2 | DNAH3; dynein axonemal heavy chain 3 | DNAH5; dynein axonemal heavy chain 5 | DNAH6; dynein axonemal heavy chain 6 | DNAH7; dynein axonemal heavy chain 7 | DNAH8; dynein axonemal heavy chain 8 | DNAH9; dynein axonemal heavy chain 9 | DNAH10; dynein axonemal heavy chain 10 | DNAH11; dynein axonemal heavy chain 11 | DNAH12; dynein axonemal heavy chain 12 | DNAH17; dynein axonemal heavy chain 17 | DNAI1; dynein axonemal intermediate chain 1 | DNAI2; dynein axonemal intermediate chain 2 | DNALI1; dynein axonemal light intermediate chain 1 | DNAL1; dynein axonemal light chain 1 | DNAL4; dynein axonemal light chain 4\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are well-documented to cause amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The pathway involving SOD1 and related genes, such as dynactin subunits and dynein heavy and light chains, is critical for cellular processes like axonal transport and mitochondrial function. These genes are involved in the transport of proteins and organelles along microtubules, a process essential for neuronal health. Mutations in SOD1 disrupt this network, leading to neuronal dysfunction and death. This contributes to the pathogenesis of ALS. \n\n\\boxed{Amyotrophic Lateral Sclerosis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein implicated in neuronal dysfunction. The pathway SNCA \u2192 VMAT2 suggests a regulatory relationship where SNCA may influence VMAT2, a vesicular monoamine transporter. Mutations or overexpression of SNCA are well-documented in Parkinson's disease (PD), where misfolded alpha-synuclein forms Lewy bodies, a hallmark of PD. This pathological accumulation disrupts synaptic function and leads to neurodegeneration. The involvement of VMAT2 may relate to dopamine transport, as VMAT2 is critical for packaging dopamine into synaptic vesicles. Dysregulation of this pathway could impair dopaminergic neuron function, contributing to the motor and non-motor symptoms of PD. Thus, the SNCA allele is strongly associated with Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function. The pathway SNCA \u2192 VMAT2 indicates a regulatory relationship, where SNCA may influence VMAT2 (vesicular monoamine transporter 2). Mutations or increased expression of SNCA are strongly associated with the aggregation of alpha-synuclein, a hallmark of neurodegenerative diseases. This contributes to the pathogenesis of Parkinson's disease, where misfolded alpha-synuclein forms Lewy bodies, leading to neuronal dysfunction and death, particularly in dopamine-producing neurons. The interaction with VMAT2 may affect monoamine storage and release, further exacerbating neuronal damage. Thus, the SNCA allele contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: SNCA* -| VMAT2\nGenes in the pathway: SNCA; synuclein alpha | SLC18A2; solute carrier family 18 member A2\n\nGiven this context, what is the biological effect of this SNCA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SNCA gene encodes alpha-synuclein, a protein involved in synaptic function. The pathway SNCA \u2192 VMAT2 suggests a regulatory relationship where SNCA may influence vesicular monoamine transporter 2 (VMAT2), which is critical for neurotransmitter storage. Mutations or aberrant expression of SNCA are strongly associated with the accumulation of alpha-synuclein aggregates, a hallmark of neurodegenerative diseases. This contributes to the pathogenesis of Parkinson's disease, where misfolded alpha-synuclein forms Lewy bodies, leading to neuronal dysfunction and death, particularly in dopaminergic neurons. The interaction with VMAT2 may affect dopamine handling, further exacerbating Parkinson's pathology. Thus, the SNCA allele contributes to the development of Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme catalyzes the conversion of glutamate to N-acetylglutamate, a key activator of carbamoyl-phosphate synthase 1 (CPS1), which initiates the urea cycle. Mutations in NAGS lead to reduced CPS1 activity, impairing the conversion of ammonia to urea. This results in hyperammonemia, a buildup of ammonia in the blood, which is toxic to the brain. This condition is known as N-acetylglutamate synthetase deficiency, a rare autosomal recessive disorder. Affected individuals may present with neurological symptoms such as seizures, ataxia, and developmental delay. The disease is part of the broader urea cycle disorders. \\boxed{N-acetylglutamate synthetase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme catalyzes the formation of N-acetylglutamate from acetyl-CoA and glutamate, which is essential for the activation of carbamoyl phosphate synthetase I (CPS1), the rate-limiting enzyme in the urea cycle. Mutations in NAGS lead to reduced CPS1 activity, causing impaired ammonia detoxification. This results in hyperammonemia, a buildup of ammonia in the blood, which can cause neurological damage. The specific disease associated with NAGS mutations is **hyperammonemia due to N-acetylglutamate synthase deficiency**, a rare genetic disorder classified as a urea cycle disorder. This condition is typically autosomal recessive and can lead to developmental delays, seizures, and in severe cases, coma or death if left untreated. \\boxed{Hyperammonemia due to N-acetylglutamate synthase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme catalyzes the formation of N-acetylglutamate from acetyl-CoA and glutamate, which is essential for the activation of carbamoyl-phosphate synthase 1 (CPS1), the rate-limiting enzyme in the urea cycle. Mutations in NAGS lead to reduced CPS1 activity, impairing urea synthesis and resulting in hyperammonemia. This condition is characterized by the accumulation of ammonia in the blood, which can cause neurological symptoms. The specific disease associated with NAGS mutations is **N-acetylglutamate synthase deficiency**, a rare autosomal recessive disorder. This disorder contributes to the pathogenesis of **hyperammonemia**, which can lead to severe neurological complications if left untreated. \\boxed{Hyperammonemia}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway involving SOD1, HSPA5, ERN1, and XBP1 is central to the unfolded protein response (UPR) in the endoplasmic reticulum (ER). SOD1, a copper/zinc superoxide dismutase, is crucial for neutralizing reactive oxygen species. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the progressive loss of motor neurons. The altered SOD1 protein disrupts ER homeostasis, leading to ER stress and activation of the UPR via ERN1 and XBP1. This pathway dysfunction contributes to neuronal toxicity and disease progression. The involvement of HSPA5, a molecular chaperone, further supports the role of protein folding and stress response in disease pathogenesis. Therefore, the SOD1 allele contributes to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 allele is part of a pathway involving ER stress response genes. SOD1 encodes superoxide dismutase 1, which detoxifies reactive oxygen species. Mutations in SOD1 are well-documented in amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by progressive motor neuron loss. The pathway SOD1 \u2192 BIP \u2192 ERN1 \u2192 XBP1 reflects a link between oxidative stress and endoplasmic reticulum (ER) stress. Misfolded proteins accumulate in the ER, activating the unfolded protein response (UPR) via ERN1 and XBP1. This leads to neuronal damage and cell death, contributing to ALS pathogenesis. Therefore, the biological effect of the SOD1 allele in this context is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: SOD1* -| BIP -| ERN1 -> XBP1\nGenes in the pathway: SOD1; superoxide dismutase 1 | HSPA5; heat shock protein family A (Hsp70) member 5 | ERN1; endoplasmic reticulum to nucleus signaling 1 | XBP1; X-box binding protein 1\n\nGiven this context, what is the biological effect of this SOD1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SOD1 gene encodes superoxide dismutase 1, an enzyme that catalyzes the conversion of superoxide radicals into hydrogen peroxide and oxygen. Mutations in SOD1 are strongly associated with amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder characterized by progressive degeneration of motor neurons. In the given pathway, SOD1 is upstream of BIP and ERN1, which are involved in the unfolded protein response (UPR) and ER stress. Mutant SOD1 can lead to ER stress and activation of the UPR, contributing to neuronal toxicity. This pathway is critical in mediating the cellular response to misfolded proteins and oxidative stress, both of which are implicated in ALS pathogenesis. Therefore, the biological effect of this SOD1 allele is the contribution to the development of \\boxed{Amyotrophic Lateral Sclerosis (ALS)}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT signaling cascade. Mutations in NRAS, like KRAS, lead to constitutive activation of downstream effectors, including AKT, which inhibits BAD, a pro-apoptotic protein. This results in suppression of apoptosis and unchecked cell proliferation. Such dysregulation is a hallmark of several cancers. Specifically, NRAS mutations are commonly found in melanoma, particularly in the context of BRAF wild-type tumors. They also contribute to other malignancies, including certain subtypes of lung cancer, colorectal cancer, and pancreatic cancer. The sustained activation of this pathway promotes cell survival, growth, and resistance to apoptosis, driving tumorigenesis. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, plays a central role in activating the PI3K-AKT signaling cascade. Mutations in NRAS, like KRAS, lead to constitutive activation of downstream effectors, including AKT, which inhibits BAD, a pro-apoptotic protein. This results in reduced apoptosis and enhanced cell survival, promoting uncontrolled cell proliferation. This pathway is critical in oncogenesis, particularly in cancers where RAS proteins are mutated. NRAS mutations are commonly found in melanoma, non-small cell lung cancer, and colorectal cancer. The dysregulated PI3K-AKT-BAD axis contributes to tumor progression by enhancing cell survival, angiogenesis, and resistance to therapy. Therefore, NRAS mutations are strongly associated with **melanoma**. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: (KRAS*,NRAS*) -> PI3K -> PIP3 -> AKT -| BAD\nGenes in the pathway: KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | BAD; BCL2 associated agonist of cell death\n\nGiven this context, what is the biological effect of this NRAS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NRAS allele, as part of the KRAS/NRAS -> PI3K -> PIP3 -> AKT -> BAD pathway, contributes to the activation of the PI3K-AKT signaling cascade. Mutations in NRAS, like KRAS, lead to constitutive activation of downstream effectors, including AKT, which inhibits BAD, a pro-apoptotic protein. This results in resistance to apoptosis and uncontrolled cell proliferation. Such alterations are commonly found in cancers where cell survival and growth signals are chronically activated. The most notable disease associated with NRAS mutations is **Melanoma**, particularly in the context of sun-exposed skin, where NRAS mutations are a frequent driver mutation. These mutations are also observed in other cancers, including non-small cell lung cancer and bladder cancer, but melanoma is the most directly linked disease. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is central to cellular response to DNA damage and stress, promoting cell cycle arrest, DNA repair, and apoptosis. Mutations in TP53 disrupt these functions, leading to genomic instability and impaired tumor suppression. The listed genes\u2014CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK\u2014are key effectors of p53-mediated responses. When TP53 is mutated, these genes are less effectively activated, reducing the cell\u2019s ability to respond to DNA damage. This results in unchecked cell proliferation and resistance to apoptosis, hallmarks of cancer. Consequently, TP53 mutations are strongly associated with a variety of cancers, including but not limited to osteosarcoma, breast cancer, and bladder cancer. The most well-documented disease linked to TP53 mutations is Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 gene is a critical tumor suppressor that regulates cell cycle arrest, DNA repair, and apoptosis. The pathway includes genes such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, all of which are involved in DNA damage response and apoptosis. Mutations in TP53 disrupt its ability to respond to DNA damage, leading to genomic instability and loss of cell cycle control. This contributes to uncontrolled cell proliferation and resistance to apoptosis, hallmark features of cancer. TP53 mutations are strongly associated with a variety of cancers, most notably **Li-Fraumeni syndrome**, a hereditary disorder characterized by an increased risk of multiple cancers, including sarcomas, breast cancer, brain tumors, and leukemia. \\boxed{Li-Fraumeni syndrome}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: \"TP53* // (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)\"\nGenes in the pathway: TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | GADD45A; growth arrest and DNA damage inducible alpha | GADD45B; growth arrest and DNA damage inducible beta | GADD45G; growth arrest and DNA damage inducible gamma | BAX; BCL2 associated X, apoptosis regulator | BAK1; BCL2 antagonist/killer 1 | DDB2; damage specific DNA binding protein 2 | POLK; DNA polymerase kappa\n\nGiven this context, what is the biological effect of this TP53 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe TP53 pathway is a central regulator of cell cycle arrest, DNA repair, and apoptosis in response to genotoxic stress. Mutations in TP53 disrupt its ability to activate downstream genes such as CDKN1A, GADD45, BAX, BAK1, DDB2, and POLK, which are critical for maintaining genomic stability. Loss of TP53 function leads to impaired response to DNA damage, unchecked cell proliferation, and resistance to apoptosis. This contributes to the development and progression of various cancers. The most significant disease associated with TP53 mutations is Li-Fraumeni syndrome, a hereditary cancer predisposition syndrome characterized by early onset of multiple malignancies, including sarcomas, breast cancer, osteosarcoma, and brain tumors. TP53 mutations are also among the most common genetic alterations in several solid tumors, making it a key driver in cancer biology. \n\n\\boxed{Li-Fraumeni syndrome}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 (DJ1*) gene encodes a protein involved in protein folding and antioxidant defense. Mutations in PARK7 are associated with impaired proteostasis and increased oxidative stress, contributing to neuronal damage. The pathway involving PARK7, TP53, and DUSP1 highlights its role in stress response and cell survival. Dysfunction in this pathway leads to impaired regulation of apoptosis and inflammation, which is critical in neurodegenerative processes. Mutations in PARK7 are a known genetic cause of Parkinson's disease, specifically early-onset forms. The interaction with TP53 and DUSP1 further supports its role in modulating cellular stress responses and apoptosis, which are key in Parkinson's pathology. Therefore, the biological effect of the PARK7 allele is the contribution to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1*, encodes a protein involved in cellular protection against oxidative stress and protein misfolding. Its interaction with TP53 and regulation of DUSP1 suggest a role in stress response and apoptosis. Mutations in PARK7 are associated with impaired mitochondrial function and neurodegeneration. Specifically, mutations in the PARK7 gene are a known genetic cause of early-onset Parkinson's disease. These mutations lead to loss of function, disrupting the protein's protective roles and contributing to the accumulation of toxic proteins and neuronal damage. The pathway involving TP53 and DUSP1 further supports its role in cell survival and stress response, reinforcing its significance in neurodegenerative processes. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: DJ1* // TP53 => DUSP1\nGenes in the pathway: PARK7; Parkinsonism associated deglycase | TP53; tumor protein p53 | DUSP1; dual specificity phosphatase 1\n\nGiven this context, what is the biological effect of this PARK7 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PARK7 gene, also known as DJ1, is involved in cellular protection against oxidative stress and is critical for mitochondrial function. When mutated, it contributes to the pathogenesis of Parkinson's disease. The pathway involving PARK7, TP53, and DUSP1 suggests a role in stress response and apoptosis regulation. Loss-of-function mutations in PARK7 impair its protective functions, leading to neuronal damage and death, particularly in dopaminergic neurons. This genetic dysfunction is associated with early-onset Parkinson's disease. The interaction with TP53 and DUSP1 further underscores its role in modulating cell survival and stress responses. Therefore, the PARK7 allele contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cellular growth and differentiation, particularly in skeletal development. Mutations in FGFR3, especially gain-of-function mutations, lead to constitutive activation of the downstream MAPK/ERK cascade, including MEK and ERK. This results in aberrant proliferation and survival signals. In particular, activating mutations in FGFR3 are strongly associated with **bladder cancer**, specifically **bladder urothelial carcinoma**. These mutations drive uncontrolled cell growth and contribute to tumor progression by promoting cell cycle entry and resistance to apoptosis. FGFR3 mutations are most commonly found in low-grade bladder tumors, where they act as oncogenic drivers. The pathway culminates in the activation of MYC, a key regulator of cell proliferation and transcription. Therefore, the biological effect of an activating FGFR3 allele is the promotion of bladder cancer.\n\n\\boxed{Bladder Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical for cell proliferation and differentiation. Mutations in FGFR3, particularly gain-of-function mutations, lead to constitutive activation of downstream signaling, including the RAS-RAF-MEK-ERK cascade. This results in aberrant cell growth and survival. In the context of chromosome 4, FGFR3 mutations are strongly associated with multiple myeloma, a malignancy of plasma cells. These mutations drive uncontrolled cell proliferation and resistance to apoptosis, contributing to tumor formation. The activation of MYC, a key oncogene in this pathway, further promotes cellular transformation and tumor progression. Therefore, dysregulation of FGFR3 on chromosome 4 contributes to the development of multiple myeloma. \\boxed{Multiple Myeloma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: FGFR3* -> GRB2 -> SOS -> RAS -> RAF -> MEK -> ERK -> MSK1 -> MYC\nGenes in the pathway: FGFR3; fibroblast growth factor receptor 3 | GRB2; growth factor receptor bound protein 2 | SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 | SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3 | RPS6KA5; ribosomal protein S6 kinase A5 | MYC; MYC proto-oncogene, bHLH transcription factor\n\nGiven this context, what is the biological effect of this FGFR3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe FGFR3 pathway is critical in cell proliferation and differentiation, particularly in bone development. Mutations in FGFR3, especially gain-of-function mutations, lead to constitutive activation of the downstream MAPK/ERK cascade. This results in uncontrolled cell growth and impaired apoptosis. Specifically, activating mutations in FGFR3 are strongly associated with **bladder urothelial carcinomas**, where they drive oncogenic signaling through the RAS-RAF-MEK-ERK-MYC axis. These mutations contribute to tumor progression by promoting cell survival, proliferation, and resistance to apoptosis. The activation of MYC further enhances transcriptional programs that support tumorigenesis. Therefore, FGFR3 mutations are a key driver in the development of **bladder cancer**.\n\n\\boxed{Bladder Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, activates the RET* node, initiating the pathway RET* -> PI3K -> PIP3 -> AKT -> MTOR. This leads to constitutive activation of the PI3K/AKT/mTOR signaling pathway, which is critical for cell survival, proliferation, and metabolism. Dysregulation of this pathway is associated with uncontrolled cell growth and resistance to apoptosis. Mutations in RET are well-documented in multiple endocrine neoplasia type 2 (MEN2), a hereditary syndrome characterized by tumors of endocrine origins, including medullary thyroid carcinoma, pheochromocytoma, and parathyroid adenomas. These mutations are typically gain-of-function, leading to oncogenic activation. Therefore, the biological effect of this RET allele is the activation of the PI3K/AKT/mTOR pathway, contributing to the development of medullary thyroid carcinoma and other tumors in MEN2.\n\n\\boxed{Multiple Endocrine Neoplasia Type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET proto-oncogene, when mutated or aberrantly activated, initiates a signaling cascade involving PI3K, PIP3, AKT, and MTOR. This pathway is critical for cell growth, survival, and metabolism. Mutations in RET, particularly in the tyrosine kinase domain, lead to constitutive activation of downstream effectors, promoting uncontrolled cell proliferation and survival. This contributes to the development of cancers originating from neural crest-derived tissues. The most well-characterized disease associated with RET mutations is Multiple Endocrine Neoplasia Type 2 (MEN2), a hereditary syndrome characterized by medullary thyroid carcinoma, parathyroid hyperplasia, and pheochromocytoma. RET mutations also contribute to sporadic medullary thyroid carcinoma and certain non-papillary renal cell carcinomas. Therefore, the biological effect of RET mutations in this pathway is the development of **medullary thyroid carcinoma** and related endocrine tumors.\n\n\\boxed{Medullary Thyroid Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> PI3K -> PIP3 -> AKT -> MTOR\nGenes in the pathway: RET; ret proto-oncogene | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin kinase\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, leads to constitutive activation of the RET receptor tyrosine kinase. This initiates downstream signaling through the PI3K-AKT-MTOR pathway, promoting cell survival, proliferation, and resistance to apoptosis. Such dysregulation is implicated in the development of various cancers. Specifically, activating mutations in RET are a key driver in medullary thyroid carcinoma (MTC), a rare but aggressive form of thyroid cancer. RET mutations also contribute to other malignancies, including certain lung and kidney cancers. The pathway's role in tumor progression makes it a therapeutic target, with inhibitors like vandetanib and cabozantinib used in MTC treatment. \\boxed{Medullary Thyroid Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 encodes profilin 1, a key regulator of actin polymerization. It binds to monomeric actin (ACTB and ACTG1) and facilitates the formation of filamentous actin, essential for cellular processes such as cytoskeletal dynamics, cell migration, and mitosis. Mutations in PFN1 disrupt this process, leading to impaired actin filament formation and stability. This contributes to neurodevelopmental disorders, particularly neurodegenerative diseases. One well-documented condition associated with PFN1 mutations is **familial adult-onset sleep-related leg cramp (FASLC)**, a rare genetic disorder characterized by nocturnal leg cramps and, in some cases, progressive neurodegeneration. The disruption of actin dynamics due to PFN1 dysfunction impacts neuronal function and integrity, leading to disease manifestations. \\boxed{Familial adult-onset sleep-related leg cramp}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 encodes profilin 1, a protein that binds to monomeric actin and promotes its polymerization into filamentous actin. This process is critical for cytoskeletal dynamics, cell motility, and intracellular transport. Mutations in PFN1 disrupt actin filament assembly, leading to impaired cellular functions. This contributes to neurodevelopmental disorders, particularly early-onset epileptic encephalopathy. The pathway involving actin monomers, PFN1, and filamentous actin is essential for neuronal development and connectivity. Disruptions in this pathway result in neuronal migration defects and synaptic dysfunction. The specific disease associated with PFN1 mutations is \\boxed{Early-onset epileptic encephalopathy}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Actin(monomeric) // PFN1* // Actin(filamentous)\nGenes in the pathway: ACTB; actin beta | ACTG1; actin gamma 1 | PFN1; profilin 1\n\nGiven this context, what is the biological effect of this PFN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPFN1 encodes profilin 1, a protein that binds to monomeric actin and facilitates its incorporation into filamentous actin structures. This process is critical for cell motility, cytoskeletal dynamics, and intracellular transport. Mutations in PFN1 disrupt actin filament assembly, leading to impaired cellular functions. This contributes to neurodevelopmental disorders, particularly in the context of neuronal migration and synaptic function. Specifically, PFN1 mutations are associated with X-linked intellectual disability, often presenting with seizures, abnormal brain development, and motor impairments. The disruption of the actin network due to defective PFN1 allele impairs neuronal development and connectivity, leading to the clinical manifestations observed in this condition. \\boxed{X-linked intellectual disability}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex involved in the cleavage of amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease (AD). These mutations lead to increased production of toxic amyloid-beta species, contributing to plaque formation in the brain. The pathway described involves calcium dysregulation through the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channel (VDAC), leading to mitochondrial dysfunction, cytochrome c release, and activation of the intrinsic apoptotic pathway via APAF1 and caspases 9, 3, and 7. This ultimately results in neuronal apoptosis. The PSEN1 mutation thus plays a central role in the pathogenesis of Alzheimer's disease by promoting neurodegeneration through multiple mechanisms, including mitochondrial dysfunction and apoptosis. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex involved in the cleavage of the amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN1 are a major cause of early-onset familial Alzheimer's disease (FAD). These mutations lead to increased production of toxic amyloid-beta species, which aggregate into plaques in the brain, contributing to neuronal damage and cognitive decline. The pathway described highlights the connection between PSEN1 dysfunction and the activation of the mitochondrial intrinsic apoptosis pathway, involving the release of cytochrome c, activation of APAF1 and caspase-9, ultimately leading to caspase-3 and -7 activation, which promotes cell death. This underscores the role of PSEN1 in neurodegeneration. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: (PSEN1*,PSEN2*) -> RYR3 -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS == APAF1 -> CASP9 -> (CASP3,CASP7)\nGenes in the pathway: PSEN1; presenilin 1 | PSEN2; presenilin 2 | RYR3; ryanodine receptor 3 | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic | APAF1; apoptotic peptidase activating factor 1 | CASP9; caspase 9 | CASP3; caspase 3 | CASP7; caspase 7\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex. This pathway describes a signaling cascade starting with PSEN1 and PSEN2, leading to the release of calcium ions (Ca2+) from the endoplasmic reticulum via RYR3, followed by mitochondrial calcium uptake through MCU and VDACs. Excess mitochondrial calcium can trigger the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS), which activates APAF1 and CASP9, ultimately leading to apoptosis via CASP3 and CASP7. Mutations in PSEN1 are well-documented in early-onset Alzheimer's disease (AD), where they cause abnormal \u03b3-secretase activity, leading to increased production of A\u03b2 peptides and neurodegeneration. These mutations are directly linked to familial Alzheimer's disease. \\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN (parkin) gene is a key component of the ubiquitin-mediated protein degradation pathway. In the given pathway, PRKN ubiquitylates PLCG1, which regulates the production of IP3, leading to calcium release via ITPR channels. Mutations in PRKN impair this process, disrupting calcium homeostasis and neuronal function. This contributes to the pathogenesis of Parkinson's disease, as PRKN mutations are associated with autosomal recessive Parkinsonism. The loss of PRKN function leads to the accumulation of damaged mitochondria and neuronal cell death, particularly in dopaminergic neurons. Therefore, the biological effect of this PRKN allele is the disruption of mitochondrial quality control, which contributes to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway is involved in mitochondrial quality control through ubiquitination and degradation of damaged mitochondria via the autophagy process (mitophagy). Mutations in PRKN lead to impaired mitophagy, resulting in the accumulation of dysfunctional mitochondria and increased cellular oxidative stress. This dysfunction is strongly associated with neurodegenerative disorders. Specifically, PRKN mutations are a key genetic cause of Parkinson's disease, a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra. The disruption of the PRKN pathway leads to neuronal death and the hallmark pathological features of Parkinson's disease, including the accumulation of alpha-synuclein aggregates. Therefore, the biological effect of a pathogenic PRKN allele is the contribution to the development of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: PRKN* -> PLCG1 -> IP3 -> ITPR -> Ca2+\nGenes in the pathway: PRKN; parkin RBR E3 ubiquitin protein ligase | PLCG1; phospholipase C gamma 1 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | ITPR2; inositol 1,4,5-trisphosphate receptor type 2 | ITPR3; inositol 1,4,5-trisphosphate receptor type 3\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN pathway involves the ubiquitination of PLCG1, which affects the production of IP3 and subsequent release of Ca\u00b2\u207a via ITPR channels. Mutations in PRKN, which encodes parkin, lead to impaired ubiquitination of PLCG1, disrupting IP3 signaling and Ca\u00b2\u207a homeostasis. This dysfunction is implicated in the loss of dopaminergic neurons, a hallmark of Parkinson's disease. PRKN mutations are a major cause of inherited Parkinson's, particularly in early-onset cases. The disruption of this pathway contributes to mitochondrial dysfunction, oxidative stress, and neuronal apoptosis. Therefore, the biological effect of pathogenic PRKN alleles is the development of Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein involved in neuronal function. Mutations in HTT, specifically expansions of the CAG trinucleotide repeat, lead to the production of an abnormally long polyglutamine tract in the huntingtin protein. This dysfunctional protein disrupts cellular processes, particularly in neurons, leading to neurodegeneration. The pathway involving HTT, UQCRFS1, and other components of complex III is critical for mitochondrial function and oxidative phosphorylation. Disruption of this pathway contributes to mitochondrial dysfunction and oxidative stress, which are key features of neurodegenerative diseases. The most well-known disease associated with HTT mutations is Huntington\u2019s disease, a progressive neurological disorder characterized by motor impairments, cognitive decline, and psychiatric symptoms. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein critical for neuronal function. Mutations in HTT, specifically expansions of the CAG trinucleotide repeat, lead to the production of an abnormally long huntingtin protein, which forms toxic aggregates. This results in neuronal dysfunction and death, primarily in the striatum and cortex. The pathway described includes components of the mitochondrial electron transport chain, particularly complex III, which is involved in ATP production and reactive oxygen species regulation. Disruption of this pathway due to HTT dysfunction contributes to oxidative stress and impaired energy metabolism, exacerbating neurodegeneration. This genetic mutation is the primary cause of Huntington's disease, a progressive neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms. \\boxed{Huntington's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 4\nNetwork Definition of the pathway: HTT* -| CxIII -> CytC\nGenes in the pathway: HTT; huntingtin | UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 | CYTB; cytochrome b | CYC1; cytochrome c1 | UQCRC1; ubiquinol-cytochrome c reductase core protein 1 | UQCRC2; ubiquinol-cytochrome c reductase core protein 2 | UQCRHL; ubiquinol-cytochrome c reductase hinge protein like | UQCRH; ubiquinol-cytochrome c reductase hinge protein | UQCRB; ubiquinol-cytochrome c reductase binding protein | UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII | UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X | UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI\n\nGiven this context, what is the biological effect of this HTT allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe HTT gene encodes huntingtin, a protein involved in neuronal function. Mutations in HTT, specifically expansions of the CAG trinucleotide repeat, lead to the production of an abnormally long polyglutamine tract in the huntingtin protein, causing it to misfold and aggregate. This results in neurodegeneration. The pathway described involves components of complex III of the mitochondrial electron transport chain, which is critical for ATP production. Disruption of this pathway due to dysfunctional huntingtin contributes to mitochondrial dysfunction and oxidative stress, exacerbating neuronal damage. This genetic alteration is the primary cause of Huntington's disease, a neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric symptoms. \\boxed{Huntington's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, as part of the RET-RAS-RAF-MEK-ERK signaling pathway, plays a critical role in cell proliferation and differentiation. Mutations in RET can lead to constitutive activation of this pathway, resulting in uncontrolled cell growth. This is particularly significant in cancers where RET is altered, such as medullary thyroid carcinoma (MTC). RET mutations or fusions are well-documented in MTC, a rare but aggressive form of thyroid cancer. These genetic alterations lead to continuous signaling through the MAPK pathway, promoting tumor initiation and progression. Therefore, the biological effect of an activating RET allele is the induction of aberrant cell growth, contributing to the development of medullary thyroid carcinoma. \\boxed{Medullary Thyroid Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, leads to constitutive activation of the RET receptor tyrosine kinase, initiating the RET-RAS-RAF-MEK-ERK signaling pathway. This results in uncontrolled cell proliferation and survival, promoting tumorigenesis. Mutations in RET are commonly associated with medullary thyroid carcinoma (MTC), a rare form of thyroid cancer. Additionally, RET mutations can contribute to other cancers, including certain lung and colon cancers. The aberrant activation of this pathway disrupts normal cellular regulation, leading to neoplastic growth. RET mutations are also implicated in multiple endocrine neoplasia type 2 (MEN2), a hereditary syndrome that predisposes individuals to MTC and other endocrine tumors. Therefore, RET mutations are strongly linked to medullary thyroid carcinoma.\n\n\\boxed{Medullary Thyroid Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 10\nNetwork Definition of the pathway: RET* -> RAS -> RAF -> MEK -> ERK\nGenes in the pathway: RET; ret proto-oncogene | HRAS; HRas proto-oncogene, GTPase | KRAS; KRAS proto-oncogene, GTPase | NRAS; NRAS proto-oncogene, GTPase | ARAF; A-Raf proto-oncogene, serine/threonine kinase | BRAF; B-Raf proto-oncogene, serine/threonine kinase | RAF1; Raf-1 proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this RET allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe RET allele, when mutated, leads to constitutive activation of the RET receptor tyrosine kinase, which initiates the RET-RAS-RAF-MEK-ERK signaling pathway. This pathway is crucial for cell proliferation, survival, and differentiation. Mutations in RET are strongly associated with medullary thyroid carcinoma (MTC), a subtype of thyroid cancer. These mutations result in uncontrolled cell growth and inhibition of apoptosis, promoting tumor formation. RET mutations are also linked to multiple endocrine neoplasia type 2 (MEN2), a hereditary syndrome that includes MTC. Therefore, the biological effect of an activating RET allele is the promotion of tumor growth, specifically contributing to medullary thyroid carcinoma.\n\n\\boxed{Medullary Thyroid Carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PI3K* -> PIP3 -> AKT -> MTOR -> S6K pathway is a key regulator of cell growth, survival, and metabolism. Mutations in PIK3CA, which encodes the catalytic subunit of phosphatidylinositol-3-kinase (PI3K), lead to increased PIP3 production, activating downstream effectors like AKT and MTOR. This results in hyperactivation of the S6K pathway, promoting protein synthesis, cell proliferation, and resistance to apoptosis. Such dysregulation is implicated in various cancers. Specifically, PIK3CA mutations are commonly found in breast, endometrial, ovarian, and colorectal cancers. These mutations drive oncogenic transformation by enhancing cell growth and survival signals. Therefore, the biological effect of this PIK3CA allele is oncogenic, contributing to the development of multiple malignancies.\n\n\\boxed{Breast Cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PI3K* -> PIP3 -> AKT -> MTOR -> S6K pathway is a central regulator of cell growth, survival, and protein synthesis. The PIK3CA gene encodes the catalytic subunit of PI3K, which phosphorylates PIP2 to generate PIP3, initiating this signaling cascade. Mutations in PIK3CA, such as gain-of-function mutations, lead to constitutive activation of the pathway, promoting uncontrolled cell proliferation and resistance to apoptosis. This aberrant signaling is implicated in multiple human cancers. Specifically, PIK3CA mutations are commonly found in cancers such as breast, endometrial, and colorectal carcinomas. These mutations drive tumor progression by enhancing cell survival, growth, and metastasis. The activation of downstream effectors like AKT and MTOR further amplifies these oncogenic effects. Therefore, PIK3CA mutations contribute to the development of \\boxed{breast cancer}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 3\nNetwork Definition of the pathway: PI3K* -> PIP3 -> AKT -> MTOR -> S6K\nGenes in the pathway: PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | AKT1; AKT serine/threonine kinase 1 | AKT2; AKT serine/threonine kinase 2 | AKT3; AKT serine/threonine kinase 3 | MTOR; mechanistic target of rapamycin | RPS6KB1; ribosomal protein S6 kinase B1 | RPS6KB2; ribosomal protein S6 kinase B2\n\nGiven this context, what is the biological effect of this PIK3CA allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PI3K-AKT-MTOR-S6K pathway is critical for cell growth, survival, and metabolism. Mutations in *PIK3CA*, which encodes the catalytic subunit of phosphatidylinositol-3 kinase (PI3K), lead to increased PI3K activity, resulting in elevated levels of PIP3 and subsequent activation of AKT and MTOR. This hyperactivation promotes protein synthesis, cell proliferation, and resistance to apoptosis. Such dysregulation is a hallmark of several cancers. The most commonly associated disease is **Breast Cancer**, where *PIK3CA* mutations are frequently observed. These mutations drive tumor growth by enhancing cell survival and proliferation, contributing to tumor progression and resistance to therapy. Other cancers, including colorectal, endometrial, and ovarian cancers, also show frequent *PIK3CA* mutations. Therefore, the biological effect of this PIK3CA allele is oncogenic, significantly contributing to **Breast Cancer**.\n\n\\boxed{Breast Cancer}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPRKN, also known as parkin, is an E3 ubiquitin ligase that plays a critical role in protein quality control and mitochondrial function. Mutations in PRKN are associated with autosomal recessive Parkinson's disease. The pathway involving PRKN, along with UBCH7/8 and alpha-Synuclein (SNCA), highlights its role in ubiquitin-mediated protein degradation. Dysfunction in this pathway leads to the accumulation of damaged proteins, including alpha-Synuclein, which contributes to the pathogenesis of Parkinson\u2019s disease. Loss-of-function mutations in PRKN impair the ubiquitin-proteasome system, leading to neuronal toxicity and degeneration, particularly in dopaminergic neurons. This genetic dysfunction is a key contributor to the development of Parkinson\u2019s disease. \n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase critical for protein degradation via the ubiquitin-proteasome system. Mutations in PRKN lead to impaired ubiquitination and degradation of damaged proteins, disrupting cellular quality control. This contributes to the accumulation of misfolded proteins, particularly alpha-synuclein (SNCA), which is associated with neurodegeneration. PRKN mutations are a well-established cause of autosomal recessive early-onset Parkinson's disease. The pathway involving UBCH7/8 (E2 conjugating enzymes) and alpha-Synuclein further supports a role in protein misfolding and aggregation. Dysfunction in this pathway impairs mitochondrial quality control and leads to neuronal death, hallmark features of Parkinson's disease. Thus, the PRKN allele contributes to Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // alphaSp22\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | SNCA; synuclein alpha\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nPRKN encodes parkin, an E3 ubiquitin ligase involved in ubiquitin-mediated protein degradation. Mutations in PRKN are associated with impaired ubiquitin-proteasome function, leading to the accumulation of misfolded proteins. This contributes to neurodegeneration. The pathway includes UBCH7/8 (E2 conjugating enzymes) and alphaSp22, which are involved in ubiquitination processes. Dysfunction in this pathway disrupts protein quality control. PRKN mutations are a known cause of early-onset Parkinson's disease. Loss-of-function mutations in PRKN result in reduced ubiquitination of substrates such as SNCA, leading to alpha-synuclein aggregation. This aggregation is a hallmark of Parkinson's disease. Therefore, PRKN mutations contribute to Parkinson's disease by disrupting ubiquitin-mediated degradation.\n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is involved in mitochondrial quality control. PINK1 and PRKN (parkin) work together in a pathway that regulates mitochondrial maintenance and degradation. Mutations in PINK1 or PRKN disrupt this process, leading to mitochondrial dysfunction and impaired autophagy. This contributes to the accumulation of damaged mitochondria, which is associated with neurodegeneration. The most well-documented disease linked to this pathway is Parkinson's disease. Loss-of-function mutations in PINK1 or PRKN are among the genetic causes of familial Parkinson's disease. The pathway's role in mitophagy makes it critical for neuronal survival, and its disruption leads to dopaminergic neuron loss, a hallmark of Parkinson's. Thus, PINK1 mutations contribute to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is involved in mitochondrial quality control. PINK1 and PRKN (parkin) work together in the ubiquitin-proteasome system to regulate mitochondrial integrity by ubiquitinating damaged mitochondria, marking them for degradation. Mutations in PINK1 or PRKN disrupt this process, leading to the accumulation of dysfunctional mitochondria, which is toxic to neurons. This pathway is critical for maintaining cellular energy homeostasis and preventing oxidative damage. Impairment of this pathway is associated with the pathogenesis of Parkinson's disease. Mutations in PINK1 are one of the most common genetic causes of inherited Parkinsonism. The loss of PINK1 function results in neuronal degeneration, particularly in the substantia nigra, contributing to the clinical features of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 1\nNetwork Definition of the pathway: PINK1* // PRKN // MFN1/2\nGenes in the pathway: PINK1; PTEN induced kinase 1 | PRKN; parkin RBR E3 ubiquitin protein ligase | MFN1; mitofusin 1 | MFN2; mitofusin 2\n\nGiven this context, what is the biological effect of this PINK1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PINK1 allele is involved in the mitochondrial quality control pathway, interacting with PRKN (parkin) and MFN1/2 to regulate mitochondrial dynamics and mitophagy. Mutations in PINK1 disrupt this process, leading to impaired mitochondrial function and accumulation of damaged mitochondria. This contributes to neurodegeneration by causing cellular stress and neuronal death. PINK1 mutations are a known cause of early-onset Parkinson's disease, characterized by the loss of dopaminergic neurons in the substantia nigra. The pathway's dysfunction is linked to the inability to properly degrade damaged mitochondria, which triggers oxidative stress and apoptosis. Thus, PINK1 mutations are strongly associated with Parkinson's disease. \n\n\\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the gamma-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating amyloid-beta peptides. Mutations in PSEN1 are among the most common genetic causes of early-onset Alzheimer's disease. The pathway involving PSEN1 -> GSK3B and the kinesin family members (KIF5 and KLC) suggests a role in neurodegeneration, neuronal transport, and protein processing. Impaired function of PSEN1 leads to aberrant amyloid-beta production and accumulation, toxic protein aggregates, and neuronal dysfunction. This directly contributes to the pathogenesis of Alzheimer's disease. The genetic alteration disrupts the clearance of misfolded proteins and synaptic function, accelerating cognitive decline. Therefore, the biological effect of this PSEN1 allele is the increased risk and severity of Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP), generating amyloid-\u03b2 peptides. Mutations in PSEN1 are the most common cause of early-onset familial Alzheimer's disease (FAD). The pathway described involves PSEN1 regulating GSK3B, which is inhibited by the kinesin family proteins (KIF5A/B/C) and their light chain partners (KLC1-4). Impaired function of this pathway disrupts neuronal transport and metabolism, contributing to neurodegeneration. The accumulation of toxic amyloid-\u03b2 plaques and neurofibrillary tangles, characteristic of Alzheimer's disease, result from PSEN1 dysfunction. Therefore, the biological effect of this PSEN1 allele is the contribution to Alzheimer's disease.\n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a key component of the gamma-secretase complex, which is critical for the cleavage of amyloid precursor protein (APP), generating beta-amyloid peptides. Mutations in PSEN1 are strongly associated with early-onset familial Alzheimer's disease (FAD). The pathway involving PSEN1 \u2192 GSK3B and the kinesin family members (KIF5A/B/C and KLC1-4) suggests a role in neurodegeneration through disrupted protein trafficking and metabolism. GSK3B, a downstream target, is implicated in tau phosphorylation and neuronal survival. Dysregulation of these pathways contributes to the accumulation of toxic proteins and neuronal loss. Thus, the PSEN1 allele contributes to the development of \\boxed{Alzheimer's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP) to generate \u03b2-amyloid peptides. Mutations in PSEN1 are a well-established cause of early-onset familial Alzheimer's disease (FAD). The pathway involving PSEN1 \u2192 GSK3B and the kinesin family members (KIF5 and KLC) suggests a role in neurodegenerative processes, including protein trafficking and neuronal function. Impairment in these pathways contributes to the accumulation of toxic protein aggregates and neuronal dysfunction. The specific PSEN1 mutations disrupt \u03b3-secretase activity, leading to increased production of amyloid-\u03b242 and reduced clearance, promoting plaque formation. This directly contributes to the pathogenesis of Alzheimer's disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a critical component of the \u03b3-secretase complex, which is essential for the cleavage of amyloid precursor protein (APP). Mutations in PSEN1 are a well-documented cause of early-onset familial Alzheimer's disease (FAD). The pathway described, PSEN1 \u2192 GSK3B -| (KIF5+KLC), reflects its role in regulating \u03b2-catenin signaling via GSK3B, a key enzyme in Wnt signaling. Disruption of this pathway leads to impaired neurogenesis, synaptic plasticity, and increased amyloid-beta production, all of which contribute to the pathogenesis of Alzheimer's disease. The involvement of kinesin family members (KIF5) and kinesin light chains (KLC) suggests a role in neuronal transport, further linking PSEN1 dysfunction to neurodegeneration. Thus, mutations in PSEN1 primarily contribute to \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: PSEN1* -> GSK3B -| (KIF5+KLC)\nGenes in the pathway: PSEN1; presenilin 1 | GSK3B; glycogen synthase kinase 3 beta | KIF5A; kinesin family member 5A | KIF5B; kinesin family member 5B | KIF5C; kinesin family member 5C | KLC1; kinesin light chain 1 | KLC2; kinesin light chain 2 | KLC3; kinesin light chain 3 | KLC4; kinesin light chain 4\n\nGiven this context, what is the biological effect of this PSEN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PSEN1 gene encodes presenilin 1, a component of the gamma-secretase complex, which is critical for the cleavage of amyloid precursor protein (APP). Mutations in PSEN1 are a major cause of early-onset familial Alzheimer\u2019s disease (FAD). The pathway described involves PSEN1 regulating GSK3B, a kinase implicated in neurodegeneration, and interactions with kinesin family members (KIF5A/B/C) and kinesin light chains (KLC1-4), which are involved in intracellular transport. Impaired function in this pathway disrupts protein processing and transport, contributing to the accumulation of pathological proteins and neuronal dysfunction. The hallmark of this disease is the accumulation of amyloid-beta plaques and neurofibrillary tangles in the brain. Therefore, the biological effect of this PSEN1 allele is the development of \\boxed{Alzheimer's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an E3 ubiquitin ligase critical for protein degradation via the ubiquitin-proteasome system. Its involvement in the pathway UBCH7/8 // PRKN* // PAELR highlights its role in ubiquitin-mediated processes. Mutations in PRKN are strongly associated with autosomal recessive Parkinson's disease. These mutations impair parkin's ability to ubiquitinate and degrade misfolded or damaged proteins, leading to the accumulation of toxic proteins in neurons, particularly in the substantia nigra. This contributes to neurodegeneration and the progressive loss of dopaminergic neurons, hallmark features of Parkinson's disease. Thus, PRKN dysfunction directly contributes to the pathogenesis of Parkinson's disease.\n\n\\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for ubiquitin-mediated protein degradation. Mutations in PRKN lead to loss of function, impairing the ubiquitin-proteasome system and causing the accumulation of misfolded proteins. This contributes to neuronal dysfunction and degeneration. PRKN mutations are a major cause of autosomal recessive early-onset Parkinson's disease (PD). The pathway includes UBE2L3 and UBE2L6, which are E2 ubiquitin-conjugating enzymes that work with parkin to tag proteins for degradation. The inclusion of GPR37 suggests potential interactions in neurodegeneration. Mutations in PRKN disrupt this process, leading to mitochondrial dysfunction and oxidative stress, which are key features of Parkinson's disease. \\boxed{Parkinson's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: UBCH7/8 // PRKN* // PAELR\nGenes in the pathway: UBE2L3; ubiquitin conjugating enzyme E2 L3 | UBE2L6; ubiquitin conjugating enzyme E2 L6 | PRKN; parkin RBR E3 ubiquitin protein ligase | GPR37; G protein-coupled receptor 37\n\nGiven this context, what is the biological effect of this PRKN allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe PRKN gene encodes parkin, an RBR E3 ubiquitin ligase critical for protein quality control and mitochondrial homeostasis. Pathogenic variants in PRKN disrupt its E3 ligase activity, impairing ubiquitin-mediated degradation of damaged proteins and dysfunctional mitochondria. This leads to the accumulation of toxic proteins and mitochondrial dysfunction, contributing to neurodegeneration. PRKN mutations are a major cause of autosomal recessive Parkinson's disease (PD), specifically PARK2. The pathway involving UBCH7/8 (E2 enzymes) and GPR37 highlights the role of ubiquitin conjugation in protein degradation. Loss of PRKN function results in impaired mitophagy and increased oxidative stress, hallmark features of PD. Mutations in PRKN are strongly associated with early-onset Parkinson's disease. \\boxed{Parkinson's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the involvement of the APP gene in a cascade leading to mitochondrial dysfunction and cell death. The initial step involves the processing of APP to produce amyloid-beta (Abeta), which activates NMDA receptors (GRIN1, GRIN2A-D). Excessive NMDA receptor activation leads to calcium influx through NMDAR, which is taken up by mitochondria via MCU and VDACs (VDAC1-3), along with SLC25A4-6 and SLC25A31. This mitochondrial calcium overload triggers the mitochondrial permeability transition pore (MPTP), releasing cytochrome c (CYCS) and initiating apoptosis. This pathway is central to neurodegeneration. The accumulation of Abeta and subsequent mitochondrial dysfunction are hallmarks of Alzheimer\u2019s disease. Thus, this APP allele contributes to \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele in this pathway is central to the pathogenesis of Alzheimer's disease. The pathway begins with APP, which is cleaved to produce amyloid-beta (Abeta). Abeta accumulation leads to NMDAR overactivation, causing excessive Ca2+ influx. This Ca2+ is transported via the mitochondrial calcium uniporter (MCU) into mitochondria, disrupting mitochondrial function and triggering the mitochondrial permeability transition pore (MPTP). This results in the release of cytochrome c (CYCS), initiating apoptosis. This cascade is closely associated with neurodegeneration and is a key mechanism in Alzheimer's disease. The involvement of NMDA receptor subunits (GRIN1, GRIN2A-D) and mitochondrial calcium handling proteins (VDAC1-3, SLC25A4-6, SLC25A31) further supports the role of this pathway in neuronal damage. \\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -> NMDAR -> Ca2+ -- MCU -> Ca2+(mito) -- MPTP -> CYCS\nGenes in the pathway: APP; amyloid beta precursor protein | GRIN1; glutamate ionotropic receptor NMDA type subunit 1 | GRIN2A; glutamate ionotropic receptor NMDA type subunit 2A | GRIN2B; glutamate ionotropic receptor NMDA type subunit 2B | GRIN2C; glutamate ionotropic receptor NMDA type subunit 2C | GRIN2D; glutamate ionotropic receptor NMDA type subunit 2D | MCU; mitochondrial calcium uniporter | VDAC1; voltage dependent anion channel 1 | VDAC2; voltage dependent anion channel 2 | VDAC3; voltage dependent anion channel 3 | SLC25A4; solute carrier family 25 member 4 | SLC25A5; solute carrier family 25 member 5 | SLC25A6; solute carrier family 25 member 6 | SLC25A31; solute carrier family 25 member 31 | CYCS; cytochrome c, somatic\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway describes the cascade starting from the amyloid precursor protein (APP), leading to the production of amyloid-beta (Abeta), which activates NMDA receptors (GRIN1, GRIN2A-D). This triggers an influx of calcium ions (Ca2+), which are transported into mitochondria via the mitochondrial calcium uniporter (MCU) and voltage-dependent anion channel proteins (VDAC1-3), as well as other solute carrier proteins (SLC25A4-6, SLC25A31). The resulting mitochondrial calcium overload leads to mitochondrial permeability transition pore (MPTP) opening, releasing cytochrome c (CYCS), initiating apoptosis. This pathway is central to neurodegeneration. The accumulation of Abeta and subsequent calcium dysregulation are key features of Alzheimer's disease. Thus, the biological effect of this APP allele is the promotion of neurotoxicity and cell death, contributing to \\boxed{Alzheimer's disease}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe thyroid peroxidase (TPO) enzyme plays a critical role in thyroid hormone synthesis by catalyzing the iodination of tyrosine residues on thyroglobulin (TG), forming monoiodo- (MIT) and diiodo- (DIT) tyrosine residues. These residues then couple to form triiodothyronine (T3) and tetraiodothyronine (T4). Mutations in the TPO gene impair this process, leading to reduced thyroid hormone production. This dysfunction contributes to autoimmune thyroid disease, specifically **Hashimoto's thyroiditis**, an inflammatory condition where the immune system attacks the thyroid gland. The defective TPO function also increases the risk of **thyroid hormone resistance** and **hypothyroidism**. These effects are linked to genetic predisposition and immune-mediated mechanisms, making TPO a key gene in thyroid autoimmunity. \\boxed{Hashimoto's thyroiditis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe thyroid peroxidase (TPO) enzyme plays a crucial role in the synthesis of thyroid hormones by catalyzing the organification of iodide onto tyrosine residues in thyroglobulin, forming monoiodo-tyrosine (MIT) and diiodo-tyrosine (DIT). These precursors then couple to form triiodothyronine (T3) and thyroxine (T4). Mutations in the TPO gene can lead to impaired iodide organification, disrupting thyroid hormone production. This results in hypothyroidism, characterized by reduced levels of circulating thyroid hormones. A well-documented condition associated with TPO dysfunction is **Hashimoto's thyroiditis**, an autoimmune disorder where TPO antibodies attack and damage the thyroid gland, leading to chronic inflammation and hypothyroidism. The TPO allele contributes to this disease through both enzymatic dysfunction and autoimmune mechanisms. \\boxed{Hashimoto's thyroiditis}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: TG+(Iodide+Tyr) -- TPO* // TG+(MIT,DIT) -- TPO* // TG+(T3,T4)\nGenes in the pathway: TG; thyroglobulin | TPO; thyroid peroxidase\n\nGiven this context, what is the biological effect of this TPO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThis pathway involves thyroglobulin (TG) and thyroid peroxidase (TPO), which are critical for thyroid hormone synthesis. TPO catalyzes the organification of iodide onto tyrosine residues in TG, forming monoiodo- and diiodotyrosine (MIT and DIT), which then couple to form triiodothyronine (T3) and thyroxine (T4). Mutations in TPO can impair this process, leading to reduced hormone production. This dysfunction contributes to autoimmune thyroid diseases, particularly Hashimoto's thyroiditis, where TPO antibodies attack the enzyme, causing inflammation and thyroid damage. Impaired TPO function also leads to hypothyroidism. The most common disease associated with TPO dysfunction is Hashimoto\u2019s thyroiditis. \n\n\\boxed{Hashimoto's thyroiditis}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme catalyzes the formation of N-acetylglutamate from acetyl-CoA and glutamate, which is a key activator of CPS1, carbamoyl-phosphate synthase 1. Mutations in NAGS lead to reduced N-acetylglutamate production, impairing CPS1 activity and disrupting the urea cycle. This results in the accumulation of ammonia, leading to neurological toxicity. The specific disease associated with NAGS mutations is **hyperammonemia**, a condition characterized by elevated blood ammonia levels. This can cause encephalopathy, seizures, and coma. NAGS deficiency is an autosomal recessive disorder, primarily affecting infants and leading to severe neurological complications if untreated. \\boxed{Hyperammonemia}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme activates carbamoyl phosphate synthetase I (CPS1), the rate-limiting enzyme in the urea cycle, by converting N-acetylglutamate from glutamate. Mutations in NAGS lead to reduced CPS1 activity, causing hyperammonemia due to impaired ammonia detoxification. This results in the accumulation of ammonia in the blood, which can be neurotoxic. The most common disease associated with NAGS mutations is **N-acetylglutamate synthase deficiency**, a rare autosomal recessive disorder characterized by hyperammonemia, developmental delays, and potentially life-threatening neurological complications. This condition is part of the broader group of urea cycle disorders. \\boxed{N-acetylglutamate synthase deficiency}", "user\nSolve the following genomic pathway question:\nChromosome Number: 17\nNetwork Definition of the pathway: Glu -- NAGS* // NAG // CPS1\nGenes in the pathway: NAGS; N-acetylglutamate synthase | CPS1; carbamoyl-phosphate synthase 1\n\nGiven this context, what is the biological effect of this NAGS allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe NAGS gene encodes N-acetylglutamate synthase, an enzyme critical for the urea cycle. This enzyme activates carbamoyl phosphate synthetase I (CPS1), which is essential for ammonia metabolism. Mutations in NAGS lead to reduced CPS1 activity, causing hyperammonemia. This condition results in elevated ammonia levels in the blood, which can be neurotoxic. The primary disorder associated with NAGS mutations is **hyperammonemia due to N-acetylglutamate synthase deficiency**, a rare inborn error of metabolism. Patients may present with neurological symptoms such as lethargy, seizures, and developmental delay. The disease is typically autosomal recessive, and treatment involves managing ammonia levels through dietary and medical interventions. The pathway involves Glu \u2192 NAGS \u2192 NAG \u2192 CPS1, where NAGS is pivotal in activating CPS1. \\boxed{Hyperammonemia due to N-acetylglutamate synthase deficiency}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in transcriptional regulation and protein degradation. Mutations in ATXN3 lead to the expansion of polyglutamine tracts, resulting in the formation of toxic protein aggregates. This contributes to neurodegeneration. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is associated with autophagy, a cellular process critical for clearing misfolded proteins. Impaired autophagy due to ATXN3 dysfunction exacerbates protein accumulation and neuronal damage. This is a hallmark of spinocerebellar ataxia type 2 (SCA2), a hereditary neurodegenerative disorder characterized by progressive loss of coordination and motor function. The accumulation of mutant ataxin-3 disrupts autophagic clearance, leading to neuronal death. Therefore, the biological effect of the ATXN3 allele is the contribution to spinocerebellar ataxia type 2.\n\n\\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in RNA metabolism and protein degradation. Mutations in ATXN3 lead to the expansion of polyglutamine repeats, which cause misfolding and aggregation of the protein. This dysfunction disrupts cellular processes, particularly in neurons, leading to neurodegeneration. The pathway includes genes involved in autophagy, which is critical for clearing misfolded proteins. The interaction between ATXN3 and autophagy-related genes suggests a role for autophagy in mitigating ATXN3 toxicity. The hallmark of ATXN3 mutations is spinocerebellar ataxia type 2 (SCA2), a hereditary neurological disorder characterized by progressive loss of coordination and motor function. The disrupted autophagy pathway exacerbates neuronal damage, contributing to disease progression. \\boxed{Spinocerebellar ataxia type 2}", "user\nSolve the following genomic pathway question:\nChromosome Number: 14\nNetwork Definition of the pathway: ATXN3* // (BECN1+PIK3C3+ATG14+PIK3R4+AMBRA1)\nGenes in the pathway: ATXN3; ataxin 3 | BECN1; beclin 1 | PIK3C3; phosphatidylinositol 3-kinase catalytic subunit type 3 | ATG14; autophagy related 14 | PIK3R4; phosphoinositide-3-kinase regulatory subunit 4 | AMBRA1; autophagy and beclin 1 regulator 1\n\nGiven this context, what is the biological effect of this ATXN3 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN3 gene encodes ataxin-3, a protein involved in ubiquitin-dependent protein degradation. Mutations in ATXN3 lead to the expansion of polyglutamine tracts, resulting in the formation of toxic protein aggregates. This is a hallmark of spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive degeneration of the cerebellum and brainstem, causing motor control deficits. The pathway involving ATXN3, BECN1, PIK3C3, ATG14, PIK3R4, and AMBRA1 is linked to autophagy, a cellular process that clears damaged proteins and organelles. Impaired autophagy due to ATXN3 dysfunction contributes to the accumulation of misfolded proteins, exacerbating neurodegeneration. Thus, the ATXN3 allele contributes to the development of \\boxed{Spinocerebellar Ataxia Type 2}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a key signaling cascade in cell proliferation and survival. The mutation in the BRAF gene, specifically the V600E substitution, leads to constitutive activation of the BRAF kinase, which in turn continuously activates MEK and ERK. This results in uncontrolled cell growth and resistance to apoptosis. The dysregulation of this pathway is strongly associated with various cancers. The most well-known disease linked to BRAF mutations is melanoma, particularly metastatic melanoma. BRAF mutations are also found in other malignancies such as non-small cell lung cancer, colon cancer, and thyroid cancer. The persistent activation of the MEK/ERK pathway promotes tumor progression and is a significant driver of oncogenesis. Targeting this pathway with BRAF inhibitors has shown therapeutic benefit in these cancers. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a critical signaling cascade involved in cell proliferation, differentiation, and survival. Mutations in the BRAF gene, particularly the V600E activating mutation, lead to constitutive activation of the MAPK/ERK pathway. This results in uncontrolled cell growth and resistance to apoptosis. The dysregulation of this pathway is strongly associated with various cancers. The most well-known disease linked to BRAF mutations is melanoma, where approximately 50% of cases harbor the BRAF V600E mutation. Additionally, BRAF mutations are found in other cancers such as colorectal cancer, non-small cell lung cancer, and thyroid cancer. The continuous activation of MEK and ERK downstream of BRAF contributes to tumor progression and metastasis. Targeting this pathway with BRAF inhibitors has shown therapeutic benefits in these malignancies. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: BRAF* -> MEK -> ERK\nGenes in the pathway: BRAF; B-Raf proto-oncogene, serine/threonine kinase | MAP2K1; mitogen-activated protein kinase kinase 1 | MAP2K2; mitogen-activated protein kinase kinase 2 | MAPK1; mitogen-activated protein kinase 1 | MAPK3; mitogen-activated protein kinase 3\n\nGiven this context, what is the biological effect of this BRAF allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe BRAF pathway is a key signaling cascade in cell proliferation and survival. Mutations in BRAF, particularly the V600E activating mutation, lead to constitutive activation of the MAPK/ERK pathway by promoting continuous signaling from BRAF to MEK and subsequently to ERK. This uncontrolled activation drives cellular proliferation and resistance to apoptosis, contributing to the development of various cancers. The most well-known disease associated with this pathway activation is metastatic melanoma, where BRAF mutations are found in approximately 50% of cases. Additionally, BRAF mutations are implicated in other malignancies such as thyroid cancer, ovarian cancer, and colorectal cancer. The persistent activation of ERK due to a hyperactive BRAF allele promotes tumor growth and is a key driver in these diseases. \\boxed{Melanoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO (Smoothened) gene is a key component of the Hedgehog (Hh) signaling pathway. The pathway definition indicates SMO interacts with SUFU and KIF7, and GLI transcription factors regulate downstream targets like BMP2/4, HHIP, GLI1, PTCH, and WNT genes. SMO activation drives GLI-mediated transcription, promoting cell proliferation and differentiation. Mutations in SMO, particularly gain-of-function variants, lead to constitutive activation of the Hh pathway, contributing to uncontrolled growth. This is implicated in various cancers, including basal cell carcinoma (BCC), medulloblastoma, and certain sarcomas. Activating SMO mutations are also linked to developmental disorders such as holoprosencephaly. The most well-documented disease associated with SMO mutations is basal cell carcinoma. \\boxed{Basal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO (Smoothened) gene is a key component of the Hedgehog (Hh) signaling pathway. The pathway definition provided, SMO -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT), indicates that SMO activity modulates GLI transcription factors, which in turn regulate downstream genes involved in development and homeostasis. Mutations in SMO, particularly gain-of-function mutations, lead to constitutive activation of the Hh pathway, resulting in uncontrolled cell proliferation and tissue growth. This is implicated in various cancers, including basal cell carcinoma (BCC), medulloblastoma, and some sarcomas. Additionally, SMO mutations are associated with holoprosencephaly, a congenital brain malformation. The most well-characterized disease linked to SMO dysregulation is basal cell carcinoma. \\boxed{Basal Cell Carcinoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 7\nNetwork Definition of the pathway: SMO* -> (SUFU+KIF7) // GLI => (BMP2/4,HHIP,GLI1,PTCH,WNT)\nGenes in the pathway: SMO; smoothened, frizzled class receptor | SUFU; SUFU negative regulator of hedgehog signaling | KIF7; kinesin family member 7 | GLI1; GLI family zinc finger 1 | GLI2; GLI family zinc finger 2 | GLI3; GLI family zinc finger 3 | BMP2; bone morphogenetic protein 2 | BMP4; bone morphogenetic protein 4 | HHIP; hedgehog interacting protein | PTCH1; patched 1 | PTCH2; patched 2 | WNT1; Wnt family member 1 | WNT2; Wnt family member 2 | WNT2B; Wnt family member 2B | WNT3; Wnt family member 3 | WNT3A; Wnt family member 3A | WNT4; Wnt family member 4 | WNT5A; Wnt family member 5A | WNT5B; Wnt family member 5B | WNT6; Wnt family member 6 | WNT7A; Wnt family member 7A | WNT7B; Wnt family member 7B | WNT8A; Wnt family member 8A | WNT8B; Wnt family member 8B | WNT9A; Wnt family member 9A | WNT9B; Wnt family member 9B | WNT10A; Wnt family member 10A | WNT10B; Wnt family member 10B | WNT16; Wnt family member 16\n\nGiven this context, what is the biological effect of this SMO allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe SMO (Smoothened) gene is a key component of the Hedgehog (Hh) signaling pathway. The SMO allele, when mutated or dysregulated, disrupts this pathway, leading to improper regulation of downstream effectors such as GLI1, GLI2, and GLI3. This pathway is crucial for cell proliferation, differentiation, and patterning during development. Mutations in SMO can lead to constitutive activation of the Hh pathway, resulting in uncontrolled cell growth. This is implicated in several cancers, including basal cell carcinoma, medulloblastoma, and certain types of sarcomas. Additionally, aberrant SMO activity has been linked to developmental disorders and ciliopathies. The most well-characterized disease associated with SMO dysfunction is **basal cell carcinoma**, a common skin cancer. \\boxed{basal cell carcinoma}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe pathway described involves the amyloid beta precursor protein (APP), which is cleaved to produce amyloid-beta (Abeta). This Abeta then interacts with CxIV, leading to the production of water (H2O). This pathway is central to the pathogenesis of Alzheimer\u2019s disease. Mutations in the APP gene can lead to the abnormal accumulation of amyloid-beta plaques in the brain, a hallmark of Alzheimer\u2019s disease. These plaques disrupt cell function and contribute to neurodegeneration. The presence of multiple cytochrome c oxidase subunits (COX1-COX8C) suggests a potential link between mitochondrial dysfunction and Alzheimer\u2019s, as impaired oxidative phosphorylation may exacerbate neuronal damage. Therefore, the biological effect of this APP allele is the contribution to Alzheimer\u2019s disease. \n\n\\boxed{Alzheimer's disease}", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP allele, as described in the pathway APP \u2192 Abeta \u2192 CxIV \u2192 H2O, is the production of amyloid-beta (Abeta), a key component in the pathogenesis of Alzheimer's disease. The amyloid-beta precursor protein (APP) is cleaved to produce Abeta peptides, which aggregate into plaques in the brain, a hallmark of Alzheimer's. The pathway also involves cytochrome c oxidase subunits, which are part of the mitochondrial electron transport chain. While the exact role of these subunits in this pathway is not fully understood, their involvement suggests a potential link between mitochondrial dysfunction and neurodegeneration. The accumulation of Abeta disrupts cellular processes, leading to neuronal damage and cognitive decline. Therefore, this pathway contributes to the development of \\boxed{Alzheimer's disease}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 21\nNetwork Definition of the pathway: APP* -> Abeta -| CxIV -> H2O\nGenes in the pathway: APP; amyloid beta precursor protein | COX3; cytochrome c oxidase III | COX1; cytochrome c oxidase subunit I | COX2; cytochrome c oxidase subunit II | COX4I1; cytochrome c oxidase subunit 4I1 | COX4I2; cytochrome c oxidase subunit 4I2 | COX5A; cytochrome c oxidase subunit 5A | COX5B; cytochrome c oxidase subunit 5B | COX6A1; cytochrome c oxidase subunit 6A1 | COX6A2; cytochrome c oxidase subunit 6A2 | COX6B1; cytochrome c oxidase subunit 6B1 | COX6B2; cytochrome c oxidase subunit 6B2 | COX6C; cytochrome c oxidase subunit 6C | COX7A1; cytochrome c oxidase subunit 7A1 | COX7A2; cytochrome c oxidase subunit 7A2 | COX7A2L; cytochrome c oxidase subunit 7A2 like | COX7B; cytochrome c oxidase subunit 7B | COX7C; cytochrome c oxidase subunit 7C | COX8A; cytochrome c oxidase subunit 8A | COX8C; cytochrome c oxidase subunit 8C\n\nGiven this context, what is the biological effect of this APP allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe biological effect of the APP (amyloid beta precursor protein) allele involves the cleavage of APP to produce amyloid-beta (Abeta), a key component in the pathogenesis of Alzheimer's disease. The pathway described, APP -> Abeta -> CxIV -> H2O, reflects the processing of APP into Abeta, which can aggregate into plaques in the brain. These plaques are a hallmark of Alzheimer's disease, contributing to neurodegeneration and cognitive decline. The involvement of cytochrome c oxidase subunits (COX1-8A, COX4I1/2, etc.) suggests a potential link between mitochondrial dysfunction and Abeta toxicity, as mitochondrial impairment is also observed in Alzheimer's. The accumulation of Abeta disrupts cellular homeostasis, leading to synaptic dysfunction and neuronal death. Therefore, this pathway is central to the development of Alzheimer's disease. \\boxed{Alzheimer's disease}"], ["user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 gene encodes a receptor tyrosine kinase that plays a critical role in cell growth, differentiation, and survival. It is a key component of the NRG-ERBB4 signaling pathway, where neuregulins (NRG1-4) act as ligands to activate ERBB4. Mutations or dysregulation of ERBB4 can lead to aberrant signaling, contributing to oncogenesis. Specifically, ERBB4 has been implicated in the development and progression of several cancers, including non-small cell lung cancer (NSCLC), glioblastoma, and breast cancer. In NSCLC, ERBB4 is frequently amplified or overexpressed, driving tumor growth and resistance to therapy. Additionally, ERBB4 has been linked to neurodevelopmental disorders when mutated, such as schizophrenia and autism spectrum disorder. However, its most well-documented contribution is to cancer, particularly \\boxed{Non-Small Cell Lung Cancer}.", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ERBB4 allele is involved in the NRG (Neuregulin) signaling pathway, which plays a critical role in cell growth, differentiation, and survival. ERBB4 is a receptor tyrosine kinase that binds Neuregulin ligands (NRG1-NRG4), activating downstream signaling cascades such as the MAPK and PI3K pathways. Dysregulation of this pathway can lead to uncontrolled cell proliferation and impaired differentiation. Mutations or overactivation of ERBB4 have been implicated in several diseases, including certain cancers and neurological disorders. Notably, aberrant ERBB4 signaling contributes to the development and progression of **non-small cell lung cancer (NSCLC)**, where it promotes tumor growth and metastasis. Additionally, ERBB4 has been linked to psychiatric disorders such as **schizophrenia**, where altered signaling may affect brain development and function. \\boxed{Non-small cell lung cancer}", "user\nSolve the following genomic pathway question:\nChromosome Number: 2\nNetwork Definition of the pathway: NRG // ERBB4*\nGenes in the pathway: NRG1; neuregulin 1 | NRG2; neuregulin 2 | NRG3; neuregulin 3 | NRG4; neuregulin 4 | ERBB4; erb-b2 receptor tyrosine kinase 4\n\nGiven this context, what is the biological effect of this ERBB4 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nERBB4 is a receptor tyrosine kinase that plays a critical role in signal transduction pathways initiated by neuregulins (NRG1-4). Activation of ERBB4 by its ligands leads to cellular processes such as proliferation, differentiation, and survival. Mutations or dysregulation of ERBB4 can disrupt these processes, contributing to disease. Specifically, aberrant ERBB4 signaling has been implicated in various cancers, including non-small cell lung cancer (NSCLC), glioblastoma, and breast cancer. Additionally, ERBB4 has been associated with neurodevelopmental disorders, such as schizophrenia, due to its role in brain development. Mutations in ERBB4 can also contribute to cardiovascular diseases by affecting cardiac development and function. However, one of the most notable diseases linked to ERBB4 is \\boxed{non-small cell lung cancer}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN1 gene encodes ataxin-1, a protein involved in transcriptional regulation. The pathway indicates that ATXN1 interacts with RORA and KAT5, leading to the activation of ITPR1, SLC1A6, and GRM1. Mutations in ATXN1 are associated with spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder characterized by progressive loss of motor coordination. The expanded CAG repeats in ATXN1 cause toxic gain-of-function, leading to neuronal dysfunction and cerebellar degeneration. This contributes to the hallmark symptoms of SCA1, including gait instability, speech impairment, and cognitive decline. The pathway highlights the role of ATXN1 in modulating signaling networks critical for neuronal survival and function. \\boxed{Spinocerebellar ataxia type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN1 gene is involved in a pathway that includes RORA and KAT5 as activators, leading to the expression of ITPR1, SLC1A6, and GRM1. ATXN1 is well-known for its role in spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder characterized by progressive loss of coordination. The gene encodes ataxin-1, a protein that, when mutated, forms toxic aggregates in neurons, particularly in the cerebellum, leading to neuronal dysfunction and degeneration. This contributes to the clinical features of SCA1, including ataxia, dysarthria, and cognitive decline. The pathway interactions suggest a role in synaptic transmission and calcium signaling, both of which are disrupted in SCA1. Therefore, the ATXN1 allele contributes to spinocerebellar ataxia type 1.\n\n\\boxed{Spinocerebellar ataxia type 1}", "user\nSolve the following genomic pathway question:\nChromosome Number: 6\nNetwork Definition of the pathway: ATXN1* -| (RORA+KAT5) => (ITPR1,SLC1A6,GRM1)\nGenes in the pathway: ATXN1; ataxin 1 | RORA; RAR related orphan receptor A | KAT5; lysine acetyltransferase 5 | ITPR1; inositol 1,4,5-trisphosphate receptor type 1 | SLC1A6; solute carrier family 1 member 6 | GRM1; glutamate metabotropic receptor 1\n\nGiven this context, what is the biological effect of this ATXN1 allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe ATXN1 gene encodes ataxin-1, a protein involved in transcriptional regulation. Mutations in ATXN1, particularly expansions of the CAG trinucleotide repeat, lead to the production of an abnormally long polyglutamine tract, resulting in protein misfolding and aggregation. This pathological mechanism is central to Spinocerebellar Ataxia Type 1 (SCA1), a neurodegenerative disorder characterized by progressive loss of motor coordination. The pathway involving ATXN1, RORA, KAT5, and downstream genes like ITPR1, SLC1A6, and GRM1 suggests a role in neuronal signaling and calcium homeostasis, which are disrupted in SCA1. These disruptions contribute to neuronal dysfunction and degeneration. Therefore, the biological effect of the ATXN1 allele is the development of \\boxed{Spinocerebellar Ataxia Type 1}."], ["user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A allele plays a critical role in the regulation of the p53 tumor suppressor pathway. CDKN2A encodes p14ARF, which inhibits MDM2, a negative regulator of TP53. This allows TP53 to remain active, promoting cell cycle arrest and apoptosis in response to DNA damage. CDKN2A also directly inhibits CDK4/6, preventing the phosphorylation of RB1, which in turn blocks E2F-driven transcription of genes required for S-phase entry. Loss or mutation of CDKN2A disrupts this checkpoint, leading to uncontrolled cell proliferation. This dysfunction is strongly associated with various cancers, particularly melanoma and pancreatic adenocarcinoma. The key role of CDKN2A in suppressing tumor growth makes it a critical gene in cancer development. \n\n\\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes a tumor suppressor protein that inhibits the activity of CDK4/6, preventing the phosphorylation of RB1. This inhibition blocks the release of E2F transcription factors, which are crucial for cell cycle progression. Mutations or inactivation of CDKN2A lead to reduced inhibition of CDK4/6, allowing RB1 to be phosphorylated and inactivated. This results in unchecked cell proliferation. The loss of CDKN2A function is commonly associated with the dysregulation of the TP53 pathway via interaction with MDM2, which promotes the degradation of TP53. This disruption of tumor suppressor mechanisms contributes to uncontrolled cell growth and genomic instability. CDKN2A mutations are strongly linked to melanoma and contribute to the development of this disease. \\boxed{Melanoma}", "user\nSolve the following genomic pathway question:\nChromosome Number: 9\nNetwork Definition of the pathway: CDKN2A* // MDM2 -| TP53 => CDKN1A -| (CCND+CDK4/6) -> RB1 // E2F\nGenes in the pathway: CDKN2A; cyclin dependent kinase inhibitor 2A | MDM2; MDM2 proto-oncogene | TP53; tumor protein p53 | CDKN1A; cyclin dependent kinase inhibitor 1A | CCND1; cyclin D1 | CCND2; cyclin D2 | CCND3; cyclin D3 | CDK4; cyclin dependent kinase 4 | CDK6; cyclin dependent kinase 6 | RB1; RB transcriptional corepressor 1 | E2F1; E2F transcription factor 1 | E2F2; E2F transcription factor 2 | E2F3; E2F transcription factor 3\n\nGiven this context, what is the biological effect of this CDKN2A allele, specifically what disease does this contribute to?\nAnswer concisely, in 150 words or less. Put your final answer within \\boxed{(DISEASE NAME)}, with no extra formatting\nassistant\n<think>\n\n</think>\n\nThe CDKN2A gene encodes for p16, a key inhibitor of CDK4/6, which prevents the phosphorylation of RB1. This inhibition stops the release of E2F transcription factors, which are crucial for cell cycle progression. In the given pathway, CDKN2A's interaction with MDM2 negatively regulates TP53, a tumor suppressor that promotes cell cycle arrest and apoptosis. Loss or mutation of CDKN2A leads to the inactivation of p16, allowing unchecked cell cycle progression and evasion of apoptosis. This contributes to genomic instability and tumorigenesis. CDKN2A mutations are strongly associated with melanoma and are also linked to other cancers such as pancreatic cancer. The loss of CDKN2A function is a critical step in the development of these malignancies. \\boxed{Melanoma}"]]